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The overall goal of the thesis is to explore novel nanotechnologies for the treatment of 
brain cancer. In particular, we used nanoparticles to deliver nucleic acid cargoes to glioblastoma 
(GBM) with the goal of altering cancer gene expression in a way that can reduce the tumor’s 
proliferative capacity, and ultimately kill the tumor cells. In Aim 1, we used poly(beta-amino 
ester) (PBAE) nanoparticles to deliver a plasmid encoding herpes simplex virus thymidine kinase 
(HSVtk) to the tumor cells. Our goal was to systemically deliver the inactive prodrug ganciclovir 
(GCV), which would be activated to its cell-killing form upon phosphorylation via HSVtk in the 
brain. We examined the ability of PBAE nanoparticles to deliver HSVtk to GBM in vitro and in 
vivo, and assessed the effect of the HSVtk/GCV therapeutic system to kill GBM and prolong 
survival in an orthotopic model of GBM. In Aim 2, our goal was to engineer PBAE 
nanoparticles for siRNA delivery by designing a novel, bioreducible PBAE nanoparticle that 
would biodegrade and release siRNA in the cytosol, its subcellular target location. We examined 
varying polymer properties to optimize siRNA delivery to GBM, and were able to show effective 
gene knockdown even with very low siRNA doses. This motivated the work presented in Aim 3, 
in which we used bioreducible PBAEs to codeliver multiple genes targeting GBM migration and 
proliferation. We also demonstrated that bioreducible PBAEs selectively deliver siRNA to brain 
cancer cells. We then used siRNA codelivery to show gene knockdown and a reduction in tumor 
growth in vivo. Finally in Aim 4, we use bioreducible PBAE nanoparticles to deliver microRNAs 
(miRNAs) to GBM. We were able to show that miRNA delivery was able to reduce GBM’s stem 
like and tumor propogating phenotype both in vitro and in vivo, and that we can reduce tumor 
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Introduction to the thesis 
 
1.1 Outline of the thesis 
The overall goal of the thesis is to explore novel nanotechnologies for the treatment of 
brain cancer. In particular, we used nanoparticles to deliver nucleic acid cargoes to glioblastoma 
(GBM) with the goal of altering cancer gene expression in a way that can reduce the tumor’s 
proliferative capacity, and ultimately kill the tumor cells. In Aim 1, we used poly(beta-amino 
ester) (PBAE) nanoparticles to deliver a plasmid encoding herpes simplex virus thymidine kinase 
(HSVtk) to the tumor cells. Our goal was to systemically deliver the inactive prodrug ganciclovir 
(GCV), which would be activated to its cell-killing form upon phosphorylation via HSVtk in the 
brain. We examined the ability of PBAE nanoparticles to deliver HSVtk to GBM in vitro and in 
vivo, and assessed the effect of the HSVtk/GCV therapeutic system to kill GBM and prolong 
survival in an orthotopic model of GBM. In Aim 2, our goal was to engineer PBAE 
nanoparticles for siRNA delivery by designing a novel, bioreducible PBAE nanoparticle that 
would biodegrade and release siRNA in the cytosol, its subcellular target location. We examined 
varying polymer properties to optimize siRNA delivery to GBM, and were able to show effective 
gene knockdown even with very low siRNA doses. This motivated the work presented in Aim 3, 
in which we used bioreducible PBAEs to codeliver multiple genes targeting GBM migration and 
proliferation. We also demonstrated that bioreducible PBAEs selectively deliver siRNA to brain 
cancer cells. We then used siRNA codelivery to show gene knockdown and a reduction in tumor 
growth in vivo. Finally in Aim 4, we use bioreducible PBAE nanoparticles to deliver microRNAs 
(miRNAs) to GBM. We were able to show that miRNA delivery was able to reduce GBM’s stem 
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like and tumor propogating phenotype both in vitro and in vivo, and that we can reduce tumor 
size and aggression.  
 
1.2 Specific Aims 
Aim 1. Use PBAE nanoparticles to deliver a tumor-killing gene to glioblastoma (GBM) as a 
cancer therapeutic.  
Biodegradable polymeric nanoparticles have the potential to be safer alternatives to 
viruses for gene delivery; however, their use has been limited by poor efficacy in vivo. In this 
Aim, we synthesized and characterized polymeric gene delivery nanoparticles and evaluated 
their efficacy for DNA delivery of HSVtk combined with the prodrug GCV in a malignant 
glioma model.  We investigated polymer structure for gene delivery in two rat glioma cell lines, 
9L and F98, to discover nanoparticle formulations more effective than the leading commercial 
reagent Lipofectamine 2000. The lead polymer structure, poly(1,4-butanediol diacrylate-co-4-
amino-1-butanol) end-modified with 1-(3-aminopropyl)-4-methylpiperazine, is a PBAE and 
formed nanoparticles with HSVtk DNA that were 138  4 nm in size and 13  1 mV in zeta 
potential.  These nanoparticles containing HSVtk DNA showed 100% cancer cell killing in vitro 
in the two glioma cell lines when combined with GCV exposure, while control nanoparticles 
encoding GFP maintained robust cell viability.  For in vivo evaluation, tumor-bearing rats were 
treated with PBAE/HSVtk infusion via convection-enhanced delivery (CED) in combination 
with systemic administration of GCV. These treated animals showed a significant benefit in 
survival (p=0.0012 vs. control). Moreover, following a single CED infusion, labeled PBAE 
nanoparticles spread completely throughout the tumor. This study highlights a new 
nanomedicine approach that is highly promising for the treatment of malignant glioma. 
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Aim 2. Synthesize, characterize, and optimize a novel polymer and assess its ability to deliver 
siRNA to GBM cells in vitro.  
siRNA nanomedicines can potentially treat many human diseases, but safe and effective 
delivery remains a challenge. DNA delivery polymers such as PBAEs were in the past unable to 
effectively deliver siRNA and require chemical modification to enable siRNA encapsulation and 
delivery. An optimal siRNA delivery nanomaterial needs to be able to bind and self-assemble 
with siRNA molecules that are shorter and stiffer than plasmid DNA in order to form stable 
nanoparticles, and needs to promote efficient siRNA release upon entry to the cytoplasm. To 
address these concerns, we designed, synthesized, and characterized an array of bioreducible 
PBAEs that self-assemble with siRNA in aqueous conditions to form nanoparticles of 
approximately 100 nm and that exhibit environmentally triggered siRNA release upon entering 
the reducing environment of the cytosol. By tuning polymer properties, including bioreducibility 
and hydrophobicity, we were able to fabricate polymeric nanoparticles capable of efficient gene 
knockdown in primary human glioblastoma cells without significant cytotoxicity. We were also 
able to achieve significantly higher knockdown using these polymers with a low dose of 5 nM 
siRNA compared to commercially available reagent Lipofectamine 2000 with a four-fold 
higher dose of 20 nM siRNA. These bioreducible PBAEs also enabled 63  16% gene 
knockdown using an extremely low 1 nM siRNA dose, highlighting their potential as efficient 
carriers for siRNA-based nanomedicine.  
Aim 3. Assess cancer-selective delivery siRNA via bioreducible PBAE nanoparticles in 
primary human GBM, and deliver functional siRNAs to combinatorially target genes 
responsible for tumor cell proliferation, migration, and invasion.  
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The goal of this Aim is to create a novel siRNA delivery nanotechnology capable of 
treating and preventing the recurrence of GBM, the most malignant primary human brain cancer. 
There is increasing evidence that brain tumor recurrence is due to the presence of brain tumor 
initiating cells. These cells are believed to be able to survive conventional treatments and to be 
able to migrate away from the primary tumor site and form new tumors. RNA interference 
(RNAi), a natural cellular process that can prevent the expression of genes in a sequence-specific 
manner, can be induced by the introduction of short interfering RNA (siRNA) into the cells. 
Using siRNA to turn off the genes that allow GBMs to survive treatment, to migrate, and to form 
new tumors has the potential to prevent tumor recurrence following treatment. However, siRNA 
delivery is challenging. Viral siRNA delivery has many potential problems such as 
tumorigenicity and immunogenicity, and is generally limited to carrying one type of siRNA, as 
multiple doses could increase the risks of using them in patients.  
For work completing Aim 2, we synthesized a novel, bioreducible PBAE-based 
nanoparticle capable of safe and effective delivery of siRNA to primary human glioblastoma 
cells. We were also able to show that we can achieve near complete gene knockdown of a 
fluorescent marker gene using only a fraction of the siRNA that we can load into the 
nanoparticles. In Aim 3, this motivated us to explore our ability to load several different siRNAs 
within the same nanoparticle. In particular, we wanted to use this technology to codeliver 
multiple genes that enable GBM cells to grow and migrate. We will also show that bioreducible 
PBAEs selectively deliver siRNA to brain cancer cells while avoiding transfection of healthy 
human brain cells. Finally, we will demonstrate that using siRNA codelivery via nanoparticles 
enables us to slow tumor cell growth in vivo. This has allowed us to optimize and characterize a 
combinatorial, tumor-specific technology for the delivery of brain cancer therapeutics.  
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Aim 4. Deliver therapeutic microRNAs (miRNAs) to human GBM with the goal of reducing 
GBM stem-like properties and sensitizing tumors to radiation treatment.  
Despite our growing molecular understanding of GBM, treatment modalities remain 
limited. Recent developments in nanomedicine provide new avenues to treat and manage brain 
tumors. Gene delivery via a novel bioreducible PBAE is of particular interest since these types of 
polymers are have high delivery efficacy and provide subcellularly-targeted cargo release. In this 
Aim, we combined bioreducible PBAE nanoparticles with newly discovered stem cell inhibiting 
miRNAs to develop miRNA nanoparticles to treat gliomas. We show these nano/miRs can 
effectively deliver miRNA mimics and inhibit the stem cell phenotype of GBM cells in vitro. 
These miRNA nanoparticles efficiently distribute throughout an established tumor in vivo, and 
more importantly, inhibit the growth of established orthotopic GBM tumor in mouse models. 
Additionally, we were able to combine our miRNA nanoparticle technology with a conventional 
cancer therapy, radiation treatment. We were able to show that miRNA delivery sensitized the 
tumor to radiation, which on its own was ineffective at slowing tumor growth. Our findings 
demonstrate that combining cancer stem cell-inhibitory miRNAs with advanced nanoparticle 





State of the Art 
 
2.1 Nanotechnology for nucleic acid delivery 
2.1.1. Introduction 
The delivery of nucleic acids to manipulate gene regulation can be both a therapeutic and 
a scientific tool. Diseases caused by missing or defective genes could potentially be cured by 
replacing these genes, such as upregulating tumor suppressor genes in cancer.1-3 The immune 
system can be modulated by the introduction of DNA-based vaccines,4, 5 or by introducing genes 
that would allow the immune system to better recognize or fight cancer.6, 7 Additionally, suicide 
genes can be introduced to kill cancer cells.8 Ex vivo, gene therapy can be used to manipulate 
stem cells for targeted differentiation,9 or to reprogram induced pluripotent stem cells from 
differentiated cells.10 Turning off or downregulating genes could treat diseases caused by gene 
overexpression.11, 12 Technology to selectively turn genes off is also a valuable biological tool to 
elucidate the function of genes within a cell and in the context of a disease.13 
 Viral gene delivery vectors, although effective, come with risks such as tumorigenicity 
and immunogenicity.14 Adenovirus-mediated gene delivery studies have found that dosage 
repeatability and concentrations can be limited by toxicity and humoral immune response.15 
Although non-viral nucleic acid delivery can avoid these issues, it is typically less effective.16 
                                                     
This chapter contains material modified from the following articles previously published or awating publication as: 
Kim, J.J.;* Kozielski, K.L.;* Wilson, D.R.;* Green, J.J.: Biodegradable polymeric nanoparticles for gene delivery. 
In Perspectives in Micro and Nanotechnology for Biomedical Applications. Xu, C. and Chan, J.M. eds.; Imperial 
College Press: London, UK, 2015, In press. 
Kozielski, K.L.;* Tzeng, S.Y;* Green, J.J.: Bioengineered nanoparticles for siRNA delivery. WIREs Nanomedicine 
and Nanobiotechnology 2013, 5, 449-468. 
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 Lipid-based and inorganic delivery vehicles have previously been examined for their 
potential to deliver nucleic acids. Lipid-based delivery is well-characterized,17-19 and 
commercially-available lipid-based delivery vehicles are available for in vitro delivery of DNA20, 
21 and siRNA.22 Lipid-based nanoparticles can potentially generate off-target and immunogenic 
effects,20 but there are strategies to attenuate these unwanted interactions such as the introduction 
of poly(ethylene glyocol) (PEG) shielding.23, 24 Calcium phosphate crystals,25-27 gold 
nanoparticles, quantum-dots and other inorganic materials have also been employed for non-viral 
gene delivery. Gold is advantageous because it’s biocompatible, easy to functionalize, and has 
malleable physical properties.28-32 Quantum dots are useful for fluorescent imaging as they are 
brighter and less prone to photobleaching than typical fluorophores.33, 34 Several lipid-based and 
inorganic nanoparticle systems have also been combined with polymeric materials for enhanced 
gene delivery, particularly through the incorporation of PEG coatings24, 35, 36 for nanoparticulate 
shielding or polyamines for improved interaction with DNA and intracellular delivery.37, 38  
Biodegradable polymeric gene delivery systems are a relatively newer class of materials 
for non-viral gene therapy.  They are promising due to key features such as safety mediated by 
their biodegradability, design flexibility due to their tunable structure, large cargo capacity, and 
relative ease in manufacture.  This chapter will focus on biodegradable polymeric nanoparticles 
for gene delivery.  They will be discussed in the context of systemic and intracellular barriers to 
gene delivery and how polymer design can be utilized to overcome these barriers. New 
developments in the field of biodegradable polymeric gene delivery and an outlook for the future 
will be highlighted. 
2.1.2. Obstacles to gene delivery 
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The central limitation of non-viral vectors for gene delivery is inefficient gene 
transfection arising from the natural mechanisms of the human body to protect itself against 
foreign substances.39 These barriers to biomaterial-mediated gene transfection span a spectrum 
from the systemic level to the cellular level (Figure 2.1).40 Different biomaterial properties and 
modifications to gene carriers are important for each step of the delivery process leading to 
successful expression of exogenous delivered nucleic acid. We will discuss seven major 
biological barriers to gene transfer using non-viral vectors and strategies to overcome each of 
these barriers. It is also important to note that the design properties seemingly optimal for one of 
the delivery obstacles could pose a challenge to other obstacles; hence further effort is needed to 
globally optimize polymeric nanoparticles to balance these potential trade-offs. 
Nucleic acid binding / encapsulation 
An efficient gene delivery vector must condense or encapsulate the nucleic acid to 
prevent enzymatic degradation and facilitate its cellular entry.41 As DNA is a strongly negatively 
charged material, early work in the field of non-viral gene delivery focused on the use of 
naturally occurring biological materials with significant positive charge that could 
electrostatically bind to the DNA. In this manner, DNA could be condensed into a smaller size, 
be made more resistant to potential enzymatic degradation, and have improved ability to enter 
cells. Polycation poly(L-lysine) (PLL) was observed to bind to nucleohistones,42, 43 and was later 
investigated as one of the earliest polymers to form nanocomplexes with DNA.44-46 PLL is 
capable of complexing with DNA to form nanoparticles that successfully undergo cellular uptake 
but fail to escape from the endosome.47 To overcome this challenge, PLL has been used in 
combination with other materials that aid in endosomal escape including other peptide molecules 
and pH sensitive moieties that make use of the proton sponge effect.48-50 To improve delivery in 
 9 
comparison to PLL, alternative gene delivery materials needed to be discovered. An off-the-shelf 
commercially produced polymer with very high charge density, polyethylenimine (PEI), was 
first reported for use in transfection in 1995 by Boussif et al., who attributed its high transfection 
efficiency to its ability to undergo endosomal escape via the proton sponge effect.51 
Unfortunately, while transfection efficacy is correlated with the molecular weight of PEI, 
cytotoxicity is similarly correlated, making unmodified high MW PEI largely unsuitable for in 
vivo applications. PEI is a non-biodegradable polycation that requires excess polymer to 
effectively transfect cells amd can lead to accumulation upon repeated administration.52, 53 To 
overcome this first obstacle to non-viral gene delivery, other biomaterials can encapsulate 
nucleic acids into particulates. Amphiphilic lipids, such as N-[1-(2,3-dioleyloxy)propylJ-N,N,N-
trimethylammonium chloride (DOTMA), and relatively hydrophobic polymers, including 
poly(lactide-co-glycolide) polymer (PLG), form DNA-encapsulated nanoparticles by either 
phase separation alone or in combination with electrostatic interaction.54, 55 
 Polymeric vectors are able to deliver different types of nucleic acids. For DNA, 
standard double-stranded plasmids as well as minicircles, which are plasmids that have had 
prokaryote sequences such as the CpG islands removed, are widely used to introduce exogenous 
genes that encode for proteins of interest.56 Because of the large size of DNA molecules, they are 
able to bind to cationic polymers such as PEI and poly(β-amino ester)s (PBAE) and form stable 
nanoparticles.57, 58 Small interfering RNA (siRNA), through the RNA interference pathway, 
causes mRNA to be broken down and inhibits translation.59 As an siRNA molecule is 
dramatically shorter (~20 bp vs > 1,000 bp) and stiffer than a plasmid DNA molecule, stable 
particle formulation through electrostatic interactions with cationic polymers is more difficult.60, 
61 Therefore, siRNA-delivering nanoparticles can require more complex engineering solutions to 
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form effective particles, such as making siRNA more multivalent by introducing short 
complementary overhangs62 or multimerizing siRNA molecules with cleavable disulfide 
linkages.63 More recently, an enzymatic RNA polymerization technique has been used to 
condense RNA structures into self-assembled RNAi-microsponges.64 While siRNA binding and 
encapsulation can be challenging, siRNA delivery overall is not necessarily more difficult than 
DNA delivery, as unlike DNA, siRNA does not require nuclear import to function.65 
Systemic circulation 
Both viral-based and non-viral based vectors face the problem of rapid clearance from the 
systemic circulation on the order of minutes.66, 67 While viruses often suffer from specific 
antibody-mediated immune response, non-viral platforms are quickly cleared by several non-
specific mechanisms. Most polymeric gene delivery materials are positively charged as 
electrostatic interaction is the prevalent driving force in forming many types of nanoparticles for 
gene delivery. The resulting positive surface charge of nanoparticles provides colloidal stability 
in aqueous solutions and facilitates interaction with cellular membrane. However, it also attracts 
anionic counter ions in physiological salt and serum proteins that cause opsonization and 
aggregation, leading to increased clearance by the mononuclear phagocyte system (MPS) and the 
reticuloendothelial system (RES).68-70 
Several strategies have been employed to minimize clearance from the systemic 
circulation, including charge shielding and shape control. One common “stealth” technology 
involves coating nanoparticles with PEG which provides a relatively inert surface due to its 
neutral and hydrophilic structure.71, 72 Conjugation of PEG or “PEGylation” to gene delivery 
particles composed of cationic polymers,73, 74 lipids,75, 76 dextran-spermine,77 and other materials 
have been reported demonstrating beneficial effects.  An alternative approach is the 
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neutralization of excess positive surface charge of particles through coatings with anionic 
biomacromolecules such as negatively charged polypeptides.78 More recently, engineering of 
particle shape has also been shown to be an important parameter to extend circulation time.  
Nanoparticles for drug delivery with higher aspect ratios had longer circulation half-lives than 
spherical particles,79 and this strategy has begun to be utilized for gene delivery nanoparticles.80 
Tissue and cell targeting 
Tissue targeting can be accomplished through design of a targeted systemically 
administered nanoparticle, through a tissue-specific promoter, or through a local injection. 
Nanoparticles can be injected into anatomically accessible sites to enhance delivery in the local 
region of interest while reducing non-specific transfection at other sites. For example, 
intracerebroventricular delivery grants direct access to the brain, retrograde intrabiliary infusion 
to the liver, and intratumoral injection to tumors.81-83  
Nanoparticles that are administered intravenously must have mechanisms to exit the 
circulation at the target tissue. The application of nanoparticles to solid tumors is often benefited 
by passive targeting. The formation of new blood vessels near rapidly growing solid tumors 
allows nanoparticles with diameters of 400 nm or less to passively leak out of the neovasculature 
and distribute to the tumor tissue. Therefore, prolonging systemic circulation by the 
aforementioned strategies, such as PEGylation, can increase the accumulation of nanoparticles at 
a tumor site, and this enhanced permeability and retention (EPR) effect has become an important 
tool in nanoparticle-mediated gene delivery for cancer therapy.84 On the other hand, molecular 
ligands and chemical moieties that bind specifically to overexpressed receptors on the vascular 
endothelial cells’ surface near a solid tumor have been conjugated to various nanoparticles as an 
active targeting mechanism. For example, arginine-glycine-aspartic acid (RGD) peptide 
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sequence and other chemical antagonists to various integrin isoforms have been covalently 
conjugated or electrostatically bound via negatively charged polypeptides to biomaterials target 
tumor vasculature.85-89 Another emerging method of conferring tissue-specificity to nanoparticles 
utilizes aptamers as targeting ligands.90   
Nanoparticles with targeting ligands can be used to target many additional cell types as 
well.  This is important as, when cell-specific RNA interference or therapeutic exogenous DNA 
expression is critical, nucleic acid delivery nanoparticles with cell-specific targeting can increase 
efficacy and reduce potential off-target side effects. Overexpressed receptors on the surface of 
specific cell types of interest are good candidates to target with ligands. The gene delivery and 
nanomedicine literature show that modification of nanoparticles ligands of many different types 
can be effective including: galactosylated PEI targeting hepatocytes, antibodies specific to the 
insulin receptor to target cancer cells in brain, synthetic peptides that bind to integrin α5β1 on 
neuroblastoma cells, small molecules targeting CD40 on ovarian cancer cells, and leukocyte 
function-associated antigen-1 to bind to melanoma cells.91-95  
Other methods for cell-specific gene delivery are also possible.  Following a polymer 
library approach, a recent study by Guerrero-Cázares et al. showed that the specific chemical 
structure of a polymer that comprises a polymer/DNA gene delivery nanoparticle can confer cell 
specificity to one type of cell over another such as primary brain tumor initiating cells over 
healthy neural progenitor cells.96 Similar results have also been shown for polymeric 
nanoparticles that can target liver cancer cells97 and endothelial cells.98, 99  A final approach is 
including a cell type-specific promoter in the plasmid to promote targeting of specific cells such 
as cancer cells.100  In this manner, even if some of the polymeric nanoparticles are delivered to 
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off-target cells, there is only successful expression of the exogenous gene in the targeted cells 
where the specific promoter is active.  
Cellular uptake 
Once nanoparticles reach the cells of interest, they must overcome several barriers at the 
cellular level before successful transfection is achieved. First, gene carriers need to cross the 
cellular membrane, for which exist both non-specific and specific mechanisms. 
Macropinocytosis is a non-specific cellular uptake mechanism, where cells engulf extracellular 
fluid through actin-driven evagination.101 However, gene vectors entered via macropinocytosis 
result in poor transfection efficacy due to high rate of recycling.102 Also, positive surface charge 
on nanoparticles formulated with cationic polymers or lipids promotes electrostatic interaction 
with relatively negative cell surface, which in turn triggers another non-specific pathway, 
adsorptive endocytosis.103 It should be noted that positive surface charge is shielded with 
PEGylation, which prevents electrostatic interaction with cellular membrane.  
On the other hand, specific uptake mechanisms are mediated by receptors on the cellular 
membrane, which can recognize various molecular ligands as well as chemical moieties of the 
vector. In the case of PEGylated nanoparticles, ligands can be conjugated to the PEG chain, and 
chemical moieties can be exposed upon environment-stimulated PEG cleavage.104, 105 There are 
two major specific uptake routes for gene carriers. Clathrin-mediated endocytosis is initiated 
with clathrin-coated pits of about 100 – 150 nm in size that pinch off from the plasma membrane 
to form endosomes.106 Nanoparticles modified with MC1SP-peptide and transferrin that target 
melanocortin receptor-1 and transferrin receptor respectively, and unmodified lipoplexes and 
liposomes are found to be endocytosed via this pathway.107-109 In comparison, caveolae-mediated 
endocytosis is characterized by flask-shaped invaginations of about 50 – 100 nm in diameter.110 
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Folic acid hat bind with folate receptors as well as unmodified polymeric nanoparticles are 
directed to caveolae-mediated uptake.109, 111   
Different uptake pathways lead to different intracellular fate, which underscores the 
importance of the cellular uptake on successful transfection.112 For example, the major route of 
uptake for PBAE nanoparticles does not necessarily lead to high transfection efficiency.113 
Therefore, nanoparticles can be modified take an uptake pathway different from its major route 
to improve the intracellular fate of the plasmid.  
Endosomal escape 
Once endocytosed, nanoparticles must escape the endosomal compartment and reach the 
cytoplasm. A common mechanism of endosomal escape for polymeric nanoparticles is the 
proton sponge effect.114 Reversibly protonated biomaterial vector can act as a buffer as the 
endosome gradually become acidic, thereby protecting the cargo. Subsequently, chloride ions 
enter the endosomes to neutralize the charge, creating osmotic pressure that eventually leads to 
endosomal burst and cargo release. PLL, owing to its primary amines that are easily protonated 
at pH 7, is unable to provide buffering capacity at endosomal pH. In order to neutralize the acidic 
pH, researchers have either co-delivered PLL with amphiphatic amines, such as chloroquine, or 
substituted its lysine residues with histidine or arginine that has titratable amines. 48, 115 PEI and 
PBAE, on the other hand, have weakly basic tertiary amines in their structure that allows for the 
proton sponge effect.51, 116 Although the hypothesis is the most widely believed mechanism of 
endosomal escape, it has been challenged and remains to be clearly elucidated.117 
 Nanoparticles can also escape the endosome by destabilizing endosomal membrane. For 
example, amphiphatic, fusogenic peptides, such as GALA (repeats of Glu-Ala-Leu-Ala) and 
KALA (repeats of Lys-Ala-Leu-Ala), have been utilized as the vector itself or associated non-
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covalently with nanoparticles.118, 119 These fusogenic peptides are able to form alpha-helical 
structure at lower pH that can be inserted and destabilize the membrane. Other amphiphatic 
lipids, such as dioleoylphosphatidylethanolamine (DOPE), that assume non-bilayer structure can 
also facilitate endosomal membrane destabilization when associated with liposomes.120, 121   
Dissociation of nucleic acid and nuclear transport of DNA 
Although strong binding or encapsulation of nucleic acid is necessary to form stable 
particles, nucleic acid must be able to dissociate from the vector once the particles escape 
endosomes. This is necessary in order to enable the nucleic acid to have a biological effect, as 
DNA that isn’t released from its carrier is unable to be transcribed as efficiently. 122, 123 This was 
illustrated by a recent study showing that the binding constant between polycations and DNA is 
biphasic with the transfection efficiency.124 Additionally, polymer degradability imparts 
decreased cytoxicity, as polymer molecular weight has been shown to positively correlate with 
toxicity.125 Lack of degradability contributes to the toxicity of conventional polymers such as 25 
kDa branched PEI.126, 127 Below, we will discuss methods that allow for the chemical 
modification of conventional polymers in order to enable them to degrade (Figure 2.2), in 
addition to the design of polymers with degradable moieties inherent in their chemical structure.  
2.1.3. Degradable polymeric moieties for cargo release and transport 
Hydrolysis 
The release of nanoparticle cargo can be achieved through polymer hydrolysis via the 
cleavage of ester, urethane, imine, and orthoester linkages. Poly[alpha-(4 aminobutyl)-L-glycolic 
acid] (PAGA) is a hydrolysable analog of PLL in which the amides linking conventional PLL 
monomers are replaced with ester linkages. PAGA based DNA delivery has been shown to lead 
to better transfection efficacy and lower toxicity versus conventional PLL.128 Hydrolytically 
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cleavable PEI can be synthesized using by linking shorter PEI polymers with ester-containing 
crosslinkers. Diacrylate monomers used to crosslink 800 Da PEI were shown to create 
nanoparticles with the same size, shape, charge, and DNA binding versus 25 kDa PEI while 
achieving 16-fold transfection efficacy with no measureable toxicity.129 PBAE polymers are 
formed via Michael addition of amine-containing monomers with diacrylate monomers and 
therefore contain esters within the polymer backbone.130 Combining various amine and acrylate 
monomers enables for the creating of large libraries of PBAEs with various chemical 
properties,131 and whose binding constants are affected by polymer molecular weight.124 Other 
poly(amino ester)s can be synthesized to have a similar chemical structure and transfection 
efficacy as 25 kDa PEI but with reduced toxicity (Figure 2.4).132 Poly(lactic-co-glycolic) acid 
(PLGA)-based nanoparticles can encapsulate nucleic acids, particularly using a double emulsion 
method and polyamines, and successfully deliver nucleic acids.133 PLGA chemically modified 
with amine-containing molecules grafted onto their polymer backbone has also been shown to 
effectively deliver DNA and siRNA.134, 135 Other hydrolytically cleavable polymer linkages have 
been explored for biodegrable polymer design. Amine containing polyurethanes can be designed 
to deliver DNA.136 Polyimines, which specifically allow for acid-labile hydrolysis, can be used to 
link short chain PEI.137 Additionally, polyorthoester polymers can form stable nanoparticles at 
neutral pH, but are acid-labile and release DNA at pH 5. 138, 139  
Reduction 
Polymer bioreducibility via the inclusion of disulfide bonds enables cargo release 
targeted to the cytoplasm. Cytosolic reduction potential is mainly due to glutathione, a molecule 
present in concentrations roughly 1000 times higher in the cytosol versus extracellular space.140 
This targeted release makes bioreducible polymers particularly useful for delivery of siRNA, 
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mRNA, and miRNA whose site of action is within the cytosol. Conversely, DNA delivery via 
disulfide-containing polymers has sometimes been found to be less-effective.141 As with 
hydrolytic linkages, reducible linkages can improve delivery efficacy and reduce cytotoxicity of 
conventional polymers. PLL linked with disulfides has shown improved nucleic acid delivery.142 
Methods to crosslink PLL with disulfides, either by incorporating cysteines into the polypeptide 
backbone,143 or by chemically modifying the lysine sidechains to contain thiols,144, 145 has led to 
improved siRNA and DNA delivery. Linear PEI linked with disulfides also showed improved 
siRNA delivery with lower toxicity than 25 kDa PEI.146 The KALA fusogenic peptide has also 
been modified with cysteines to allow for crosslinking.147  
Polymer bioreducibility can also be imparted by synthesizing polymers from disulfide-
containing monomers. Poly(amido amine)s (PAAs) are synthesized with diacrylamide and 
amine-containing monomers, and are therefore not biodegradable. However, disulfide-containing 
diacrylamides can also form PAAs and impart targeted cargo release to the cytoplasm. Disulfide-
containing PAAs have been extensively studied for both DNA and siRNA delivery. 146, 148-151 
PBAEs can also be bioreducible, either by end-capping with disulfide-containing monomers,9, 152 
or using diacrylate monomers with disulfides to incorporate them into the polymer backbone.153 
Bioreducible PBAEs have been shown to be very successful siRNA delivery vehicles, often 
achieving near-complete gene knockdown with little toxicity,154 even using very low siRNA 
doses.141  
Other modes of degradation 
Other modes of degradability can also enable targeted delivery. Enzyme-cleavable 
linkages, specifically matrix-metalloproteinase (MMP)-cleavable groups, can allow for release 
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within tumor space.155 Light-induced degradation, although not biodegradable, allows for user-
controlled release and could allow for spatially controlled cargo release.156 
Nuclear transport 
Lastly, unlike siRNA, DNA has to be transported to the nuclear membrane and enter the 
nucleus for transcription to occur. The simian virus 40 large T antigen nuclear localization signal 
(NLS), which is a peptide sequence rich of lysine amino acid, is known to facilitate the nuclear 
transport.157 Many vectors, including cationic peptides and lipids, or the DNA itself have been 
modified with variant forms of NLS in order to enhance transfection.158-160  
2.1.4. Degradable polymeric gene delivery vectors 
Peptides 
Poly(L-lysine) 
While PLL, shown in Figure 2.3a, had low efficacy for gene delivery by itself, 
multicomponent nanoparticles utilizing PLL as the polycation to bind the nucleic acid have been 
more successful. Notably, PEG modified PLL nanoparticles created by Meyer et al. for the 
delivery of siRNA utilized the lytic peptide melittin (Mel) shielded by pH cleavable 
dimethylmaleic anhydride (DMMAn) to only expose the lytic peptides for endosomal escape 
once a pH of 5.50 In addition to the pH sensitive lytic peptide exposure, siRNA release was 
achieved via disulfide cleavage between the siRNA and polymer.50 These PEG-PLL-DMMAn-
Mel nanoparticles were shown to achieve 90% knockdown in vitro but at only 70% metabolic 
activity measured by an MTT cytotoxicity assay.50 While results of this nanoparticle formulation 
were promising for siRNA delivery in vitro, in vivo testing revealed a high level of toxicity in 
health mice and tumor bearing mice alike requiring sacrifice of the animals shortly after 
application.50  
 19 
More recent uses of PLL for nucleic acid delivery have included pH cleavable PEGylated 
PLL-cholic acid nanoparticles shown to have a nine-fold reduction in gene expression in vitro 
equal to that of INTERFERin with cell viability over 90%.161 In vivo results of PEGylated PLL-
chlolic acid nanoparticle delivery of VEFG siRNA achieved a tumor size reduction of 41% with 
a measured 70% qPCR knockdown of VEGF mRNA without a significant weight reduction in 
treated mice.161 Another PLL nanoparticle formulation utilizing dendritic PLL for the 
knockdown of Apolipoprotein B to reduce serum low-density lipoprotein levels was shown to 
achieve significant knockdown in vivo leading to a 40% reduction in serum LDL.162 PLL has 
been shown to be an effective polycation when modified to enable endosomal escape and cellular 
targeting but its current use is limited as it lacks the versatility of many other polycations for the 
delivery of nucleic acids. 
Cell-penetrating peptides 
Peptides have been incorporated in many other nanoparticles designs as both the 
backbone structure and as surface molecules. Amphipathic endosomal escape peptides such as 
GALA and KALA, as mentioned previously, are well documented for improving transfection 
among many different cell types and with many different nanoparticle formulations.118, 163 Other 
CPPs have been used in the creation nanoparticles for the delivery of siRNA with the residue 
lysine often being used to increase the cationic nature of the peptides.164 Peptides have also been 
incorporated into nanoparticles for purposes of endosomal release. The use of sHGP, a 15 amino 
acid oligopeptides from HIV gp41, has been shown to improve endosomal release.165 Peptide 
sequences from influenza, specifically Inf7, have also been utilized in the design of nanoparticles 
to aid in endosomal escape and has been shown to improve efficacy of transfection with 
siRNA.166 Control over enzymatic degradation rate of peptide based nanoparticles has also been 
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achieved by Chu et al. who designed nanoparticles utilizing both D and L amino acids for 
controlled cleavage by Cathepsin B.167 In this way stereospecific enzymatic degradation was 
shown to offer excellent stability extracellularly with rate controlled intracellular degradation 
and release of nucleic acids.167 
CPP based nanoparticles termed PF6 for the delivery of siRNA created by Andaloussi et 
al. were demonstrated to be able to knockdown a reporter gene up to 90% in serum containing 
media with minimal cytotoxicity and inflammatory effects.164 Importantly, PF6 nanoparticles 
were shown to be stable over a span of weeks in water as well as being stable over a short term 
in serum containing media at a diameter between 125-200 nm and zeta potential of 
approximately -10 mV.164 Intravenous administration of PF6 with luc-siRNA to transgenic mice 
with bioluminescent liver cells showed effective knockdown peaking on day 5 at a 75% 
reduction.164 PF6 knockdown of the functional protein HPRT1 was observed to be greatest in the 
liver, but was followed closely by silencing of greater than 60% in the kidneys, which the 
authors note is likely due to blood supply similarities between the organs.164 Further modification 
of PF6 for targeting of organs or tumors or local injection will be required for functional siRNA 
delivery. Particularly since PF6 is known to have a negative zeta potential, targeting organs other 
than the liver may prove to be a challenge. 
Synthetic polymers 
Poly(ethylene imine) 
High molecular weight 25 kDa PEI, shown in Figure 2.3b, has previously been shown to 
condense DNA to form nanoparticles, undergo endosomal escape, and successfully deliver 
DNA.51, 168 Unfortunately while transfection efficacy is correlated with the molecular weight of 
PEI, cytotoxicity is likewise correlated making unmodified 25 kDa PEI largely unsuitable for in 
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vivo applications.168 Related to issues of immediate cytotoxicity, PEI is a non-biodegradable 
polycation that requires excess polymer to effectively transfect cells that can lead to 
accumulation upon repeated administration.52, 53 The 50 kDa and 800 kDa PEI initially used was 
quickly replaced in use by lower molecular weight PEI of approximately 25 kDa, which was 
shown to have higher transfection efficiency but still suffered from cytotoxicity in vivo in 
mice.51, 169 To further minimize the cytotoxicity of non-biodegradable PEI, even lower molecular 
weight branched PEI was initially used followed shortly after by partially biodegradable 
crosslinked PEI and hyperbranched oligoethyleneimine.170-173 Biodegradable linkages between 
low molecular weight PEI segments have primarily included bioreducible disulfides and 
hydrolysable esters, both of which have been shown to improve transfection efficacy as well as 
decrease cytotoxicity compared to 25 kDa PEI.129, 172 In 2003, Forrest et al. created hydrolysable 
PEI polymers 800 Da PEI and diol-diacrylate monomers that improved transfection efficiency 
and reduce cytotoxicity.129 Using disulfide cross-linked 1.8 kDa low molecular weight PEI, Liu 
et al. were able to achieve greater than 60% transfection with 90% cell viability in serum 
containing media in 2010.174  
These improvements to the polymer structure have made PEI much less toxic in vitro but 
fail to avoid problems of polycation accumulation in vivo that plague non-biodegradable 
polymeric delivery systems. Even with that limitation, a PEI based nanoparticle formulation for 
the delivery of a plasmid encoding interleukin-12 for 13 patients with recurrent ovarian cancer 
was tested in an initial Phase I clinical trial with favorable results for safety published in 2009.175 
The nanoparticle composed of lipopolymer, PEG-PEI-cholesterol was administered in a series of 
four increasing doses every 4 weeks intrapleurally.175 
Poly(beta-amino ester)s  
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The development of PBAEs, shown in Figure 2.3c, as a material for transfection has 
been greatly advanced by high throughput screening of PBAE polymer libraries in which 
monomers and end cap groups are varied.131, 176-178 This rapid screening technique has allowed 
for a large variety of PBAEs to be tested and patterns in transfection to be determined. 
Transfection by PBAEs has been shown to be largely cell type specific with cellular uptake and 
transfection differences between healthy cells and tumor cells able to be screened for to 
determine polymer candidates targeted to only the cell population of interest.96, 97, 179 Using 
polymer libraries and high throughput screening, PBAE nanoparticle formulations for the 
delivery of siRNA and DNA to glioblastoma cells have been achieved up to 85% and 90% 
respectively in vitro, significantly greater than Lipofectamine or any commercial transfection 
reagent (Figure 2.4).153 While most PBAE nanoparticles for the delivery of nucleic acids have 
used linear PBAEs for rapid intracellular degradation and release of DNA polyplexes, cross-
linked PBAEs formed by Michael addition using triacrylate monomers and N,N-
dimethylethylenediamine have been created to reduce the rate of degradation and DNA 
release.180 
In vivo results of PBAE nanoparticle delivery in mice of both siRNA and DNA have 
demonstrated transfection or knockdown with reporter genes as well as functional transfection 
for treating diseases such as ovarian cancer.181 Transfection of brain tumor-initiating cells 
(BTICs) in 3D oncospheres with pDNA has been accomplished with PBAE nanoparticles at up 
to 76% transfection in vitro.96 In this work, PBAE nanoparticle specificity of transfection for 
BTICs over fetal neural progenitor cells (fNPCs) has been demonstrated both in vitro and in vivo, 
supporting the notion that in vitro monolayer culture screening of PBAE nanoparticles has 
relevance for in vivo efficacy. Transfection of ovarian tumor bearing mice via intratumoral 
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injection of PBAE nanoparticles containing a plasmid encoding diphtheria toxin showed a mean 
tumor load reduction greater than that of administration with dual chemotherapeutics.181 The 
intrapleural injection route used in this study mirrors the current injection route of 
chemotherapeutics for advanced ovarian cancer, supporting the clinical relevance of the work.181 
Of greater importance to clinical relevance, PBAE nanoparticles with pDNA have been 
demonstrated to be stable when stored at -20C for up to two years upon lyophilization with 
sucrose as a cryoprotectant.96  
PBAEs have also been used as a cationic polymer to supplement other materials in the 
creation of nanoparticles for the delivery of siRNA. Cohen et al. have created acetalated-dextran 
nanoparticles with 10 wt% PBAE that showed pH sensitive degradation and release of DNA.182 
PBAE has been used as a cationic polymer for binding DNA in conjunction with PLGA to form 
microspheres capable of transfecting macrophages to express a tumor specific antigen and induce 
an adaptive immune response in mice.183 
For localized delivery of DNA and siRNA amenable to tissue engineering applications, 
PBAEs have been used in the development of multilayer polyelectrolyte films shown to enable 
contact dependent transfection.184 These multilayered films developed in the lab of David Lynn 
rely on charge association between layers of polycation, specifically a PBAE, and DNA to 
respond in a pH and temperature dependent way for localized transfection.185 DNA release was 
shown to be largely dependent multilayer film degradation and released DNA in a relaxed 
conformation compared to the typical supercoiled conformation resulting from nanoparticle 
delivery.184 Multilayered polyelectrolyte films have been further developed for localized delivery 
of siRNA with release shown to be subject to diffusion out of the film instead of due to film 
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degradation186 Notably, the multilayer film design allowed for sustained release of DNA 30 
hours, while siRNA was released in a burst manner.184, 186 
Poly(amido amine)s 
Dendrimers are symmetrically branched polymer structures that have been used as base 
units to encapsulate and deliver various materials through charge interactions or conjugation. 
Many dendrimers, including poly(amidoamine) (PAA or PAMAM) shown in Figure 2.3d, are 
synthesized by a series of Michael addition reactions, allowing for great specificity of size and 
nitrogen content for complexation with nucleic acids by a fine-tuned N:P ratio. The exterior 
surface of dendrimer molecules can also be modified with hydrophilic groups to allow for 
improved solubility in water or with targeting ligands for attempted improved active cellular 
uptake. The most frequently used dendrimer for nucleic acid delivery to date has been PAMAM, 
although peptide dendrimers have also been utilized with some success.187 Bioreducible 
PAMAM nanoparticles for the delivery of  DNA have been created with very high cell viability 
and transfection efficiency up to 200 times that of branched PEI.188 The degree to which the 
structure of these hyperbranched PAMAM particles were able to be reduce was able to be finely 
tuned by the changing the monomer molar ratios used in the Michael addition reactions used to 
create the polymer.188  Beyond PAMAM, Barnard et al. developed an ester hydrolysable 
dendrimer with surface amine groups capable transfection of in vitro up to 10 times more 
efficiently than PEI.189 
Poly(lactide-co-glycolide) and poly(caprolactone) 
PLGA microparticles containing 25 w% PBAE were used to transfect macrophages with 
reporter gene DNA both in vitro and in vivo.183 In vivo results showed that these microparticles 
containing a plasmid for the expression of a tumor antigen were able to induce rejection of the 
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transplanted tumor specific antigen.183 The resulting adaptive immune response was sufficient to 
cause a reduction in measured tumor growth by day 11 following transfection.183 In another 
nanoparticle formulation, copolymer hybrid poly(ester amine) nanoparticle formulations of 
polycaprolactone and PEI have been formulated with improved transfection over 25 kDa PEI for 
a number of cell lines.190   
Polysaccharides 
Chitosan 
Chitosan, a linear polysaccharide derived from chitin and shown in Figure 2.3e, has been 
used in the delivery of pDNA and siRNA but generally has had low transfection efficiency due 
to chitosan’s low performance as a proton sponge.191 Chitosan varies by the degree of 
deacetylation from chitin expressed as a ratio of β-(1–4)-linked D-Glucosamine to N- acetylated-
D-glucosamine.192 Highly deacetylated chitosan has been used more frequently for nucleic acid 
delivery due to its greater cationic nature and corresponding ability to complex with the 
negatively charged backbone of DNA or RNA. In 2001, Mao et al. created PEGylated chitosan 
DNA nanoparticles with the targeting molecule transferrin capable of transfection, but only at a 
fraction of the efficiency of Lipofectamine A.193 Since then, chitosan  thiamine pyrophosphate 
nanoparticles for the delivery of siRNA have been shown to achieve knockdown up to 70% with 
cell viability above 90% in vitro for hepatocarcinoma cells, notably greater than 
Lipofectamine.194 Trimethyl chitosan has also been used in conjunction with the polysaccharide 
polysialic acid (PSA) for the delivery of transcription factor decoy oligonucleotides resulting in a 
reduction of inflammation measured by excreted cytokines in vitro.195 
Hyaluronic acid 
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Hyaluronic acid (HA), shown in Figure 2.3f, has been utilized in nanoparticles for the 
delivery of nucleic acids as well as a targeting molecule for the CD44 cell receptor often 
overexpressed on the surface of tumor cells.196, 197 HA chitosan-PEG nanoparticles synthesized 
for the delivery of pDNA and siRNA have been shown to have transfection efficiency equivalent 
to that of Lipofectamine 2000 in vitro in 2010.196 Nanoparticles for siRNA delivery composed of 
HA-spermine and HA-PEI have achieved above 90% knockdown in vitro with specificity for the 
CD44 receptor.197 When the HA-PEI particles were tested in vivo for targeting of a metastatic 
lung cancer model implanted subcutaneously in mice, knockdown measured by qPCR up to 55% 
was observed.197  Improving serum stability of nanoparticles is another area in which HA has 
been utilized in combination with polycations such as PEI, functioning in much the same way as 
glycosylation of proteins in vivo.198 HA has also been utilized in the creation of hydrogels 
capable of delivering DNA at controlled rates for in vivo tissue engineering applications.199 
Cyclodextrin 
β-Cyclodextrin, shown in Figure 2.3g, is a three-dimensionally stable oligomer of 
glucose that forms cup like structures with a hydrophobic core. Chemical modification of β-
cyclodextrin with acetyl groups enables the polymer structure to complex with nucleic acids as a 
cationic polymer. Cyclodextrin based nanoparticles developed in the lab of Mark Davis for the 
intravenous delivery of siRNA have notably reached clinical trials. These nanoparticles, shown 
in Figure 2.5a, are formulated from β-cyclodextrin, adamantine-PEG and the targeting ligand 
transferrin and have been shown to have many favorable characteristics for the delivery of 
siRNA including a size between 60-80 nm, a zeta potential +10-20 mV and the ability to protect 
siRNA from nuclease activity in the presence of serum for at least 4 hours.200 In 2009 following 
animal trials in monkeys this nanoparticle formulation for the delivery of RRM2-siRNA was 
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tested in FDA Phase I clinical trials as a cancer therapeutic.201 The Phase I trial involving 24 
patients has since concluded with favorable results for the nanoparticle safety, including 
evidence for the lack of a complement response.202 Additionally, RRM2 mRNA levels 
intratumorally were shown to have been reduced up to 77% and a 32% partial knockdown of 
RRM2 was measured for RRM2 protein levels in the tissue and shown in Figure 2.5b.203 While 
this level of knockdown is unlikely to be effective as a solitary treatment for tumors, it provides 
the first evidence that siRNA can be targeted to tumor cells in vivo with measurable knockdown 
of a specific protein. 
Dextran 
Dextran, shown in Figure 2.3h, a branched polysaccharide of repeating glucose units, has 
been used in the formation of many nanoparticles for the delivery of siRNA and pDNA. Dextran 
is often acetelated to improve solubility in organic solvents and allow for pH dependent 
degradation.204 While the structure of unmodified dextran does not fit the requirements of an 
ideal material for the delivery of nucleic acids, its status as an easily modified biocompatible and 
biodegradable polymer does allow for it to be utilized for other materials in the formulation of 
nanoparticles for nucleic acid delivery. Acetalated dextran has been used in conjunction with 
PBAE and spermine for the delivery of both siRNA and DNA.182, 205 The Ac-DEX/PBAE 
particles created for the delivery of DNA were shown to undergo endosomal pH dependent 
degradation and also coated with cell penetrating peptides for improved endosomal escape.182 
Spermine 
Spermine, shown in Figure 2.3i, is a natural oligoamine that has been used primarily as 
an oligomer grafted onto non-cationic polymers to allow for the polymer to have a charge 
association with DNA. Biodegradable polysaccharide based particles using spermine as the 
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polycation have been explored with varying degrees of success. In 2002, a library of over 300 
polysaccharide-oligoamine particles were created with some polysaccharide-spermine particles 
reaching transfection efficiency equal to that of Transfast cationic lipids.206 Since then, 
acetalated-dextran spermine nanoparticles have been created for siRNA as well and shown to 
cause up to 60% knockdown of GFP in HeLa cells.205 
Nucleic acid based particles 
Nanoparticles composed entirely of nucleic acids have been created for the delivery of 
siRNA. Lee et al. used six 30 bp segments of DNA with complementary overhanging siRNA 
segments to create self-assembling tetrahedral oligonucleotide nanoparticles by complementation 
between the DNA and overhanging siRNA as shown in Figure 2.3j.207 These particles, each 
carrying six siRNA molecules, were shown to have a circulation time four times longer than 
unprotected siRNA.207 Oligonucleotide nanoparticles improved siRNA delivery for the 
knockdown of luciferase both in vitro and in vivo with a 60% reduction in bioluminescence of 
luciferase expressing tumors in a rat model two days after treatment.207 These initial studies, 
particularly for improved in vivo delivery of siRNA have indicated that nucleic acid origami 
particles are a high capacity siRNA delivery method that deserves further study.207 
2.1.5. Conclusion 
Gene therapy holds great promise in treating various diseases of genetic origin by 
introducing exogenous nucleic acid to express desired proteins or knock down the expression of 
undesirable genes. A key challenge to gene therapy is effective delivery, and significant effort 
has been invested into developing biomaterials that can form nanoparticles to deliver genes to 
specific targets safely and efficiently. As highlighted in this chapter, a number of non-viral, 
biodegradable polymers have been developed to form biodegradable nanoparticles for gene 
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delivery and are promising due to their ease of synthesis, low toxicity, and efficacy at 
transfection. Importantly, strategies for polymer modifications have been identified to overcome 
major biological barriers to gene delivery. While a polymeric nanoparticle system for human 
gene therapy has yet to be FDA-approved, numerous systems for polymeric DNA and siRNA 
delivery are in preclinical and clinical trials.  These systems, or their future derivatives, may be 
able to achieve the promise of genetic medicine. 
 
2.2. Nanotechnology optimized for siRNA delivery 
2.2.1. Introduction 
Since its discovery in 1998,208 the RNA interference (RNAi) gene silencing pathway has 
been a focus of many major areas of research. Chief among these are the natural mechanism of 
viral defense in plants and insects,209-211 the discovery of endogenous protein function by 
reducing its production,13 and the treatment of diseases that are caused by overproduction of a 
specific gene.212, 213 The last of these applications in particular requires safe and effective 
methods for siRNA delivery in order to maximize the clinical potential of RNAi.  
The natural RNAi pathway begins with double-stranded RNA (dsRNA) that is cleaved by 
the protein Dicer into ~21-base pair dsRNA known as short interfering RNA (siRNA). The 
antisense strand of siRNA is incorporated into the RNA-induced silencing complex (RISC), 
which binds and subsequently cleaves, in a catalytic fashion, strands of mRNA complementary 
to the siRNA. This prevents protein production and results in sequence-specific gene knockdown 
(for review, see Hannon214). Early methods to non-virally induce RNAi included direct injection 
of dsRNA215-217 or mechanical agitation of cells in the presence of dsRNA.218 However, these 
methods are not clinically translatable, and introduction of dsRNA longer than 30 base pairs has 
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been shown to induce an interferon (IFN) response.219 As a result, delivery of siRNA to 
circumvent IFN is more frequently employed.  
Although very effective, viral methods for nucleic acid delivery have been associated 
with immunogenicity and tumorigenicity.14 Non-viral nucleic acid delivery systems are 
traditionally less effective16 but can be designed to avoid issues typical of viruses. Several types 
of materials have been used for delivery of nucleic acids and of siRNA in particular. Because 
many early efforts at siRNA delivery used materials that were already well-studied in the context 
of DNA delivery, we first discuss properties of these materials that make them suitable for 
nucleic acid delivery in general and then describe their utility for overcoming barriers to siRNA 
delivery (Figure 2.6) in particular. 
2.2.2. General properties of nucleic acid delivery nanoparticles 
Nucleic acid binding or encapsulation ability 
 The biomaterial transfection agent must have sufficient ability to bind to or encapsulate 
the nucleic acid. Because nucleic acids are negatively charged, positively charged biomaterials 
are commonly used. Poly(L-lysine) (PLL)'s ability to bind DNA was discovered through studies 
of DNA-histone binding and conformation,43 and it was later explored for delivery of exogenous 
DNA.220, 221 PLL, however, lacks the ability to escape the endosome, an essential step in 
intracellular delivery through the endocytic internalization route.222, 223  Other biomaterials such 
as liposomes are able to encapsulate nucleic acids within their aqueous interior. These artificial 
vesicles can be made with tight control over physical properties by changing the amphiphilic 
lipids that compose them as well as by varying fabrication methods.18, 19, 224 Nucleic acid binding 
or encapsulation is generally a necessary, but not sufficient, biomaterial attribute to prevent 
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degradation of the nucleic acid and to facilitate the entry of such highly negatively charged 
molecules into the cell. 
Shielding 
 Liposomes, as well as other types of nanoparticles (NPs), often suffer from quick 
clearance from the circulation by cells of the mononuclear phagocyte system (MPS).225, 226 
Chemical structure of specific materials aside, most NPs for nucleic acid delivery rely at least 
partially on ionic interactions for cellular uptake and carry charge on their surface.  Although 
electrostatic repulsion contributes to NP colloidal stability in aqueous suspension, physiological 
salt225, 226 and serum227 conditions are often enough to coat the NPs non-specifically with 
proteins, and cause aggregation, leading to decreased delivery efficiency and increased clearance 
by MPS cells. One way to overcome this potential problem is to coat the NP surface with a 
shielding molecule, commonly poly(ethylene glycol) (PEG), whose hydrated structure can 
prevent non-specific interactions with biomolecules.228 This strategy, dubbed "PEGylation," has 
been employed in a number of gene delivery systems, including NPs based on chitosan,229 
gelatin,230 cationic polymers,231 lipids,232 and metallic NPs.233 
It should be noted that PEGylation has also been found to prevent desirable interactions, 
such as those leading to intracellular delivery to target cells. As a result, researchers have 
explored the use of cleavable PEG chains on NP surfaces to increase circulation time but also 
allow effective transfection.104  
Targeting and cellular internalization 
 A number of methods can be used to promote uptake of nucleic acids by cells of interest. 
For example, taking advantage of the properties of the lipid bilayer of cell membranes, cationic 
lipids can facilitate cellular uptake by interacting with anionic cell surface molecules.234-236 
 32 
Similarly, other cationic materials, such as polymers, also show high uptake into cells compared 
to neutral or anionic materials due to interactions with the relatively negative cell surface.103 
Unfortunately, these interactions with NPs and the cell membrane can also contribute to 
cytotoxicity.237 
 Various chemical moieties and biological ligands can also be incorporated into the 
material or into the NP as an alternative or additional method of increasing cellular 
internalization. For instance, the amphipathic peptide GALA (30 residue polypeptide containing 
4 Glu-Ala-Leu-Ala repeats) forms an alpha-helical structure that promotes interaction with lipid 
bilayers,163 as does the KALA peptide ( 30 residue polypeptide containing 3 Lys-Ala-Leu-Ala 
repeats),238 which has the additional advantage of being positively-charged at neutral or low pH 
for binding to nucleic acids. The transition from random coil to alpha helix, and therefore the 
ability to disrupt membranes, is pH-dependent for both of these peptides, making them 
potentially useful specifically for environmentally triggered membrane fusion.239, 240 Other cell-
penetrating peptides (CPPs) used for this purpose include the trans-activating transcriptional 
activator (TAT) peptide derived from the human immunodeficiency virus (HIV).241, 242 This 
strategy can be combined with a disassembly approach by synthesizing a high molecular-weight 
form of TAT peptide, linked with disulfide bridges, that can be degraded by bioreduction to 
reduce potential cytotoxicity.243 
 In addition to general, non-specific cellular uptake, it is often desirable to be able to 
deliver siRNA to a specific cell or tissue type. Ligands such as sugars, aptamers, peptides, and 
proteins for cell- or tissue-specific cell surface proteins can also be coated on89, 244 or conjugated 
to245, 246 a biomaterial or NP to enhance uptake and delivery in a targeted manner. 
Endosomal Escape  
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For successful intracellular delivery of nucleic acids, it is critical that that the NP be able 
to reach the cytoplasm safely and efficiently. A common method of overcoming the endosomal 
escape barrier is the proton sponge mechanism, in which a reversibly protonated material is 
believed to act as a buffer. This not only protects the cargo from acidification of the endosomal 
compartment but also causes a water influx that leads to endosome lysis and release of the cargo 
into the cytosol. This mechanism was proposed to explain the effectiveness of polyethylenimine 
(PEI) for gene transfer, as PEI contains reversibly protonated tertiary amines,247 and while its 
validity has not been incontrovertibly proven and has been challenged,248 it nonetheless remains 
the most widely believed hypothesis.114, 249 Other materials like PLL can be modified to contain 
titratable amines, such as by substituting histidine or arginine for lysine residues,48, 250 leading to 
improved transfection. Other materials like poly(amidoamine) (PAA) dendrimers are also 
reversibly protonated at physiologically relevant pH.251 However, while these materials increased 
DNA delivery efficacy, some, like PAAs, bind siRNA less tightly, compromising their ability to 
act as siRNA delivery agents without additional modifications.149  
Other methods for endosomal escape include hydrophobic biomaterials that can fuse with 
the membrane, such as dioleoylphosphatitylethanolamine (DOPE) in lipid-based particles.252, 253 
Polyanionic biomaterials have also been employed to promote membrane destabilization, often 
in a pH-dependent manner that allows triggered endosomal escape when NPs are in certain 
environments.254 Membrane-disruptive peptides, such as GALA and KALA, can also be 
conjugated to or non-covalently associated with NPs to cause endosomal escape.221, 239, 240 KALA 
in particular maintains α-helical character even at low pH (4.5), thus making it capable of 
membrane disruption and leakage even in lower pH environments comparable to late endosomes. 
KALA was shown to cause nearly 100% leakage of endosomal contents over pH range 4.5-8.238  
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Degradability and nucleic acid release 
 Release of a NP into the cytoplasm after endosomal escape is not necessarily sufficient 
for biological effect. It was shown that DNA plasmids must unbind sufficiently from a delivery 
vehicle for transfection to occur.122, 123 However, while DNA must be trafficked to the nucleus, 
siRNA must be released in the cytoplasm, its principal site of action.255 A number of factors can 
affect material degradation and cargo release rate; for example, poly(beta-amino ester)s (PBAE)s 
are hydrolytically degradable,130 with their degradation and complex disassociation rate 
dependent on the local pH and the polymer conformation.256 Because hydrolytic degradation of 
free PBAEs in solution takes place in hours at pH 7 at 37C, these nanoparticles can diffuse or be 
convected to cells and release their cargo shortly thereafter. Moreover, the polymers showed 
slowed degradation at the lower pH (5-6) found in endosomal compartments, which could 
provide some protection for nucleic acids until after endosomal escape to the cytoplasm. 
Aside from hydrolysis, as is characteristic of PBAEs and other polyesters, another mode 
of degradation useful in siRNA delivery is bioreduction due to disulfide linkages (for review, see 
Son et al.257). The latter mechanism takes advantage of the reducing cytoplasmic environment to 
cause quick, environmentally-triggered degradation and siRNA release into the correct cellular 
compartment. 
 NPs that do not have a mechanism to stimulate siRNA release may cause low 
knockdown. Gold NPs, for example, without an siRNA release mechanism may achieve lower 
knockdown or require higher siRNA doses37 versus similar delivery vehicles that contain an 
efficient release mechanism.38  
Biocompatibility 
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It is critical that materials administered to a patient be biocompatible. Although cationic 
lipids have been studied often for nucleic acid delivery, their disruption of the membrane, while 
an advantage for cellular uptake, can also cause excessive cytotoxicity.258  Biomaterial 
degradation is one mechanism of increasing biocompatibility. Degradation of a biomaterial can 
reduce cytotoxicity, as molecular weight of cationic polymers has been positively correlated with 
cytotoxicity.125 For instance, poly[alpha-(4-aminobutyl)-l-glycolic acid] (PAGA), a 
hydrolytically degradable PLL analogue containing ester bonds in place of the amide bond of the 
polypeptide, showed not only increased transfection efficacy but also negligible toxicity in vitro 
compared to unmodified PLL.128 A hydrolytically degradable form of branched PEI showed a 
similar increase in biocompatibility129 compared to the typically high cytotoxicity of unmodified 
PEI.126, 259  
Stability 
Although many of the above biomaterials have been explored for siRNA delivery, and 
most continue to be investigated for this purpose, several challenges remain to be overcome. 
Many of these biomaterials and NPs were initially developed for DNA delivery. Aside from 
differences in the site of action of these two nucleic acids, there are also biophysical differences 
between them. Although both are composed of similar anionic bases, siRNA molecules are much 
smaller in size than DNA plasmids.  In addition, dsRNA is stiffer than dsDNA,61, 260 and 
segments as short as siRNA act as rigid rods. This has important implications for nucleic acid 
binding properties261, 262: there is less multivalency in siRNA than in DNA when interacting with 
a cationic polymer because of fewer binding sites per molecule.  In addition, the stiff RNA 
molecule, which is expected to condense very little, may not be able to bend to the 
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conformations ideal for high affinity binding and encapsulation, and this can lead to weak 
stability of siRNA-containing NPs.  
In addition to low binding affinity, instability of the RNA cargo itself is a major problem 
in many of the delivery systems currently investigated. siRNA is more prone to enzymatic 
degradation than DNA, though less so than single-stranded RNA. Therefore, protection from the 
extracellular and endosomal environments is necessary for successful delivery. Stability is a 
challenge for lipid-based materials as well since lipid-based colloids often exhibit low 
stability.263 
2.2.3. Nanoparticles for siRNA delivery 
Examples of broad classes of biomaterials used for siRNA delivery are presented in 
Figure 2.7. Below and in Table 2.1, we will discuss illustrative examples of next-generation 
materials that address many of the challenges listed here, including siRNA binding and 
protection, particle stability, cellular internalization and targeting, material biocompatibility and 
efficacy, endosomal escape and intracellular targeting, and siRNA release. 
Lipid-based nanoparticles 
 Lipid-based materials are the most widely-used biomaterials for nanoparticulate 
siRNA delivery. Of over 20 siRNA phase I clinical trials, nearly half use NPs as the delivery 
vehicle, and almost all of these are lipid-based.264 Many of the leading commercially available 
reagents are lipid-based, including LipofectamineTM 2000,21 1,2-dioleoyl-3-trimethylammonium-
propane (DOTAP),20 RNAifect,20 and TransIT-TKO and TransIT-siQuest.22  It has become clear, 
however, that careful controls are necessary for the successful interpretation of results, as siRNA 
in combination with cationic lipids can cause off-target effects. For example, an in vivo study in 
mice showed that intravenous injection of naked siRNA had no measurable effect; however, 
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injection of liposomal siRNA NPs based on 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP), a commonly used cationic lipid for nucleic acid delivery, induced a potent IFN 
response, including the upregulation of downstream molecule STAT1 (signal transducer and 
activator of transcription 1).20 Although the greatest effect was seen with DOTAP/siRNA 
complexes, including several different siRNA sequences, DOTAP alone did cause an IFN and 
STAT1 response, emphasizing the importance of careful design of the material used for lipid-
based NPs to avoid potentially adverse side effects as well as careful interpretation of results. 
Some researchers have focused on overcoming this problem in particular; for example, Chono et 
al.23 used the additional components of hyaluronic acid, a polysaccharide with low 
immunogenicity, PEG, and a targeting ligand, and found that their liposome elicited no 
significant immunotoxicity, measured by cytokine expression, within their therapeutic range. 
Other strategies have been employed to reduce the off-target immunological response to siRNAs, 
particularly when delivered within liposomes; for instance, 2'-O-methyl-modified siRNAs were 
designed and delivered in stable nucleic acid lipid particles (SNALPs)265 with less unwanted 
immune stimulation observed. 
To bypass problematic toxicity and particle instability and to maximize siRNA delivery 
and gene knockdown, several strategies can be employed. Akinc et al. used a combinatorial 
library to link acrylate esters or acrylamides containing 9- to 18-carbon hydrocarbon tails via one 
of many different amine-containing small molecules,266 thereby creating a wide range of lipidoid 
materials with slightly varying structure (Figure 2.8). These lipidoid molecules were mixed with 
cholesterol and a PEG-lipid (polyethylene glycol conjugated to a lipid moiety for incorporation 
into liposomes via hydrophobic interactions) and loaded with siRNA. Using this method, the 
authors optimized nanocomplex stability and efficacy in vitro, then used top materials to achieve 
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>90% knockdown in vivo after two daily intravenous injections of 2 mg siRNA/kg mouse. A 
follow-up study showed increased efficacy of their material to nearly 100% when the siRNA 
dose was increased to 10 mg/kg, though high toxicity associated with cationic lipids necessitated 
a lower lipid concentration to be tolerable. The authors improved the biocompatibility by 
maximizing siRNA loading, thereby reducing the total lipid content delivered, and optimized the 
PEG chain length to improve in vivo particle stability.267 
Lipid material optimization and selection has also been done to examine very specific 
aspects of transfection. For example, one reason for the use of cholesterol in liposome 
formulations is to increase fusion with the cell membrane for internalization,268, 269 in addition to 
affecting the fluidity or rigidity of the liposome bilayer. Other lipids have also been found to 
promote fusion of the liposome with the endosomal membrane because their structure requires 
less energy to transition to a non-lamellar phase, forming tubular structures with hydrophobic 
tails exposed and promoting siRNA release into the cytoplasm.270, 271 While many groups have 
incorporated fusogenic lipids into their NP formulations and some trends had been implicated in 
increasing fusogenicity, Heyes et al. specifically studied the effect of saturation and chain length 
on fusogenic phase transition as well as on transfection efficacy.272 They and others have 
investigated siRNA delivery from SNALPs by selecting the best fusogenic lipid for the 
endosomal escape step. Semple et al. used in vivo screening in mice to develop siRNA-
containing SNALPs that could be administered i.v. to non-human primates and cause 80% 
knockdown of a target gene.273 
The in vivo studies described, while showing high efficacy, required ~1 mg/kg of siRNA 
to achieve knockdown. By using a similar combinatorial method to that mentioned above, Love 
et al. identified a linker molecule, N-(2-(4-(2-aminoethyl)piperazin-1-yl)ethyl)ethane-1,2-
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diamine, that, after reaction with the 12-carbon epoxide 1,2-epoxydodecane, formed lipid-based 
NPs that were primarily taken up by macropinocytosis rather than endocytosis, as with their 
previously-studied materials.29 They were able to achieve one to two orders of magnitude better 
efficiency (0.03-0.3 mg/kg dose) in non-human primates with up to ~75% knockdown at the 
lowest dose, possibly because their internalization route allowed their particles to avoid the 
endosome. The authors note that lower siRNA doses, while causing the same initial effect, had 
lower knockdown duration compared to high siRNA doses. This high nucleic acid efficiency 
allowed the authors to reduce the total amount of lipidoid material needed for therapeutic benefit, 
lowering potential toxicity, and also allowed them to knock down several genes in a single 
combined dose. 
In addition to nanomaterial composition, siRNA delivery efficacy in vivo can also depend 
heavily on the route of administration. Leconet et al., using commercially available reagents (the 
lipid-based Invivofectamine 2.0 and the polymeric JET-PEI), achieved transient knockdown in 
diabetic mice, with a single injection of siRNA/lipid-based carrier able to knock down a target 
gene for at least seven days in their system.274 In particular, they found that pancreatic immune 
cells were transfected with much greater efficacy after intraperitoneal injection compared with 
intravenous injection. All of these various factors, therefore--specific siRNA sequence and 
chemical modification, material composition, dose of siRNA and/or material, additives into the 
liposome, route of cellular entry, and route of in vivo administration--can each have enormous 
effects on RNAi mediated by lipid-based nanocarriers. 
The ability of lipid-based materials to stably encapsulate siRNA has led to their prolific 
use in ongoing clinical trials relative to other siRNA delivery technologies (for review, see 
Forbes and Peppas264). In particular, the decreased immunogenicity and enhanced in vivo 
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stability and shielding promoted by the PEG layers surrounding SNALPs has enabled multiple 
clinical trials involving SNALPs. Drug TKM-080301 sponsored by Tekmira Pharmaceuticals 
Corporation and Alnylam Pharmaceuticals is a SNALP containing siRNA targeting polo-like 
kinase-1 (PLK-1). This drug has completed a Phase I trial administered via hepatic arterial 
infusion for primary or secondary liver cancer, and is currently undergoing an additional Phase I 
trial targeting solid tumors via intravenous infusion.275, 276 SNALP-based siRNA drug ALN-
TTR01, also sponsored by Alnylam Pharmaceuticals, has completed a Phase I trial using siRNA 
targeting transthyretin in an effort to treat Transthyretin-Mediated Amyloidosis.277 Cationic lipid 
nanoparticle-based siRNA drug Atu027 sponsored by Silence Therapeutics AG has completed a 
dose-escalation, Phase I clinical trial to assess toxicity.278 These and other lipid-based siRNA 
delivery technologies represent the class of material nearest to reaching the clinic for siRNA 
delivery. 
Polymeric nanoparticles 
Although lipid-based nanoparticles have been historically more widely used for nucleic 
acid delivery, polymer-based nanoparticles are very promising newer class of materials for the 
delivery of nucleic acids and are an active subject of ongoing research. Because many of the 
polymers used for siRNA delivery were originally investigated as DNA delivery materials, many 
of them have gone through iterations of modification as various hurdles specific to siRNA 
delivery were discovered. Key classes of materials are described below, along with examples of 
the bottlenecks encountered and the strategies used to sidestep them. 
Poly(l-lysine)- and polyethylenimine-based materials 
PLL and PEI, as mentioned above, were early candidate materials for siRNA delivery, 
with PEI still used frequently in research today. Derivatives of both polymers continue to be 
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developed and optimized and are the basis of many of the polymeric systems being studied for 
siRNA delivery. Because PLL/nucleic acid complexes can be taken up by cells but cannot 
efficiently escape the endosome, Meyer et al. developed PLL- and PEI- based materials by 
conjugating the polycation to an endosomolytic mellitin peptide sequence modified with pH-
labile protecting groups (dimethylmaleic anhydride), which restrict the lytic activity of the 
peptide until they are cleaved at acidic pH.279 However, because the peptide was negatively 
charged and was necessary in high number for effective endosomal escape, this covalent 
modification destabilized the polymer/siRNA complex, precluding the formation of sufficiently 
small NPs for cell uptake. As a solution for this, the authors grafted PEG to the polycation before 
modification with the peptide, which increased the stability of the complex and caused gene 
knockdown in vitro in human neuroblastoma cells. 
Miyata et al. used a previously-developed280, 281 PEG-b-PLL copolymer to deliver nucleic 
acids.145 By modifying some of the lysine sidechains with thiol-containing functional groups, 
they could form micelles via electrostatic interactions with anionic DNA and then oxidize the 
complexes, forming disulfide bridges to stabilize the particles.145 This method was also effective 
for in vitro siRNA delivery to Huh7 human hepatoma cells, with ~80% knockdown seen after 
delivery of 100 nM siRNA to Huh7 cells in the presence of serum. Because of weaker binding 
seen in siRNA polyplexes compared with DNA polyplexes, the authors further modified their 
polymer with 2-iminothiolane to increase the cationic character and thus strengthen siRNA 
binding.144 Because of the difference in redox potential between the cytoplasm and extracellular 
environment, this system carries with it the advantage of quick siRNA release once in the desired 
cellular compartment. Further improvements on this system included the conjugation of cyclic 
RGD peptide to the PEG block, thereby providing a method to target tissues in vivo (Figure 
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2.9a).282 These siRNA-containing micelles accumulated in tumor tissue and the surrounding 
vasculature in a subcutaneous HeLa tumor model. Delivery of 24 g siRNA per mouse (~0.5-1 
mg/kg) against vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR-2) 
two times every four days for 12 days showed ~50% decreased in measured VEGF mRNA levels 
in the tumor and significantly slowed tumor growth (~60-70% smaller tumor volume after 12 
days compared to control) without apparent toxic side effects on the animal. Similar strategies 
have also been employed with PEI, using PEGylated siRNA against VEGF to form PEI-based 
micelles that caused VEGF knockdown in an in vivo PC-3 prostate cancer model.283 
With toxicity as a major problem limiting the use of PEI, forms of degradable PEI have 
been studied extensively for siRNA as well as DNA delivery. Breunig et al. linked low-
molecular weight linear PEI segments with disulfide bridges to form a bioreducible PEI.146 
Combining the efficacy of high-molecular PEI with the biocompatibility of shorter polymer 
chains, they delivered 100 nM siRNA in vitro to Chinese hamster ovary cells (CHO-K1) in 
serum-free medium and were able to achieve in vitro RNAi of green fluorescent protein (GFP) 
expression (~50% knockdown) that was comparable in efficacy to that of high-molecular weight 
branched PEI (bPEI) while being less cytotoxic. This design carried with it the additional benefit 
of targeted siRNA release into the cytoplasm, as disulfide bridges would be expected to be 
reduced to thiols. 
Other classes of polymers 
Also capitalizing on bioreducible linkages for targeted release, Jeong et al. described the 
use of a bioreducible PAA, designated SS-PAEI [poly(amido ethylenimine)], for siRNA 
delivery.148 Having found previously that SS-PAEI had higher buffering capacity than PEI,284 
they further demonstrated that their bioreducible polymer could cause significant knockdown of 
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vascular endothelial growth factor (VEGF) expression from human prostate cancer cells in vitro 
with 30 nM siRNA delivered in serum-free medium. Their polymer was more effective (up to 
~80% less mRNA expression) and less toxic than the linear PEI used as a comparison. Because 
there was not a significant increase in cellular uptake of SS-PAEI/siRNA particles compared to 
PEI/siRNA, the authors concluded that intracellular events, likely the disulfide reduction step, 
was the main reason for the increased efficacy. The siRNA binding efficiency of SS-PAEI is 
lower than that of PEI; therefore, SS-PAEI was copolymerized with a polymer block containing 
ethylene diamine.149 The increased amine content and therefore increased positive charge caused 
tighter siRNA binding and, at optimized ratios, better in vitro knockdown efficiency in human 
head and neck carcinoma cells (UM-SCC-14C) and non-small-cell lung carcinoma (H1299). 
Further optimization of this system included PEGylation by adding PEG-amine into the 
SS-PAEI synthesis, then mixing PEG-containing SS-PAEI with PEG-free SS-PAEI in order to 
improve particle stability in the presence of blood components like serum.285 However, while 
particles with higher PEG content were more stable against aggregation in serum or salt, they 
were also more easily dissociated in the presence of heparin, suggesting less stable binding 
interactions between siRNA and highly PEGylated polymers. Toxicity in erythrocytes as well as 
H1299 cells decreased with increasing PEG content, although this came at the cost of strongly 
compromised knockdown efficacy as well. 
 Similar to PAAs are poly(ester amine)s (PEAs) or poly(beta-amino ester)s (PBAEs), 
which are hydrolytically degradable through their ester groups. Initially studied primarily for 
DNA delivery, some early attempts to use PBAEs for siRNA delivery fell short without 
additionally conjugating siRNA to solid particles.286 As with other cationic polymers, this class 
of materials faced obstacles in polymer-siRNA binding efficiency and intracellular release. By 
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increasing the ratio of PBAE to siRNA (100:1 or greater PBAE:nucleic acid ratio by weight, 
compared to ~50:1 for DNA delivery), better particle formation and siRNA complexation was 
achieved, resulting in successful knockdown (~70%) in human umbilical vein endothelial cells 
when 60 nM siRNA was delivered in medium with 2% serum.141  
Other groups were able to show ~70% in vitro knockdown in hepatoma cells in serum-
free medium with lower PBAE:siRNA weight ratios when using PBAEs of similar chemical 
structure.287 Interestingly, the PBAE molecular weight reported was higher than that of the 
previous two studies cited and this may have enabled the increased efficacy at lower 
PBAE:siRNA weight ratios. Trends in PBAE structure with siRNA delivery efficacy have since 
been further examined,256 confirming the general trend of increasing knockdown efficacy with 
increasing PBAE molecular weight, as well as other polymer properties like hydrophobicity. 
This study also showed that the siRNA dose could be decreased by a factor of twelve (as low as 
5 nM) without negatively affecting the knockdown efficacy (~90% knockdown in serum-free 
medium) as long as the total polymer concentration was not altered. Transfection in 10% serum-
containing medium was lower (~70%), which the authors believed was due to some 
destabilization of the nanoparticles in the presence of serum proteins. In particular, this was 
observed with the top PBAEs in the study, most of which contained a primary amine terminal 
functional group that could be cleaved in a reducing environment. By utilizing disulfide bonds, 
this study and others9, 288 have found bioreducible linkages can be a key attribute for successful 
non-viral siRNA delivery. In another study, poly(ethylene oxide) (PEO)-b-PBAE NPs were 
made for siRNA delivery in combination with PEO-b-poly(-caprolactone) (PCL) NPs loaded 
with paclitaxel.213 This study showed successful knockdown of MDR-1, a cause of multiple drug 
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resistance in cancer cells, and consequently increased efficacy of a chemotherapeutic in vitro in 
SKOV3 ovarian cancer cells. 
The combination of PEGylation with disulfide linkages has also been applied to 
polypeptides, including KALA.147 Mok et al. conjugated PEG to siRNA via a disulfide bridge. 
Cysteine-containing KALA was then self-crosslinked to form a high-molecular weight, but 
bioreducible polymer, which electrostatically complexed with siRNA-PEG. This system was 
able to achieve nearly 50% gene knockdown in MDA-MB-435 melanoma cells, cultured in vitro 
in the presence of 10% serum with siRNA concentration of ~60 nM. 
 Woodrow et al. had an interesting finding while investigating the effectiveness of 
poly(lactic-co-glycolic acid) (PLGA) NPs at siRNA-mediated silencing in vivo.289 Although a 
positively-charged component, spermidine, was included in the encapsulation formulation, it was 
used as an excipient rather than as a primary delivery agent. The PLGA/siRNA NPs themselves 
were small enough for cellular internalization, and siRNA released over time from the particles 
could be isolated and delivered separately without loss of function. Using these particles, the 
authors delivered siRNA across the vaginal mucosal barrier and effected knockdown in cells in 
the vaginal tract. A major advantage of this system is the biocompatibility of PLGA and related 
polyesters, which have been used in a number of FDA-approved devices. In addition, being solid 
particles, this delivery system does not suffer from unstable binding interactions as do many 
polymeric electrostatic complexes. Researchers are interested in adding cationic materials, such 
as chitosan or the above spermidine, as part of PLGA-based NPs to increase siRNA loading into 
anionic PLGA NPs and increase knockdown efficacy.290 
A study by Zhou et al.291 provides an example of how several components can be 
combined in a NP design to incorporate many different functions and properties. The authors 
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used as its base material a PEG-grafted PLGA-b-PLL block copolymer previously developed for 
fabrication of surface-functionalized NPs.292, 293 DNA or siRNA was loaded into the NPs during 
synthesis, along with palmitoyl-avidin, allowing biotinylated peptides to be conjugated to the NP 
surface. In this way, the authors were able to design NPs containing polycations for nucleic acid 
complexation; PLGA as a biocompatible matrix; PEG to improve stability and circulation time; 
two encapsulated drugs to enhance delivery efficacy and siRNA processing; and three peptides 
to promote cellular uptake, endosomal escape, and tissue homing (Figure 2.10). While this type 
of drug delivery vehicle is more complex than some of the other examples described here, it 
provides flexibility in formulation and design details and was effective in vitro for ~91% 
knockdown in A549 lung cancer cells in culture medium.  
Other elegant polymer designs for siRNA delivery, including a multifunctional, 
cyclodextrin-based vehicle, have had successful siRNA delivery preclinical studies and have 
moved forward to clinical testing.294  This formulation, denoted CALAA-01, is a self-assembled 
complex of siRNA with a multi-component delivery vehicle, consisting of (i) a cyclodextrin-
containing polymer, which also contains positive charges for siRNA binding; (ii) adamantane-
conjugated PEG, with PEG added for particle stability and adamantine used to bind to 
cyclodextrin; and (iii) an adamantine-PEG-transferrin conjugate for targeting. This polymeric 
siRNA formulation, designed for good in vivo stability and site-specific delivery, is currently in a 
phase I trial. 
Inorganic NPs 
Calcium Phosphate 
Calcium phosphate (CaP) crystals were originally developed for DNA delivery and were 
fabricated by highly saturated solutions of DNA and CaP that resulted in spontaneous 
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coprecipitation.25-27 In an effort to limit the rapid and often difficult-to-control growth of CaP 
crystals, Kakisawa et al. developed an inorganic-organic NP hybrid for DNA delivery in which 
polyaspartate segments of polyaspartate-PEG block copolymers could adsorb onto the expanding 
crystal surface, thereby limiting continued growth.35 The PEG segments impart biocompatibility 
and particle stability.  
This NP formulation was eventually used for in vitro siRNA delivery to human 
embryonic kidney 293 cells and was able to achieve roughly 50% gene knockdown using a 125 
nM siRNA dose in serum-containing media.295 However, these particles required chloroquine for 
efficient endosomal escape, so the same researchers replaced polyaspartate with 
poly(methacrylic acid) (PMA), as PMA becomes more hydrophobic in pH 4-6 and could disrupt 
the endosomal membrane. To assess the siRNA delivery of this CaP-PMA-PEG system to 293 
cells in a more physiologically relevant way in vitro, the group incubated all siRNA transfection 
agents in serum-containing media for 30 min prior to transfection. They were able to show 
significantly lower toxicity than Lipofectamine™ 2000 and a significantly higher gene 
knockdown of 65% versus RNAifect™ at 42%.295  
siRNA loading into CaP based NPs was improved five-fold versus previously described 
systems by Zhang et al. via the covalent linkage of PEG to siRNA before precipitation with CaP. 
These NPs achieved roughly 60% gene knockdown in HeLa cells with 100 nM siRNA in serum-
containing media.296 
Gold 
 Gold-based nanoparticles (AuNPs) are attractive drug delivery candidates due to their 
low cytotoxicity,32 easily tunable physical properties,31 and readily functionalizable surface 
chemistry.28, 30, 297 Elbakry et al. used AuNPs and the ionic layer-by-layer (LbL)298 surface 
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modification process for siRNA delivery. These researchers took advantage of sulfur-gold 
binding to coat AuNPs with 11-mercaptoundecanoic acid (MUA), then used electrostatic 
interactions to coat the particles with a layer of PEI, followed by siRNA and another layer of 
PEI. In vitro delivery to CHO-K1 cells using 290 nM siRNA in serum-containing media resulted 
in approximately 80% knockdown.37 However, this particular NP formulation required a high 
siRNA dose most likely because it included no siRNA release mechanism. Cytoplasmically-
targeted siRNA release was achieved by Lee et al. in a AuNP formulation in which siRNA was 
attached to AuNPs via a PEG linker and bioreducible disulfide bonds, then coated with PBAEs. 
This formulation achieved near-complete gene knockdown in HeLa cells when a 90 nM dose of 
siRNA was delivered in serum-containing media.38 Giljohann et al. have also demonstrated 
transfection agent-free delivery of siRNA through the use of AuNPs densely functionalized with 
RNA oligonucleotides.299 In this study, ~100 nM of RNA duplex (3 nM AuNPs) caused 73% 
knockdown in HeLa cells. In an intriguing recent development, spherical nucleic acids, 
consisting of 13 nm AuNP cores and 30 siRNAs per particle densely functionalized around the 
surfaces, were able to penetrate skin and cause functional knockdown in hairless mice following 
topical treatment in vivo.300    
Silica  
As NP-based siRNA therapeutics are developed for clinical use, an important obstacle 
will be to create optimal dosing regimens, ideally those that minimize dosing frequency. 
Multistage release vectors were developed to address this issue by using nanosized lipid-based 
siRNA carriers loaded into micron sized, porous silicon particles.301 In an in vivo study of 
orthotopic mouse ovarian carcinoma, this systemic delivery system extended gene knockdown 
from a few days to more than three weeks and effectively reduced angiogenesis, cell 
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proliferation, and tumor burden. Another formulation was developed in which porous silicon 
nanoparticles were loaded with the chemotherapeutic doxorubicin and siRNA targeting a drug 
efflux transporter, and then coated with siRNA. In vitro delivery of these particles to multidrug-
resistant KB-V1 cells showed knockdown of the drug transporter, resulting in increased 
intracellular and intranuclear doxorubicin levels.302 
Quantum Dots 
Quantum dots (QDs) are inorganic semiconductor nanoparticles and can be used as 
fluorophores. QDs with easily tunable emission properties, such as CdSe/ZnS nanoparticles, are 
promising candidates for imaging purposes in that they are brighter,34, 303 less susceptible to 
photobleaching,33 are easier to detect amongst in vivo  background fluorescence versus most 
fluorescent dyes,34 and are able to be made biocompatible enough to be used with cells.304, 305 
Chen et al. first codelivered siRNA and QDs in order to trace the delivered siRNA in vitro.306 
This concept was extended to make QDs part of the delivery system itself by Derfus et al., in 
which QDs were covalently modified with PEG, siRNA, and a tumor homing peptide (F3) to 
deliver siRNA to HeLa cells.36 They were able to show that cell uptake was facilitated by F3 
conjugation, and the NPs achieved approximately 30% gene knockdown in serum conditions 
with a 50 nM dose of siRNA. Although the NPs could not improve upon the knockdown 
achieved by Lipofectamine™ 2000, this delivery system showed an exciting proof-of-concept 
for a method to deliver and specifically track siRNA molecules using QDs. 
Engineered RNA-based NPs 
 As gene knockdown via direct delivery of siRNA is a transient, dose-dependent process, 
siRNA loading into the delivery system is critical for complete and long-lasting gene 
suppression. Delivery systems in which siRNA is conjugated directly to a biomaterial or in 
 50 
which engineered RNA is the delivery material itself present exciting strategies to maximize 
loading. An example of increased loading was examined earlier in this review when siRNA was 
directly conjugated to PEG and coprecipitated with CaP to improve siRNA loading five-fold.296 
Additionally, particle stability can be enhanced with the use of multimeric siRNAs, a class of 
material created by either covalently or noncovalently linking siRNA molecules. These 
multimeric siRNAs promote multivalent biomaterial-nucleic acid interactions similar to those 
seen with plasmid DNA, resulting in improved NP stability with RNA. Strategies for modifying 
siRNA while maintaining its biological activity are discussed below. 
siRNA Conjugates 
 Important considerations for chemically modifying siRNA include assuring that the 
modification will not interfere with RNAi,307 and, for modifications where multiple siRNAs are 
attached to each other, that the long chain of RNA will not induce an IFN response.219 Singh et 
al. examined the former issue using the PEGylated siRNA-QD conjugates described earlier in 
this review. The authors found that decreasing the length of the siRNA-QD linker resulted in less 
RNAi, while lengthening this linker promoted more RNAi. They also found that the site of 
conjugation on the siRNA molecule, 5’ versus 3’, sense versus antisense, did not seem to effect 
RNAi.308 These results confirmed what an earlier study had concluded with conjugation to 
magnetic NPs.309 
 Another investigation into PEG-siRNA conjugation utilized a disulfide linker and formed 
NPs using PEG-siRNA and PEI. These NPs were able to achieve 80% and 96.5% gene 
knockdown in serum and serum-free conditions, respectively, in human prostate carcinoma PC-3 
cells using a 100 nM siRNA dose.310 The same material in an in vivo study using subcutaneous 
PC-3 tumors and IV injection of NPs with 1.5 nmol VEGF-targeting siRNA showed 86 ± 4% 
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decreased VEGF expression, resulting in a 78 ± 9% reduction in microvessel formation and a 
ten-fold decrease in tumor volume.283 
An alternative siRNA conjugation strategy involves conjugating the 3’ end of the sense 
strand of siRNA to cholesterol. Such a system can cause 50% knockdown in HeLa cells with a 
~200 nM siRNA dose without using any additional transfection agent or nanoparticle.311 
Cholesterol-siRNA, but not unmodified siRNA, has improved pharmacokinetic properties and 
can mediate knockdown in mice following i.v. administration. Other lipophilic modifications to 
siRNA can also enhance in vivo knockdown.312 
Multimeric siRNA  
 While most strategies focus on tuning vector material properties to make DNA delivery 
vehicles work for siRNA delivery, another approach is to adjust the siRNA itself to make it 
physically more like DNA. Multimeric siRNA allows for increased multivalent interactions in 
addition to lending the geometric flexibility that is favorable for higher affinity binding. An 
interesting method to form multimeric siRNA was introduced by Bolcato-Bellemin et al. in 
which they synthesized siRNA strands with 5-8 bp overhangs to yield “sticky siRNA ends” that 
would reversibly concatemerize to form long repeats of siRNA.313 When delivered with linear 
PEI to A549 human lung carcinoma cells in serum-free conditions, these NPs achieved 80% 
gene knockdown with 50 nM siRNA and 70% knockdown with as little as 20 nM siRNA. The 
authors also showed that this material triggered no IFN response. This concept was later 
expanded upon by covalently linking siRNA strands with either a bioreducible or non-degrading 
linkage.314 When complexed with linear PEI, both the cleavable and non-cleavable siRNA NPs 
achieved near complete gene knockdown in PC3 cells with a 90 nM siRNA dose in serum-free 
conditions. However, when using rapid amplification of cDNA ends to look for the specific 
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cleaved target mRNA, the authors only found a significant concentration of the expected 
fragment in the samples treated with the disulfide-linked siRNA.  
A unique method to create an siRNA-based material was recently suggested by Lee et 
al.315 The group employed rolling circle transcription316 to make connected repeats of hairpin 
RNAs, which then crystallized into growing sheets to eventually form microsponges. From these 
microsponges, micron-sized, spherical particles could be pinched off and coated with bPEI to 
compact them into roughly 200 nm sized particles. These particles achieved such incredibly high 
siRNA loading that the authors were able to show comparable knockdown to commercially 
available siRNA delivery systems using three orders of magnitude fewer particles. In vitro 
delivery of these particles to T22 cells achieved nearly 60% knockdown with 100 nM siRNA, 
and an in vivo intratumoral injection to T22 cells showed significant gene knockdown at 4 days 
post-transfection. 
An additional class of three-dimensional nucleic acid-only structures for RNA delivery 
are polyvalent nucleic acid nanostructures. These have been synthesized by Chad Mirkin and his 
research group by constructing intra-crosslinked spherical nucleic acids with an inorganic 
nanoparticle core and then subsequent dissolution of this core.317 These polyvalent nucleic acid 
nanostructures share many of the characteristics of spherical nucleic acids including being able 
to cause comparable efficient gene knockdown.   
2.2.4. Conclusion  
Despite its clinical potential, use of siRNA as a therapeutic has been hampered by a lack 
of effective and safe methods of delivery. Many different materials have been explored in the 
laboratory, with some, mostly lipid-based, having been translated to the clinic in early-phase 
trials. It is important to note, however, that both the siRNA molecule itself and also the delivery 
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vehicle can have off-target effects that may confound results and affect the translation of this 
technology.  
As each biomaterial is developed, challenges in siRNA delivery are illuminated, aiding in 
the design of improved carrier NPs. New biomaterials have now been developed to fit the 
chemistry, biophysical structure, and biological function of siRNA. Many research groups are 
exploiting the benefits of increased siRNA binding affinity, for example, by increasing the 
positive charge of a biomaterial or by synthesizing multimeric siRNA molecules, to improve 
stability and delivery efficacy. Similarly, other researchers are investigating triggered release 
properties, such as disulfide bonds to cause siRNA release upon entering the cytoplasm, to 
improve delivery efficacy and reduce cytotoxicity. These next-generation materials have shown 
promise in the laboratory both in vitro and in vivo. As better ways for siRNA delivery are 
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Figure 2.1. Major barriers to nucleic acid delivery using nanoparticles include stable particle 
formation, systemic circulation, tissue and cell targeting, cellular uptake, endosomal escape, and 
release of nucleic acid. Reprinted by permission from Macmillan Publishers Ltd: Nature reviews. 




Figure 2.2. Commonly used chemical moieties for the creation of degradable polymers. 
Chemicals listed above the reaction scheme arrow indicate those necessary for the reaction, 





















































































Figure 2.4. Large libraries of PBAEs can be generated by combining different acrylate and amine-
containing monomers (A). DNA-containing nanoparticles can be lyophilized and stored prior to in 
vivo administration (B). PBAE DNA nanoparticles selectively transfect tumor cells while avoiding 
healthy tissue (C). Reprinted with permission from ACS Nano. 2014, 8, 5141-5153, copyright 2014 
American Chemical Society.96   
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Figure 2.5. (A) The formulation of CALAA-01, a cyclodextrin containing nanoparticle for RRM2 
RNAi tested in FDA phase I clinical trials (B) mRNA and protein levels of RRM2 in the targeted 
tissue of one patient (C) RRM2 staining (red) of  human tumor tissue comparing tissue from before 
and after systemic administration of CALAA-01. . Reprinted by permission from Nature 
Publishing Group: Nature. 2010, 464, 1067-70, copyright 2010.203 
  
A 




Figure 2.6. siRNA faces several barriers during intracellular delivery. Representative biomaterials 
that are able to overcome these barriers are shown above, along with the particular strategy 









Figure 2.8. Various approaches have been taken to lipid-based siRNA delivery. While some 
groups use rational design and focus on specific delivery aspects, such as lipid polymorphism 
leading to membrane fusion (A), others have employed high-throughput methods to screen through 
a wide array of different molecules to empirically determine the best structures (B-C). Reprinted 
by permission from Macmillan Publishers Ltd: Nature Biotechnology,266, 318 copyright (2010) (A) 
and copyright (2008) (B-C). 
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Figure 2.9. Widely-used approaches to improving polymeric siRNA delivery include 
conjugation to PEG and targeting ligands (A) and introduction of disulfide bridges for controlled 
cytoplasmic release (B). Part A reprinted with permission from Christie, R. J.; Matsumoto, 
Y.; Miyata, K.; Nomoto, T.; Fukushima, S.; Osada, K.; Halnaut, J.; Pittella, F.; Kim, H. J.; 
Nishiyama, N.; Kataoka, K.: Targeted Polymeric Micelles for siRNA Treatment of Experimental 
Cancer by Intravenous Injection. ACS Nano 2012, 6, 5174-5189.282 Copyright (2012) American 
Chemical Society. Part B reprinted from Journal of Controlled Release, 150/2, van der Aa et al, 
Optimization of poly(amido amine)s as vectors for siRNA delivery, 177-186,150 Copyright 





Figure 2.10. PLGA-b-PLL-g-PEG NPs contain siRNA, two drugs, and three ligands for 
targeting, cell penetration, and trafficking. Reprinted from Biomaterials, 33/2, Zhou et al, Octa-
functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors, 177-186,291 
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Glioblastoma (GB) remains one of the most lethal cancers in humans with a median 
survival after maximal therapy of less than 2 years after first diagnosis.1-3 Despite improvements 
in the past few decades with intraoperative surgical techniques, chemotherapy, and radiation 
therapy, predictable curative treatment for GB does not exist yet. New insights into specific gene 
mutations and dysregulated signaling pathways of the pathogenesis of brain tumors4, 5 have 
highlighted gene therapy as a potential approach for the treatment of GB. This approach is based 
on the local delivery of a vector or nanoparticle carrying genetic material to cause 
overexpression of a gene or replace a gene that is missing or under-expressed in order to kill 
cancer cells.6  
Approaches to gene therapy for GB include: (1) delivery of suicide genes, which convert 
pro-drugs in situ and cause tumor cell death;7 (2) delivery of cytokine genes, which mobilize 
immune cells to fight the tumor;8, 9 (3) delivery of tumor-suppressor genes, which induce 
apoptosis in tumor cells;10, 11 and (4) delivery of conditionally-replicating viruses to specifically 
lyse tumor cells while sparing normal tissue.12, 13 Gene therapy has most often been performed 
using viral carriers. However, viruses pose significant safety risks due to their inherent toxicity, 
immunogenicity, and tumorigenicity.14 
                                                     
This chapter contains material modified from the following article, previously published as: 
Mangraviti, A.;* Tzeng, S.Y.;* Kozielski, K.L.;* Wang, Y.;* Pedone, M.; Buaron, N.; Liu, A.; Wilson, D.R.; 
Hansen, S.K.; Rodriguez, F.J.; Gao, G.; DiMeco, F.; Brem, H.; Olivi, A.; Tyler, B.; Green, J.J.: Polymeric 
nanoparticles for non-viral gene therapy extend brain tumor survival in vivo. ACS Nano 2015, 9, 1236-1249. 
(*These authors contributed equally) 
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Non-viral gene delivery vectors have traditionally been unable to match the efficacy of 
viral gene delivery;15 however, they can be engineered to avoid the risks that viruses pose. Non-
viral methods of gene delivery have recently expanded and several effective nanomaterials exist 
including lipid-based,16, 17 polymeric,18-20 and inorganic21-23 nanoparticles, some of which have 
reached clinical trials.24 Successful DNA delivery can be achieved by designing materials that 
can overcome extra- and intracellular barriers.25-28  Cationic, primary amine-containing polymers 
such as poly(L-lysine) (PLL) can bind anionic DNA and compact it into positively charged 
nanoparticles. This protects the DNA and promotes cellular uptake via the electrostatic 
interaction between the cationic nanoparticle and anionic cell surface.28, 29 Tertiary amine-
containing polymers with high buffering capacities, such as poly(ethyleneimine) (PEI), enable 
endocytosis and are then able to escape the endosome via the proton sponge mechanism.29 DNA 
release can be achieved by hydrolytic polymer degradation in the cytoplasm of the cell following 
escape from the endosome. Poly(-amino ester)s (PBAEs) are a class of polymers that can be 
engineered to contain primary, secondary, and tertiary amines and hydrolytically cleavable ester 
bonds.30 These chemical properties enable effective DNA binding, endocytosis, endosomal 
escape, and intracellular DNA release within minutes to hours, all of which are prerequisite to 
nuclear uptake of the DNA31-33 PBAEs have previously been shown to be safe and effective 
DNA delivery vectors in vitro to several cell types and in vivo to retinal and brain tumor tissue.32-
34  
In previous studies, we have also shown that these polymers degrade quickly under 
physiological conditions, with a half-life of only a few hours.35 We believe that this is important 
both to minimize potential nanoparticle cytotoxicity as well as to ensure successful release of the 
DNA cargo.35 Interestingly, PBAEs can also be engineered to exhibit cell-type specificity and to 
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selectively transfect tumor tissue while avoiding surrounding healthy tissue.34, 36  These 
advantages make this class of polymers a promising option to use for the fabrication of 
polymeric gene delivery nanoparticles for the treatment of brain tumors. Convection-enhanced 
delivery (CED) has recently been shown to be effective for the delivery of polymeric 
nanoparticles encapsulating small molecule drugs, such as dithiazanine iodide, Doxil, and O6-
benzylguanine , to brain tumors.37-39 Moreover, CED and gene therapy have been suggested as a 
promising combination for the treatment of glioma.40 Specifically, CED leads to better volume of 
distribution by maintaining a pressure gradient which enhances diffusion throughout the tumor 
mass.41 We hypothesized that intratumoral infusion via CED may represent an effective 
approach for the delivery of PBAE/DNA nanoparticles, as they are “soft” nanocomplexes which 
can be deformed and may more easily be convected though small spaces while encapsulating 
large DNA molecules.  
  The present study investigates the efficacy of PBAE nanoparticles for the intracellular 
delivery of the herpes simplex virus (HSV)-derived enzyme thymidine kinase (HSVtk), which 
acts as a suicide gene in an aggressive gliosarcoma model. Suicide therapy is based on the 
systemic delivery of an inactive prodrug with tumor-specific expression of a drug-activating 
enzyme (the suicide gene)42 in order to avoid toxicity in normal cells. The HSVtk-ganciclovir 
system has been previously used for gene therapy in several viral approaches such as with non-
replicating herpes virus or adenovirus.43-45  HSVtk catalyzes the phosphorylation of the cytotoxic 
nucleoside analogue ganciclovir (GCV) that can be incorporated into the DNA of actively 
proliferating cells, which disrupts DNA replication and halts cell division.46, 47 Since the prodrug 
nucleosides are poor substrates for mammalian thymidine kinase, the toxic effect is initially 
restricted to cancer cells, as active GCV kills proliferating cells only.48 An attractive aspect of 
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the HSVtk/GCV enzyme/prodrug system is that this therapy benefits from the phenomenon 
known as “bystander effect”, whereby even cancer cells that do not express HSVtk become 
sensitive to GCV due to the activation of GCV in neighboring transfected cancer cells.49, 50 
 This work presents a biodegradable nanomedicine capable of effectively and selectively 
delivering DNA to malignant glioma in vivo. A library of PBAE nanoparticles was evaluated in 
vitro to optimize DNA delivery while minimizing toxicity. The optimal nanoparticle formulation 
was then physically characterized. We demonstrate that these nanoparticles can deliver an 
HSVtk transgene in vitro and initiate glioma cell killing via the local activation of GCV. We also 
demonstrate transfection of malignant gliomas in vivo. Using this nanoparticle-based therapy, we 
were able to statistically improve survival of rats with malignant glioma (Scheme 1). This work 
presents an exciting frontier in nanomedicine with significant potential to treat malignant 
gliomas.  
 
3.2. Materials and methods 
3.2.1. Polymer materials 
 Monomers used for polymer synthesis were purchased as follows: 1,4-butanediol 
diacrylate (B4; Alfa Aesar, Ward Hill, MA); 1,5-pentanediol diacrylate (B5; Monomer-Polymer 
and Dajac Laboratories, Trevose, PA); 3-amino-1-propanol (S3; Alfa Aesar); 4-amino-1-butanol 
(S4; Alfa Aesar); 5-amino-1-pentanol (S5; Alfa Aesar); pentane-1,3-diamine (E3; TCI America); 
2-(3-aminopropylamino)ethanol (E6; Sigma-Aldrich); 1-(3-aminopropyl)-4-methylpiperazine 
(E7; Alfa Aesar). Lipofectamine® 2000 was purchased from Invitrogen (Carlsbad, CA) and used 
according to manufacturer’s instructions. The pEGFP-N1 plasmid (GFP) was purchased from 
Elim Biopharmaceuticals and amplified by Aldevron (Fargo, ND). Herpes simplex virus type 1-
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derived thymidine kinase (HSVtk) gene was cloned into the pcDNA3.1 vector (Life 
Technologies) according to the manufacturer's protocols.  Label IT® Tracker Cy5 Kit was 
purchased from Mirus Bio (Madison, WI). For staining, 2-(4-amidinophenyl)-1H -indole-6-
carboxamidine (DAPI) was purchased from Life Technologies, propidium iodide (PI) was 
purchased from Invitrogen (Carlsbad, CA), the conjugated antibody anti-Ki67 Alexa Fluor® 647 
(rabbit anti-rat 1:50) was purchased from Cell Signaling Technology (Beverly, MA). CellTiter 
96® AQueous One MTS assay was purchased from Promega (Fitchburg, WI). Ganciclovir was 
purchased from both Invivogen (San Diego, CA) and Euroasian Chemicals PVT LTD (Lower 
Parel, Mumbai, India). 
3.2.2. Polymer synthesis  
 PBAEs were synthesized using a two-step reaction (Figure 1) in a manner similar to 
Bhise et al.51 Base monomers B4, B5, or B6 were each polymerized by Michael Addition of one 
of the side chain monomers S3, S4, or S5 at ratios following Table S1, for 24 h at 90°C in the 
absence of solvent. Monomer acrylate-to-amine molar ratios used for synthesis ranged from 
1.2:1 to 1.05:1.  For the second step of synthesis, the diacrylate-terminated base polymers (B-S) 
were dissolved in anhydrous tetrahydrofuran (THF, Sigma) at 100 mg/mL and combined with 
0.2 M amine-containing small molecules (E3, E6, or E7) as polymer endcapping groups. The 
reaction was conducted for 1 h at room temperature while shaking. Polymers were then purified 
to remove excess monomer via precipitation in diethyl ether. The ether was decanted to collect 
polymer, the polymer was washed again with ether, the ether was decanted, and then the polymer 
was allowed to dry under vacuum for 48 h. The neat polymers were then dissolved in dimethyl 
sulfoxide (DMSO) at 100 mg/mL and stored at -20°C in small aliquots to limit freeze-thaw 
cycles. The molecular weight and polydispersities of the polymers were determined by gel 
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permeation chromatography (GPC; Waters, Milford, MA) in BHT-stabilized tetrahydrofuran 
with 5% DMSO and 1% piperidine.  Number-averaged and weight-averaged molecular weights 
(Mn and Mw, respectively) were measured using polystyrene standards (Table S1). Purity of the 
leading polymer, 1-(3-aminopropyl)-4-methylpiperazine end-modified poly(1,4-butanediol 
diacrylate-co-4-amino-1-butanol) (447), was confirmed by 1H NMR spectra (Figure S1).  
3.2.3. Preparation of Cy5-labeled DNA 
GFP DNA was labeled with Cy5 using the Label IT® Tracker Cy5 Kit following 
manufacturer instructions.  The amount of Cy5 labeling was measured to be approximately one 
dye molecule per 205 base pairs.  
3.2.4. Cell culture  
F98 glioma cells were provided from R. Barth (Ohio State University, Columbus, OH) 
and the 9L gliosarcoma line was obtained from the Brain Tumor Research Center (University of 
California, San Francisco, CA).  Cells were grown in high glucose Dulbecco’s modified Eagle’s 
medium (DMEM; Gibco® Life Technologies, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS; Sigma-Aldrich), 0.8 mM L-glutamine, and 1% penicillin-streptomycin 
(Gibco® Life Technologies, Carlsbad, CA). Cells were cultured at 37°C in a humidified 
incubator with 5% CO2.  
3.2.5 In vitro DNA delivery to rat glioma cells 
In vitro DNA delivery to glioma cells utilizing PBAE nanoparticles  
 One day prior to transfection, 9L and F98 cells were plated in 96-well cell culture plates 
at a cell density of 10,000 cells/well in 100 L of complete medium, and allowed to adhere at 37 
°C overnight. For nanoparticle preparation, following previously reported protocols,34, 51 GFP 
DNA was diluted to 60 μg/mL in 25 mM sodium acetate pH 5 buffer (NaAc). PBAEs were 
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diluted from their stock solutions in DMSO in 25 mM NaAc and added to DNA solutions at 
PBAE/DNA mass ratios (w/w) of 30, 60, or 90. Polymers were added to DNA 1:1 (v/v), mixed 
via pipetting, and incubated at room temperature for 10 min to allow for self-assembly, which 
has previously been shown to be sufficient time for DNA binding to the polymer.52 
Nanoparticles (20 μL) in NaAc were added directly to the cells that were in 100 μL/well of cell 
culture medium in 96-well plates (final DNA concentration of 600 ng/well).  Nanoparticles were 
incubated with the cells for 2 h at 37 °C, after which the media was removed and replaced with 
fresh, complete media. Four replicates were evaluated for each transfection condition. For 
lyophilized nanoparticle formation and evaluation (Figure 4), nanoparticles were initially 
formed as described above, including allowing 10 min for self-assembly. Subsequently, D-
sucrose was added as a cyroprotectant to a final concentration of 30 mg/mL sucrose, the 
nanoparticles were frozen at -80 °C, and they were lyophilized as we have recently described.53  
Lyophilized nanoparticles were stored at −20 °C until use and were then reconstituted in sterile 
water and used at the same concentration as freshly prepared nanoparticles.  
Evaluation of transfection by flow cytometry and fluorescence microscopy 
 Transfection efficacy was evaluated by measuring the percentage of cells expressing the 
exogenously delivered GFP DNA. Fluorescence microscopy images were obtained using a Zeiss 
Axio observer A1 microscope with a Zeiss Axiocam MRm camera using AxioVision Release 
4.8.2 software.  Transfection efficacy was evaluated by microscopy after 48 hrs at 5X 
magnification. 
Flow cytometry was completed 48 h following transfection using an Intellicyt high-
throughput autosampler attached to an BD Accuri™ C6 flow cytometer (emission filter: 530/30 
nm). Hypercyt software was used to assign events to each well and FlowJo 7 software (Treestar) 
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was used to analyze the flow cytometry results. Plates were prepared for flow cytometry by 
trypsinization using 30 L of 0.05% Trypsin-EDTA, followed by addition of 170 L of a 
solution of 2% FBS in PBS. Samples were transferred to round bottom 96-well plates, 
centrifuged, and 170 L of volume was removed. Cells were then resusupended via pipetting and 
loaded onto the Hypercyt autosampler.  
Measurement of cytotoxicity 
 Non-specific cell toxicity was defined as the loss of metabolic activity in each well 
following transfection. Cell toxicity was determined at 24 h post-transfection using a CellTiter 
96® AQueous One MTS assay following manufacturer’s instructions. A BioTek® Synergy™ 2 
Microplate Reader was used to read absorbance at 490 nm, and cell toxicity was determined by 
normalizing the metabolic activity values of treated wells to untreated wells.   
3.2.5. Evaluation of HSVtk/GCV-induced cytotoxicity in 9L and F98 glioma cell lines 
 Cells were transfected as described above using polymer 447 at 30 w/w, using either HSVtk 
or GFP DNA (n=4). GCV was added to the cell culture medium at 24 h post-transfection at 
concentrations from 0 to 50 g/mL and replenished every two days. At five days post-transfection, 
cells were stained with PI, fixed, and then stained with DAPI. Each well was photographed at 5X 
magnification to capture PI and DAPI fluorescence as well as a brightfield image using a Zeiss 
Axio observer A1 microscope with a Zeiss Axiocam MRm camera using AxioVision Release 4.8.2 
software. Cells positive for PI and/or DAPI were counted using ImageJ v1.47 software. PI cell 
counts were subtracted from DAPI cell counts to remove dead cells from the total cell count, and 
then the total cell count of each well was normalized to that of untreated wells.  
3.2.6. Nanoparticle Physical Characterization 
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 The hydrodynamic radius and zeta-potential of the leading nanoparticle formulation, 447 
30 w/w, was determined via dynamic light scattering (DLS) using a Malvern Zetasizer NanoZS 
(Malvern Instruments, Malvern, U.K). Fresh and lyophilized nanoparticles were formed as 
previously described for transfection, and then diluted into PBS at a 1:6 v/v dilution in order to 
better approximate the physiological salt concentration and pH that particles would experience in 
cell culture or in an organism. To measure particle size, the intensity-weighted Z-average of the 
particle diameter is reported in nm. Zeta potentials were analyzed using the Smoluchowski model 
and average electrophoretic mobilities were measured at 25 °C at pH 7.4. 
 Transmission electron microscopy (TEM) was used to image 447 30 w/w nanoparticles 
using a Philips/FEI BioTwin CM120 transmission electron microscope. Nanoparticles were 
formed as described for transfection, and 5 L of the nanoparticle solution was loaded onto a 
carbon-coated copper TEM grid and allowed to dry completely prior to imaging. 
3.2.7. In vivo modeling of rat glioma 
Animals 
Female F344 rats, weighing 125-175 g each (Harlan Bioproducts, Indiana, IN), were 
housed in standard facilities and were provided with ad libitum access to food and water. The 
policies and guidelines of the Johns Hopkins University Animal Care and Use Committee were 
strictly followed throughout the study.  
Tumor implantation 
F344 rats were intracranially implanted with 9L gliosarcoma, which was maintained and 
passaged every 2-3 weeks. For surgical intracranial implantation, the tumor was removed from the 
carrier animal, cut into 2-mm3 pieces, and placed in sterile 0.9% saline on ice as previously 
described.54  Rats were anesthetized with an intraperitoneal injection of 3-5 mL/kg of a stock 
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solution containing ketamine HCl (75 mg/kg; 100 mg/ml), xylazine (7.5 mg/kg; 100 mg/ml), and 
ethanol (14.25%) in sterile 0.9% NaCl.  For the orthotopic tumor inoculation, the head was shaved 
and prepared with alcohol and Prepodyne solution (DeLaval, Inc.). In order to expose the sagittal 
and coronal sutures, a midline scalp incision was made. A small hole was made using an electric 
drill in the skull centered 3 mm lateral to the sagittal suture and 5 mm posterior to the coronal 
suture. The superior sagittal sinus was carefully avoided. Under microscopic magnification, a dural 
opening and then a cortical opening were made. A small area of cortex and white matter was 
resected. Once hemostasis was achieved, a single tumor piece (2 mm3) was placed into the 
resection cavity. The skin was then closed with surgical staples. All surgical procedures were 
performed using standard sterile surgical technique.  
3.2.8. In vivo delivery of cancer-killing therapy via nanoparticles 
In vivo nanoparticle administration 
Under full anesthesia, six days after tumor inoculation, the original incision was opened and the 
original burr hole was located. For Convection-Enhanced Delivery (CED), a 25-gauge needle 
was stereotactically placed at a depth of 3 mm into the rat striatum. The infusion was performed 
using an UltraMicroPump (UMP3) with SYS-Micro4 Controller (World Precision Instruments, 
Inc., Sarasota, FL, USA) at a rate of 1 μL/min for 25 min. After the injection the needle was 
maintained in the cortex for another 5 min to avoid backflow. Following needle removal the 
incision was stapled and the animal was allowed to awaken and recover. Bolus administration 
delivered the same volume of nanoparticles by manual injection as previously described.54  
Throughout the study three types of DNA were complexed with 447 30 w/w to form 
nanoparticles and used in vivo in lyophilized form: (1) GFP, (2) Cy5-labeled GFP, and (3) 
HSVtk. The nanoparticles were stored in -20°C and were resuspended in water prior to injection. 
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The particles were injected both by bolus (manual injection) or infused by CED.  The two 
methods of nanoparticle administration were compared using 12 tumor-bearing rats infused with 
PBAE/GFPs 6 days after tumor implantation. The animals were euthanized at 24 h post-infusion 
and the brains were fixed in formalin for imaging. The efficacy study was performed using CED 
In vivo safety studies   
The safety of intracranial injection of PBAEs was evaluated. PBAE 447/GFP DNA nanoparticles 
(26 µg DNA/780 µg polymer) were infused in a volume of 25 µL using CED in six wild type 
healthy rats and three 9L tumor-bearing rats for a total number of 9 rats. All rats were observed 
daily for any signs of neurotoxicity. Three animals from each group were euthanized 3 days after 
nanoparticle infusion, while the remaining non-tumor-bearing animals were observed for 60 days 
after nanoparticle infusion and then euthanized. Subsequently, their brains were harvested and 
placed in formalin for histopathological analysis. Specifically, the brains were cut in 3 slices of 2 
mm: one centered on the site of the injection and the other two centered 2 mm anteriorly and 
posteriorly from it.  
The safety of systemically injected ganciclovir was assessed in 6 rats for 10 days: 3 rats 
were treated with intraperitoneal administration of 50 mg/kg once a day and the other 3 with 50 
mg/kg twice a day for 10 days. Rats were evaluated daily for signs of pain and distress, including 
ruffled fur, dehydration, hunched position, weakness, lethargy, immobility, lack of coordination, 
labored respiration, or cyanosis according to the Johns Hopkins Animal Care and Use 
Guidelines. At the end of the study the brains were fixed, sectioned and processed for light 
microscopic analysis to determine histopathology and to evaluate tissue damage. 
Efficacy studies 
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For intracranial implantation, 48 F344 rats (24 rats for the first study and 24 for the second) were 
anesthetized and received tumor as described above. Six days after tumor implantation, when 
tumor area was approximately 2×3 mm, the rats were randomized into the following groups: 
Control group, which received an intracranial infusion of 25 µL of saline by CED (n=16); GCV 
group which received intraperitoneal administration of 50 mg/kg of GCV twice a day (n=8); NP-
GFP + GCV group, which received intracranial infusion of  PBAE/GFP nanoparticles plus 
intraperitoneal administration of GCV (n=8); DNA + GCV group, which received intracranial 
infusion of HSVtk DNA plus intraperitoneal administration of GCV (n= 8); and the NP-HSVtk + 
GCV group, which received intracranial infusion of PBAE/HSVtk nanoparticles plus 
intraperitoneal administration of  GCV (n= 8).  
GCV was administered for 10 days, from Day 4 to Day 13, i.e. starting 4 days after tumor 
implantation and 2 days before PBAE/HSVtk infusion due to the aggressive nature of the 9L 
glioma, as described previously.48 The animals were monitored daily and assessed for 
neurological impairment. The animals were perfused as they became moribund and brains were 
placed in formalin for histological analysis. 
3.2.9. Histological analysis of therapeutic efficacy of nanoparticle drug delivery 
Brain imaging 
Immunofluorescence staining of the in vivo transfection was assessed. A total of 6 rats were used 
for imaging in vivo transfection 24 hr post-infusion via CED. Animals were infused at 6 days 
after tumor implantation with Cy5-labeled GFP DNA using the DNA/polymer ratio used for the 
efficacy study. A comparison of nanoparticle delivery via bolus injection and CED infusion was 
subsequently conducted. The image analysis was performed with ImageJ as previously 
described55  and the whole tumor was considered as the region of interest (ROI). The boundaries 
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of the tumor area were determined by a neuropathologist via blind analysis of H&E and DAPI 
stained slides. The corrected total cell fluorescence (CTCF) intensity of the whole tumor area, 
both after CED infusion and after bolus injection was compared and calculated as follows: 
integrated density - (area of selected cell × mean fluorescence of background readings), 
normalized by the number of pixels in the tumor area.  To evaluate PBAE distribution between 
the two administration methods and how this might affect transfection efficacy, 12 9L tumor-
bearing rats were divided into two groups: a CED group (n=6) and an intracranial bolus injection 
group (n=6). Cy5 labeled GFP-nanoparticles were infused via CED infusion or bolus injection 
on Day 6 and the rats were sacrificed 24 hr later. The animals were anesthetized and perfused 
with 0.1 M phosphate-buffered saline (PBS), followed by 4% paraformaldehyde in 0.1 M PBS 
solution. The brain was immediately removed from the skull and transferred to 4% 
paraformaldehyde at 4°C for 24 hours.  
Immunohistochemistry 
The brains, fixed in 4% paraformaldehyde at 4°C for at least 24 hr, were cryoprotected by 
sinking in 30% sucrose in 0.1 M PBS for 3 days and then embedded in Optimal Cutting 
Temperature compound (OCT) compound. Cryosection slides were prepared at 10 m using a 
Leica CM1905 cryostat. The slices were imaged to assess transfection by confocal laser scanning 
microscope (Leica TCS SP5 Microsystems) and captured with Axiovision software (Axiovision 
Rel 4.9).   
3.2.10. Data analysis and statistical methods 
Transfection efficacy of PBAE nanoparticles was compared to Lipofectamine® 2000 using One-
way ANOVA and Dunnett posttests (GraphPad Prism 5.0).  Comparisons of fresh and 
lyophilized nanoparticles were conducted using two-tailed t-tests (GraphPad Prism 5.0).  The 
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statistical analysis for survival was completed using Kaplan-Meier survival plots (GraphPad 
Prism 5.0), and the survival curves were compared using the Log-rank (Mantel-Cox) test. p<0.05 
was considered statistically significant in all cases.   
 
3.3 Results and Discussion 
3.3.1. PBAE-Based Nanoparticles Show High in Vitro Gene Delivery to Glioma Cells 
 A library of poly(β-amino ester)s (PBAEs) was synthesized following methods that we 
have previously described.31 Briefly, base monomers 1,4-butanediol diacrylate (B4) or 1,5-
pentanediol diacrylate (B5) were polymerized via a Michael Addition reaction with side chain 
monomers 3-amino-1-propanol (S3), 4-amino-1-butanol (S4), or 5-amino-1-pentanol (S5) at 
ratios of either 1.05:1, 1.1:1, or 1.2:1 following Table 3.1, yielding acrylate-terminated 
polymers. These polymers were then endcapped with endcapping monomers pentane-1,3-
diamine (E3), 2-((3-aminopropyl)amino)ethan-1-ol (E6), or 1-(3-aminopropyl)-4-
methylpiperazine (E7). As an example, the polymer made from base monomer B4, side chain S4, 
and endcap E7 is 1-(3-aminopropyl)-4-methylpiperazine end-modified poly(1,4-butanediol 
diacrylate-co-4-amino-1-butanol) and will be referred to as 447 for the duration of the 
manuscript. Figure 3.1 shows the monomer structures and the polymerization and endcapping 
reaction schemes. Gel permeation chromatography (GPC) was used to determine polymer size 
and polydispersity (Table 3.1). The Mn of the polymers varied from 3 kDa – 16 kDa, with the 
average being 10 kDa.  The PDI of the polymers varied from 1.74-8.07 among the polymer 
types, with average PDI being 3.28.  The lead polymer, 447, had a Mn of 11,345 Da, a Mw of 
36,814 Da, and a PI of 3.25.  It was chosen as the lead polymer based on its high gene delivery 
efficacy. It is possible that the small proportion of polymer chains in the batch that are of 
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relatively high molecular weight help in increasing the transfection.  Some of our previous work 
has shown that increased PBAE polymer molecular weight can increase the binding affinity of 
the polymer with DNA and this can improve gene delivery efficacy.56   Polymer structure of 
polymer 447 was characterized via 1H-NMR, and was shown to match previously described 
structures (Figure 3.2).53, 57  
 The in vitro DNA delivery efficacy of the PBAE library was assessed in 9L rat 
gliosarcoma (9L) and F98 rat glioma (F98) cell lines using plasmid DNA coding for green 
fluorescent protein (GFP). Cytotoxicity was measured using an MTS assay, and transfection was 
assessed using high-throughput flow cytometry and fluorescence microscopy. Nanoparticles 
were formed by mixing polymer and DNA at mass ratios of 30, 60, or 90 polymer-to-DNA 
(w/w) in aqueous conditions and delivering to the cells at a final DNA concentration of 5 ng/L 
(Figure 3.3). Of the nanoparticle formulations tested on 9L cells, ten nanoparticle formulations 
enabled greater than 50% transfection with less than 20% toxicity (Figure 3.3a,c). In F98 cells 
eight nanoparticle formulations enabled GFP expression in greater than 50% of cells while 
maintaining less than 20% toxicity (Figure 3.3b,d). Compared to Lipofectamine® 2000, a 
leading commercially available non-viral transfection reagent, we found that three PBAE 
nanoparticle formulations had superior performance in 9L cells and fifteen had superior 
performance in F98 cells. Interestingly, the polymer structures that were found to lead to the 
highest efficacy in one glioma cell type were not necessarily the optimal structures for the other 
glioma cell type. For example, 453 30 w/w transfected 68  3% of F98s, but only 9  1% of 9Ls.  
In contrast, 457 90 w/w shows some signs of potential cytotoxicity in F98, but has higher 
transfection (64  4%) and no cytotoxicity in 9Ls. This potential cell-type specificity based on 
polymer structure is something that we have observed with other PBAE structures and other cell 
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types, such as human endothelial cells.58, 59 In considering polymer structure that makes up the 
nanoparticles, the E7 endcapping group 1-(3-aminopropyl)-4-methylpiperazine generally led to 
improved transfection compared to the E3 or E6 endcapping groups across the base polymers 
and glioma cell types evaluated. This is consistent with prior work done in other cell types, 
showing that the E7 endcap is generally one of the most effective in our library.34, 52, 57 Among 
the non-E7 polymers, 536 60 w/w and 536 90 w/w nanoparticles had the most robust gene 
expression (respectively, 59  5% and 65  2 % in 9L cells, and 73  3% and 71  5% in F98 
cells). 
Critically, certain polymeric nanoparticle formulations, such as 447 30 w/w, transfected 
both glioma cells lines at similarly high levels and without any cytotoxicity, also in keeping with 
prior investigation of the differential activity of PBAEs,52 in which we found that polymers of 
moderate hydrophobicity led to high transfection rates without overly compromising cell 
viability. Based on the results of this study, we chose polymer 447 at 30 w/w as the optimal 
nanoparticle formulation for both 9L and F98 cells (77  3% and 68  1% transfection, 
respectively). Polymer 447 formed nanoparticles with GFP DNA through self-assembly that 
were 131  3 nm in size and 15  0.4 mV in zeta potential and with HSVtk DNA that were 138  
4 nm in size and 13  1 mV in zeta potential (neither particle size nor zeta potential is 
statistically different between these two formulations).  Even though the plasmid sizes were 
different, the total nucleic acid mass that was used to form the nanoparticles was the same and 
this led to nanoparticles with the same biophysical properties.  This finding also matches our 
lab’s previous finding that DNA plasmid sequence and length does not affect the nanoparticle 
size or charge of these PBAE-based nanoparticles within the plasmid DNA size range of 2-26 
kilobases.52 These nanoparticles also compared favorably to transfection with a leading 
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commercially available non-viral transfection reagent, Lipofectamine® 2000, which led to 52  
1% and 37  4% transfection in 9L and F98 cells, respectively (see Table 3.2 for full statistical 
analysis on transfection efficacy).   
The polymer that makes up these nanoparticles, 447, has also recently shown robust 
transfection of other cancer types, including human brain cancer cells.34 Although the 
physicochemical properties that govern the efficacy and activity of PBAE-based nanoparticles 
currently under investigation and likely include the chemical structure and molecular weight of 
the polymer, the polymer-DNA binding strength, and the cellular uptake pathway of the 
nanoparticles,52, 56, 60 the exact mechanisms have not yet been fully elucidated. For example, 
although cellular uptake is certainly an important first step in transfection, previous work in our 
group has shown that PBAE-DNA nanoparticles often have very high overall uptake by cells 
without necessarily leading to successful gene expression.34, 61 Similarly, we have seen that two 
cell types with very different transgene expression rates can show statistically similar 
nanoparticle uptake rates.31 Early work in our group also suggests that the particular cell uptake 
pathway can affect successful transfection rates with PBAE nanoparticles.60 Nonetheless, we 
have consistently observed certain trends across various cell types and culture systems. For 
instance, the polymers used here were synthesized using monomer ratios that yielded products 
with relatively high molecular weight, which we and others have shown to have a generally 
positive correlation with transfection efficacy,52, 56, 62 and the small molecules used for polymer 
library synthesis were chosen based on their transfection efficacy in other work.52, 56, 60 
3.3.2. PBAE/HSVtk Nanoparticles and a Ganciclovir Prodrug Kill Glioma Cells in Vitro 
We sought to examine the anti-tumor efficacy of the PBAE/HSVtk nanoparticles in vitro. 
Using the optimal nanoparticle formulation 447 at 30 w/w, we delivered plasmid DNA encoding 
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either GFP or HSVtk, and treated the cells with GCV at 0, 5, and 50 g/mL. Viability was 
assessed quantitatively via cell counting in 9L and F98 cells (Figure 3.4b,d). We found that 
cancer cell death was dependent on the presence of both HSVtk and GCV, as HSVtk-transfected 
cells were viable when no GCV was present, while GFP-transfected cells were viable in spite of 
the presence of GCV. Specifically, we observed that the nanoparticle-mediated HSVtk/GCV-
induced cytotoxicity was powerful, resulting in 106  3% cell death of 9Ls and 96  7% cell 
death of F98s at 5 g/mL GCV when the cells were transfected with HSVtk versus GFP. At 50 
g/mL GCV, 104  5% of 9L cells and 101  2% of F98 cells were dead. These measurements 
of approximately 100% cell death are consistent with the complete cell death that was observed 
by microscopy (Figure 3.4a,c).  
 Although the two plasmids used, GFP and HSVtk, are of different size and may result in 
slightly different transfection rates, the lack of difference in the physicochemical properties of 
nanoparticles formed with different types of DNA allows the use of the GFP plasmid as a non-
functional control for the HSVtk plasmid.  As both these types of nanoparticles are formed with 
the same total mass of polymer and nucleic acid and have the same physicochemical properties, 
there is not expected to be a difference in polymer- or nanoparticle-induced toxicity between the 
two plasmids or their particle distribution. While the percent of cells transfected with GFP 
cannot be assumed to be exactly the same as the percent of cells positive for HSVtk, the strong 
cytotoxic effect of GCV in HSVtk-transfected cells shows that this transfection, like the GFP 
transfection, is sufficient for a significant biological effect. These data suggest that nanoparticle-
based delivery of the HSVtk gene enables local activation of GCV into a cell-killing drug, which 
is known to cause cell death in malignant glioma lines via activation of apoptosis.47, 63 Moreover, 
the proportion of cells killed (approximately 100%) was greater than the transfection efficiency 
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of the glioma cells (<80%), illustrating the strong bystander effect of the HSVtk/GCV 
therapeutic strategy. This is particularly important in the treatment of a tumor, as even if <100% 
of the cancer cells are transfected in vivo, the fraction of cancer cells that positively express 
HSVtk can lead to the apoptosis of neighboring untransfected tumor cells. This nanoparticle-
mediated suicide gene therapy finding is consistent with studies done in other laboratories with 
an analogous HSVtk/GCV viral gene therapy strategy.64, 65 Few previous studies have been 
conducted using non-viral HSVtk gene delivery in cancer models.  Two examples in the 
literature include Neurotensin (NTS)-polyplex nanoparticles66 used to transfect triple negative 
breast cancer cells (MDA-MB-231), and poly(ethylene glycol)-poly(gamma-benzyl-L-
glutamate) (PEG-PBLG)67 nanoparticles used to transfect oral squamous cell carcinoma 
(Tca8113). The transfection efficacy with these non-viral nanoparticle systems was lower than in 
our present study, with only 18% and 30% transfected, respectively. In those cases, the efficacy 
of GCV treatment was shown to increase cancer cell death to 50% and 80% through the 
bystander mechanism. In contrast, our approach with PBAE nanoparticles led to 70% 
transfection efficacy with 100% cell death.  To our knowledge, this is the first demonstration of 
significant efficacy and anti-cancer effects of PBAE/DNA delivery to treat brain cancer.  
3.3.3. PBAE/DNA Nanoparticles Can be Lyophilized with no Change in Properties or 
Efficacy 
Lyophilization of nanoparticles prior to in vivo administration has several benefits. 
Drying the nanoparticles enables subsequent reconstitution at a higher concentration, which was 
particularly beneficial for intracranial injections, in which volumes were limited due to size and 
pressure constraints within the brain. Lyophilized PBAE nanoparticles can also be stored for 
years without losing efficacy34, 53 and are easier to administer, as the user simply needs to add 
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water and inject. The amount of solutes added to the particles during formulation is easily 
adjustable to ensure that the resulting aqueous suspension is isotonic after adding water. To 
ensure that the 447 30 w/w nanoparticles did not lose efficacy after lyophilization, lyophilized 
particles were compared to freshly prepared particles. We compared the size and zeta potential of 
447 30 w/w nanoparticles and found no significant difference between freshly prepared and 
lyophilized nanoparticles (Figure 3.5a). We also compared in vitro transfection of fresh versus 
lyophilized nanoparticles and found that measurements of transfection efficacy, percent of GFP-
positive cells, and geometric mean fluorescence showed no statistical difference (p > 0.05) 
(Figure 3.5b). Finally, we imaged fresh and lyophilized nanoparticles via transmission electron 
microscopy (TEM), and found that nanoparticles from each batch were morphologically similar 
(Figure 3.5c,d). 
3.3.4. PBAE Nanoparticles are Safe to Deliver to the Brain 
We assessed the safety of delivering PBAE/DNA nanoparticles to the brain in vivo in both wild 
type healthy rats (at day 3 and at day 60 post-nanoparticle infusion) and 9L tumor-bearing rats 
(at day 3 post-nanoparticle infusion).  We used 25 µL as the infusion volume, which was 
previously shown to be safe.68  PBAE/GFP 447 30 w/w nanoparticles were injected in 10% (w/v) 
sucrose and were tested at 26 µg DNA with 780 µg PBAE. This dose was found to be safe and 
was used for subsequent in vivo studies. 50 mg/kg GCV injected twice a day was well tolerated 
and was therefore chosen for all efficacy studies.  
With the exception of animals euthanized at the early time point (day 3 post-nanoparticle 
infusion) for histopathological analysis, all non-tumor-bearing animals survived until the end of 
the study (60 days post-nanoparticle infusion). No signs of neurotoxicity or paralysis were 
observed.  The histopathology from day 3 (healthy wild type rats and 9L tumor-bearing rats) and 
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day 60 (healthy wild type rats) showed no discernable signs of early or late tissue damage and 
did not include cytological changes, edema, gliosis, neuroinflammation, or necrosis (Figure 3.6).  
These data provide in vivo confirmation of one of the strengths of biodegradable PBAEs, a 
strong safety profile, even when used at high concentration. 
3.3.5. Intratumoral Infusion of PBAE/GFP Nanoparticles Leads to Wide Distribution and 
Transfection in the Brain  
The intratumoral distribution and transfection of PBAEs nanoparticles after local brain 
delivery was assessed. To evaluate the nanoparticle distribution and transfection through the 
tumor in vivo, we used nanoparticles containing Cy5-labeled GFP DNA and examined the 
distribution of Cy5+ and GFP+ cells (Figure 3.7a-d). On Day 7, 24 h post-nanoparticle infusion, 
the tumor mass was approximately 2x3 mm, extending from the cortex towards the ipsilateral 
caudate/putamen area and invading the left lateral ventricle (Figure 3.7a). Immunofluorescence 
staining showed high GFP signal in the corresponding area of the tumor. Specifically, 24 h after 
CED infusion of Cy5-labeled GFP DNA-containing nanoparticles, the nanoparticles transfected 
the tumor mass, while the normal brain remained GFP-negative (Figure 3.7b). Importantly, the 
nanoparticles transfected cells fairly homogeneously throughout the entire tumor mass, even 
distant from the site of infusion (Figure 3.7d-f).   
Limited tumor penetration and low transfection rates are major obstacles in non-viral 
gene therapy for the treatment of brain tumors.37 Transport depends on physio-anatomic 
barriers69 and the physicochemical characteristics of the particle, including its size, shape, and 
surface charge. In this study we show that CED positively affects the biodistribution of the 
PBAE nanoparticles compared to bolus injection (Figure 3.8).  This is due to the creation of a 
positive pressure gradient, which creates bulk fluid movement in the brain interstitium. Tumor-
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bearing rats treated with a bolus injection of an equal amount of PBAE/DNA nanoparticles 
underwent brain analysis via immunofluorescence staining as well.  Analysis showed that bolus 
injection led to transfection in the areas around the needle-path at the bottom of the tumor, with 
much of the core and margins without nanoparticle-mediated gene transfer. After CED infusion, 
on the other hand, the nanoparticle-mediated exogenous gene expression led to positive GFP 
signal across the whole tumor mass, from the core to the top, bottom, and margins. Moreover, 
the normalized GFP fluorescence per pixel of the tumor area (using Image J software) showed a 
36% increase by CED infusion compared to bolus injection (15.8  0.1 RFU vs. 11.6   0.2 RFU, 
p<0.0001) These findings show for the first time that PBAE nanoparticles can penetrate the 
entirety of the tumor volume and therefore are promising for gene delivery when combined with 
CED. 
3.3.6. PBAE/HSVtk Nanoparticle/GCV Treatment Leads to Prolonged Survival of 9L 
Gliosarcoma-Bearing Rats 
After demonstrating the in vitro efficacy of PBAE/HSVtk nanoparticles in F98 and 9L 
glioma cells and the in vivo safety of PBAE nanoparticles for intratumoral transfection, we 
proceeded to test their in vivo therapeutic efficacy in 9L tumor-bearing rats (Figure 3.9). 9L 
gliosarcoma is a highly aggressive syngeneic glioma model 70, 71 and is well known as a 
challenging survival model due to its fast rate of growth. This model, although rodent-based, has 
achieved undisputed clinical relevance as it has been used as a preclinical model for multiple 
clinical trials in the investigation of novel chemo and immunotherapies, drug delivery strategies, 
and gene therapies.72-77 Animal survival after treatment with PBAE/HSVtk nanoparticles in 
combination with GCV was significantly longer compared to the untreated control group (p = 
0.0012) (Figure 3.10). PBAE/HSVtk nanoparticles were also found to provide survival benefits 
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compared to all the other control groups: GCV only (p = 0.0102), PBAE/GFP +GCV (p = 
0.027), and HSVtk DNA+ GCV (p = 0.027).  
Considering that 9L is characterized by an exponential-Gompertzian curve of growth 
after 6 days,70, 71, 78 such a statistically significant benefit in survival in the group treated with 
PBAE/HSVtk plus GCV is promising. The efficacy of the HSVtk/GCV paradigm has previously 
been shown in the 9L model using other strategies79, 80 and the bystander effect and a resulting 
immune response can both contribute to the overall cytotoxicity of the PBAE/HSVtk GCV 
treatment.81, 82 Due to the positive relationship between the bystander effect and the percent of 
HSVtk transfected cells,50 the improvement in survival observed here is highly indicative of 
strong PBAE transfection efficacy in vivo matching what was also observed in vitro.  PBAE-
based gene delivery has a potential role as alternative strategy to virus mediated gene therapy for 
glioblastoma. 
HSVtk/GCV therapy has previously been used in brain tumor treatment clinical trials 
with retroviral83-85 and adenoviral86 vectors with limited success in progression-free and overall 
survival. This has been attributed to poor distribution of the carrier and limited delivery of 
HSVtk into the tumor. The HSVtk/GCV system has also been used to investigate the efficacy of 
non-viral vectors in Phase I-II studies conducted with cationic liposomal vectors, which showed, 
via positron emission tomography with a 124I-labeled specific substrate for HSV-1, presence of 
thymidine kinase in one out of five patients.87 A subsequent study using liposomes had 
encouraging results by showing reduction of the tumor volume mass in two out of eight 
patients.88 Yet, non-viral gene therapy is generally considered less efficient than viral gene 
therapy.89 While siRNA delivery nanomedicine approaches have been progressing rapidly, 
including approaches such as spherical nucleic acids for the treatment of glioblastoma,90 DNA 
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delivery has been more challenging.  This is likely due to in large part to the much larger size of 
DNA as a nanomedicine drug cargo and the need for it to be delivered into nucleus rather than 
just into the cytoplasm.87 Due to the wide tumor penetration, high exogenous gene expression, 
and bystander effect capabilities, the PBAE/HSVtk nanoparticles may be able to overcome the 
previously encountered limitations and be a promising new nanomedicine for brain cancer.   
 
3.4. Conclusion 
In this work, we have developed a new gene transfer nanomedicine that causes the 
expression of suicide gene herpes simplex virus type I thymidine kinase (HSVtk) within brain 
tumor cells in vitro and in vivo. Biodegradable nanoparticles were synthesized, characterized, 
and utilized to treat malignant glioma using convection-enhanced delivery (CED). The lead 
polymer structure, poly(beta-amino ester) 1-(3-aminopropyl)-4-methylpiperazine end-modified 
poly(1,4-butanediol diacrylate-co-4-amino-1-butanol), formed DNA nanoparticles with suitable 
biophysical properties for intracellular delivery and a wide biodistribution when injected 
intracranially. CED led to improved levels of tumor transfection. These PBAE/HSVtk 
nanoparticles combined with systemic administration of ganciclovir as a prodrug led to a 
significant increase in survival in a 9L glioma model (p=0.0012 vs. control). Our results provide 
the first demonstration of a successful non-viral nanomedicine method for HSVtk/GCV 
treatment of brain cancer.  
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Table 3.1. Gel permeation chromatography (GPC) results of all polymers indicating the  
number average (MN) and weight average (MW) molecular weight and polydispersity (PDI) of 




Table 3.2. Results of one-way ANOVA with Dunnett’s post-test in 9L and F98 cells versus  
Lipofectamine 2000 delivering either 0.6 or 0.3 μg GFP DNA per well. (ns = not significant, * 






Figure 3.1.  Polymer synthesis scheme and monomer chemical structures. Base monomers (B) 
and side chain monomers (S) are polymerized, and polymers are then endcapped with 




Figure 3.2. H1-NMR spectrum of polymer 447 (CDCl3, 400 Hz). Protons peaks are labeled  






Figure 3.3.  PBAE nanoparticles effectively transfect 9L and F98 malignant glioma cells in 
vitro. All polymers were screened at 30, 60, and 90 w/w delivering 0.6 g of GFP DNA (A, B). 
Of the nanoparticles tested on 9L and F98 cells, three and fifteen formulations,  respectively, 
were found to deliver GFP DNA more effectively than commercially available transfection 
reagent Lipofectamine 2000 (* = p < 0.05 versus Lipofectamine with 0.6 g DNA via one-way 
ANOVA with Dunnett’s post-test). Fluorescence microscopy shows cells transfected with GFP 
using PBAE nanoparticles (C, D). Transfection efficacy was quantified using flow cytometry. 
Loss in metabolic activity was quantified using an MTS assay with colorimetric readout, 





Figure 3.4. PBAE delivery of HSVtk plasmid enables GCV-mediated killing of malignant 
glioma cells in vitro. 9L and F98 cells were transfected with plasmids encoding either GFP or 
HSVtk and then treated with 0, 5, or 50 g/mL GCV prodrug. Cells treated with both HSVtk and 
GCV exhibit 100% cancer cell killing, measured by cell counting, versus GFP-transfected cells 
treated with GCV, showing that GCV-induced cell killing is dependent on the presence of 






Figure 3.5. Nanoparticles maintain their physical characteristics and transfection capability 
following lyophilization. Fresh and lyophilized nanoparticles showed no statistical difference (p 
> 0.05) in their sizes and zeta-potentials (A) and showed no statistical difference in percent 
transfection and geometric mean GFP in 9L cells (B). TEM imaging of fresh (C) and lyophilized 
(D) nanoparticles shows nanoparticles of the same size and morphology (scale bar = 100 nm). 




Figure 3.6. Safety of local brain delivery of PBAE nanoparticles. Representative coronal 
sections of rat brains from wild type and 9L tumor-bearing animals infused with PBAE/GFP 
nanoparticles. The H&E images taken within 1 mm around the site of the infusion show no sign 
of neuropathological damage.  (A1) Wild type animal euthanized 3 days post-nanoparticle 
infusion. The image shows indentation into the cortex with inflammation, consistent with acute 
injury at the injection site. No sign of neurotoxicity. Under microscopic view: presence of 
neutrophils with a few macrophages within the injection site (black arrows) (A2).  (B) Wild type 
animal euthanized 60 days post-nanoparticle infusion. The figure shows a very small indentation 
with tissue shrinkage. Under microscopic view: astrocytes are present (black arrows), and the 
tissue shows no sign of inflammation (B2). (C) 9L tumor-bearing animal euthanized 3 days post-
PBAE/GFP nanoparticle infusion. The image shows a tumor mass causing contralateral brain 
midline shift and robust mass effect on the surrounding structures. There is a distinguishable sign 
of needle entrance within the tumor mass. Under microscopic view: characteristic cellular 
density of tumor tissue and no inflammation or tissue damage referable to any cause of damage 





Figure 3.7.  Local brain delivery of PBAE/GFP Nanoparticle via CED leads to effective tumor 
transfection in vivo. Coronal section of a 9L tumor bearing rat brain at 7 days post PBAE/GFP 
infusion showing the tumor region (A, scale bar=2 mm). Fluorescence microscopy images show 
GFP+ transfected cells in the tumor area (B, scale bar=2 mm). Enlarged area shows a wide 
distribution of GFP+cells within the entire tumor area including the periphery (C, scale bar=500 
µm). The co-localization of GFP and Cy5 shows that the nanoparticles penetrate into the cells 
and successfully transfect them (D-F, scale bar: 50 µm). Red: Cy5, green: GFP, blue: DAPI 





Figure 3.8. Convection-enhanced delivery of PBAE/GFP nanoparticles improves the level of 
intratumoral transfection. Coronal section of 9L-bearing rats infused via CED (A) and injected 
with bolus administration (B). Fluorescence microscopy of both brains show higher intratumoral 
transfection efficacy after CED infusion (A2, B2, scale bar=2mm). The images focused on the 
tumor area show a distribution of Cy5 and GFP signal that is favorable in CED compared to 
bolus (A3-5, B3-5 scale bar=1 mm). Red: Cy5, green: GFP, blue: DAPI. (Reproduced from 





Figure 3.9. Schematic representation of the in vivo study. The 9L bearing rats were treated with 
intraperitoneal administration of ganciclovir twice a day beginning on day 4 and then treated 
with a single CED infusion of PBAE/HSV-tk nanoparticles on day 6 (A).  These treated animals 
showed a significant benefit in survival (p=.0012 vs. control) (B-D). (Reproduced from 





Figure 3.10. PBAE/HSVtk nanoparticles and ganciclovir (GCV) extend survival in a 9L 
glioasarcoma model. Kaplan-Meier plots of F344 rats that were implanted with 9L and either 
given no treatment (9L Control, n=16); 50mg/kg/ twice a day of systemic administration of GCV 
on days 4-10 (GCV Alone, n=8); intracranial infusion of PBAE/GFP nanoparticles plus systemic 
administration of GCV (NP-GFP + GCV, n=8); intracranial infusion of HSVtk DNA plus 
systemic administration of GCV (DNA + GCV n=8); or intracranial infusion of PBAE/HSVtk 
nanoparticles plus systemic administration of GCV (NP-HSVtk + GCV, n=8). The median 
survival of the group receiving PBAE/HSVtk nanoparticles in combination with GCV is 
significantly longer compared to that of the untreated control group (p = 0.0012). (Reproduced 
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Synthesis, characterization, and optimization of a novel polymeric 




 RNA interference (RNAi) is a naturally occurring cellular mechanism that ultimately 
results in sequence-specific gene knockdown and can be externally induced by intracellular 
delivery of short interfering RNA (siRNA).1 Targeted gene knockdown via siRNA delivery has 
exciting potential for the treatment of diseases caused by aberrant gene expression.2, 3 However, 
safe and efficient intracellular siRNA delivery remains a challenging obstacle.  
 Promising siRNA delivery strategies have been suggested that employ lipid-based,4, 5 
inorganic,6-8 or polymeric materials9-11 similar to those designed for DNA delivery. Certain siRNA 
delivery material design parameters can be addressed using the same materials found to effectively 
deliver DNA. Cationic polymers with high buffering capacities, such as poly(ethyleneimine) 
(PEI), promote nucleic acid compaction and protection, cellular internalization, and endosomal 
escape.12 Polymer degradability such as that afforded by hydrolytically cleavable poly(-amino 
ester)s (PBAE)s results in cargo release far superior to nondegradable PEI.13  
 Two key delivery obstacles specific to siRNA are unstable particle formation and 
cytoplasmic targeting. The former concern results from the relatively small size and rigidity of 
siRNA, which is ~200 times smaller than most plasmids used for DNA delivery and is stiffer than 
                                                     
This chapter contains material modified from the following articles, previously published as: 
Kozielski, K.L.; Tzeng, S. Y.; Green, J. J.: A bioreducible linear poly(beta-amino ester) for siRNA delivery. 
Chemical Communications 2013, 49, 5319-5321. 
Kozielski, K.L.; Tzeng, S. Y.; Hurtado de Mendoza, B. A.; Green, J.J: Bioreducible cationic polymer-based 
nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery to primary human brain 
cancer cells. ACS Nano 2014, 8, 3232-3241.  
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DNA.14, 15 Shorter length results in reduced mutivalency of electrostatic interactions between a 
cationic polymer and anionic siRNA molecule, while rigidity may prevent siRNA from 
conforming into shapes favorable for binding and nanoparticle (NP) self-assembly. In addition, 
cytoplasmic targeting of siRNA is required for optimal gene knockdown, as the cytosol is the site 
of RNAi-induced mRNA degradation.16 Polymer bioreduction by glutathione (GSH) in the 
reducing cytoplasmic environment is a simple and specific method to engineer triggered 
cytoplasmic siRNA release.17 This can be achieved by the inclusion of bioreducible disulfide 
linkages as a crosslinking agent,18 adjacent to cationic groups on polymer end-caps19, 20 or along 
the polymer backbone.21  
 The use of bioreducible moieties in other siRNA delivery vehicles has met with success in 
the past. Linear, low-molecular weight PEI segments linked with disulfide bonds were shown to 
be as effective as commercially-available, branched 25 kDa PEI (bPEI) while being less cytotoxic. 
In particular, this material was capable of roughly 50% knockdown of a fluorescent marker gene 
during in vitro, serum-free siRNA delivery to Chinese hamster ovary cells (CHO-K1) using 100 
nM siRNA.9 Disulfide-containing poly(amido amine)s have shown successful in vitro siRNA 
delivery in human head and neck carcinoma cells (UM-SCC-14C),22 non-small cell lung 
carcinoma (H1299),11 and human prostate cancer cells in which ~80% knockdown was achieved 
with 30 nM siRNA.23 The KALA peptide (a 30-residue peptide containing 3 Lys-Ala-Leu-Ala 
repeats)24 modified with cysteine residues and crosslinked to form a bioreducible polymer was 
electrostatically complexed with PEGylated siRNA.25 This delivery system achieved nearly 50% 
gene knockdown in vitro in 10% serum-containing media to MDA-MB-435 melanoma cells using 
~60 nM siRNA.  PBAEs containing disulfides in the polymer end-caps achieved ~70% knockdown 
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in human umbilical vein cells in an in vitro study in which 60 nM siRNA was delivered in the 
presence of 2% serum.26 
 PBAE-nucleic acid nanoparticles allow nucleic acid release by hydrolytic degradation of 
esters along the polymer backbone on the time scale of several hours to a few days.13, 27 However, 
this release mechanism limits control over where release will occur. In order to specifically target 
release to the cytoplasm, we have synthesized a novel linear PBAE polymer with disulfide bonds 
along the polymer backbone.  
 We sought to create a new bioreducible nanobiotechnology that could be highly effective 
for siRNA delivery to human cells.  As the literature shows that lipid-based transfection reagents, 
such as the leading commercially available reagent Lipofectamine™ 2000, are generally superior 
for siRNA delivery compared to polymers such as PEI, we used Lipofectamine™ 2000 as the 
benchmark positive control. Recently, other disulfide-containing PBAE nucleic acid delivery 
vehicles for RNAi have been investigated. Yin et. al. formed disulfide-containing PBAEs for 
plasmid delivery of short hairpin RNA (shRNA), but as diamines and diacrylates were used for 
polymerization, degree of branching was not user-controlled, which could compromise the 
reproducibility of the material properties.28, 29 Additionally, while this method was effective for 
delivery of plasmid DNA, reports have shown standard linear PBAEs are generally ineffective for 
siRNA delivery without the use of additional components.30  This is not unexpected as siRNA is 
a molecule ~200-times smaller than DNA and its delivery may require different biomaterials. Our 
group recently described linear PBAEs containing disulfide bonds only in the polymer end-cap 
groups, not in the main base polymer, and used them for siRNA delivery to promote siRNA 
triggered released into the cytosol.20 These polymers were effective and presented an interesting 
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initial step for creating PBAE-based siRNA delivery polymers, and motivated the work presented 
herein.  
 We hypothesized that a new reducible, disulfide-containing analog of a previously 
established non-reducible PBAE polymer would promote enhanced siRNA-mediated gene 
knockdown. Our goal was to create reducible nanoparticles that would be as physically identical 
as possible to their non-reducible analogs when in an extracellular environment, but would then 
efficiently release siRNA when in a reducing cytoplasmic environment.  
 We synthesized a new reducible form of a monomer that we have previously used, hexane-
1,6-diyl diacrylate (B6) to form “reducible B6,” 2,2’-disulfanediylbis(ethane-2,1-diyl) diacrylate 
(BR6), in order to form polymers with similar structure and the same charge density as B6 
polymers.21 In more recent work, we sought to improve siRNA delivery with bioreducible PBAE-
based nanoparticles by specifically addressing the instability of siRNA nanoparticles and the need 
for cytoplasmic targeting. We wanted to engineer a class of polymers for siRNA nanoparticle 
formation and efficient siRNA delivery by balancing polymer bioreducibility and hydrophobicity, 
as PBAE hydrophobicity may enhance particle stability and has been shown to promote enhanced 
delivery of both DNA and siRNA.19, 31 Polymer bioreducibility was used to reduce potential 
cytotoxicity and to impart cytoplasmic targeting of siRNA release. To further elucidate ideal 
siRNA delivery criteria, we also examined the effects of changing nanoparticle formulation 
parameters and physical properties on gene knockdown and cytotoxicity. The results presented 
herein show that bioreducible PBAE chemical properties and nanoparticle physical properties can 
be engineered for simple, safe, and effective siRNA delivery. 
 
4.2. Materials and methods 
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4.2.1. Materials 
 All chemicals used for the synthesis of monomer BR6 were purchased from Sigma-Aldrich 
Chemical Co. (St. Louis, MO) and used without further purification. All other monomers were 
purchased from Alfa Aesar (Ward Hill, MA). YO-PRO®-1 Iodide was purchased from Life 
Technologies™ (Carlsbad, CA). Lipofectamine™ 2000 and Opti-MEM™ I were purchased from 
Invitrogen (Carlsbad, CA) and used according to manufacturer’s instructions. Ambion® Silencer® 
eGFP and Ambion® Silencer® Negative Control #1 siRNA were purchased from Life 
Technologies™. CellTiter 96® AQueous One MTS assay was purchased from Promega (Fitchburg, 
WI) and used according to manufacturer’s instructions. Cells were grown in 89% GIBCO® 
DMEM-F12, 1% GIBCO® Antibiotic-Antimycotic (Invitrogen), and 10% Corning Cellgro® 
Heat-Inactivated FBS.  
4.2.2. Bioreducible monomer synthesis 
Bis(2-hydroxyethyl) disulfide (15.4 g, 10 mmol) and triethylamine (TEA, 37.5 mL, 300 mmol) 
were dissolved in 450 mL of tetrahydrofuran (THF) (previously dried with Na2SO4) in a 1 L round 
bottom flask; the contents were then flushed with N2 for 10 min and maintained under a N2 
environment for the remainder of the reaction time. Acryloyl chloride (24.4 mL, 300 mmol) was 
dissolved in 50 mL of dried tetrahydrofuran, added to the flask dropwise over 2 hrs while stirring, 
and the reaction was allowed to continue at room temperature for 24 h. Following reaction, TEA 
HCl precipitate was removed by filtration, and THF was removed by rotary evaporation. The 
product was dissolved in 200 mL dichloromethane (DCM) and washed five times with 200 mL of 
aqueous 0.2 M Na2CO3 and three times with distilled water. The solution was dried with Na2SO4 
and DCM was removed by rotary evaporation. The product 2,2’-disulfanediylbis(ethane-2,1-diyl) 
(BR6) was confirmed via 1H NMR: (CDCl3, 400Hz), δ2.95 (2H, t, CH2CHCOOCH2CH2S), δ3.95 
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(2H, t, CH2CHCOOCH2CH2S), δ5.8-5.9 (1H, d, CH2CHCOOCH2CH2S), δ6.1-6.2 (1H, dd, 
CH2CHCOOCH2CH2S), δ6.4-6.5 (1H, d, CH2CHCOOCH2CH2S). 
4.2.3. Bioreducible polymer synthesis 
Polymer synthesis was carried out in a method similar to Bhise et al.32 The diacrylate base 
monomers used for polymerization were BR6 (see above) or hexane-1,6-diyl diacrylate (B6). 
Backbone monomers BR6 and hexane-1,6-diyl diacrylate (B6) were mixed at a molar ratio of 
either 1:0, 3:1, 1:1, 1:3, or 0:1 prior to polymerization. Side chain monomers used were 3-amino-
1-propanol (S3), 4-amino-1-butanol (S4), or 5-amino-1-pentanol (S5). The end-caps used were 2-
(3-(aminopropyl)amino)ethanol (E6) and 1-(3-aminopropyl)-4-methylpiperazine (E7). For all 
polymers, polymerization was completed using a base monomer to side chain ratio of 1.01:1 at 
500 mg/mL in dimethyl sulfoxide (DMSO) at 90ºC for 24 hrs while stirring. The polymers were 
end-capped in DMSO at 100 mg/mL with 0.2 M E7 for 1 h at room temperature while shaking. 
Excess E7 monomer was not removed from the polymer solution, however examining E7 
monomer cytotoxicity showed that free E7 was not significantly cytotoxic to GBM 319 cells 
(Figure 4.1).  As we have found with our prior work with this class of polymers,32 the step growth 
polymerization of the bifunctional monomers leads to short linear polymers without any 
byproducts or side reactions.  Purity of polymers and the identity of copolymers is confirmed by 
1H NMR spectra.  The 1H NMR spectra for representative polymers R647, 1:1 R647, and 647 are 
shown in Figure 4.2.  The integration of the peaks of the copolymers validate that base monomers 
B6 and BR6 incorporate into a copolymer at the same molar ratio as is used during polymer 
synthesis. 
4.2.4. In vitro siRNA Delivery to human GBM cells and cell viability 
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 GFP+ GBM 319 glioblastoma cells were plated at a cell density of 15,000 cells/well in 96-
well tissue culture plates in 89% GIBCO® DMEM-F12, 1% GIBCO® Antibiotic-Antimycotic 
(Invitrogen), and 10% Corning Cellgro® Heat-Inactivated FBS and allowed to adhere overnight. 
fNPC 34 cells were utilized to compare siRNA delivery between primary human glioblastoma 
cells and healthy human primary cells found in the brain.  fNPC 34 cells are primary fetal neural 
progenitor cells obtained as described previously following procedures approved by the Johns 
Hopkins University Institutional Review Board.33 fNPC 34 cells were plated at a density of 15,000 
cells/well in 96-well tissue culture plates in 97% GIBCO® DMEM-F12, 1% GIBCO® Antibiotic-
Antimycotic (Invitrogen), 2% B-27® Serum-Free Supplement, and 20 g/mL each of basic 
fibroblast growth factor (Roche Applied Science) and epidermal growth factor (Sigma) and 
allowed to adhere overnight prior to transfection. The siRNAs used were either siRNA targeting 
eGFP with sequence 5'-CAAGCUGACCCUGAAGUUCTT (sense) and 3'-
GAACUUCAGGGUCAGCUUGCC (antisense), or a scrambled control siRNA (scRNA) with 
sequence 5'-AGUACUGCUUACGAUACGGTT (sense) and 3'-
CCGUAUCGUAAGCAGUACUTT (anti-sense). AllStars Human Cell Death siRNA was 
purchased from Qiagen. For all transfections, siRNA and polymers were diluted in 25 mM NaAc 
at twelve times the final concentration listed for each group, and siRNA and polymers were 
combined in a 1:1 v/v ratio and allowed to form cells for 10 min at room temperature. As an 
example, nanoparticles listed at final concentrations of  “180 g/mL and 20 nM siRNA” were 
formed by mixing a 2.16 mg/mL solution of polymer with a 240 nM solution of siRNA. The cell 
culture media was removed and replaced with serum-free media prior to adding nanoparticles. 
Nanoparticle formulations were diluted in each well in quadruplicates in a 1:6 v/v ratio to yield 
the final siRNA and polymer concentrations listed for each group. Cells were incubated with 
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nanoparticles for 4 h for siGFP experiments and 2 h for death siRNA experiments, after which the 
nanoparticle solutions were removed and fresh, serum-containing media was added. Cytoxicity for 
siGFP transfections was assessed 24 h after transfection CellTiter 96® AQueous One MTS assay 
following manufacturer’s instructions and read using a BioTek® Synergy™ 2 Microplate Reader. 
 Cell death in death siRNA experments was assessed by staining cells with propidium iodide 
(PI) in DMEM-F12 at 1:200 (v/v) PI prior to fixation and 750 nM 2-(4-amidinophenyl)-1H -
indole-6-carboxamidine (DAPI) following fixation in 10% formalin. Cell images were taken at 5X 
magnification using a Zeiss Axio observer A1 microscope with a Zeiss Axiocam MRm camera 
using AxioVision Release 4.8.2 software. Fluorescence was provided by an Exfo X-Cite® series 
120Q. Live and dead cells were quantified using ImageJ v1.47 software, and dead cells were 
subtracted from the live cell count to yield the total cell count for each well.  
4.2.5. Flow cytometry 
 All flow cytometry was completed at 9 d post-transfection using an Intellicyt high-
throughput loader attached to an BD Accuri™ C6 flow cytometer (emission filter: 530/30 nm). 
Hypercyt software was used to discriminate events between each well and FlowJo 7 software was 
used to analyze the flow cytometry results. Cells were prepared for flow cytometry by 5 min of 
trypsinization with 30 L of 0.05% trypsin-EDTA, followed by the addition of 170 L of a buffer 
of PBS containing 1:50 (v/v) FBS and 1:200 (v/v) propidium iodide (PI). Cell suspensions were 
moved to round-bottom 96-well plates and centrifuged for 5 min at 1000 rpm. 170 L of 
supernatant was removed and cells were resuspended in the remaining buffer. PI signal was used 
to distinguish dead or dying cells from live cells so that the unhealthy cells could be removed from 
analysis. GFP knockdown was determined by finding the geometric mean FL1 fluorescence signal 
for each sample. Percent knockdown was calculated by normalizing the GFP expression of siRNA-
 139 
treated cells to scRNA-treated cells. All the transfections were carried out using the same cell line, 
siRNAs, controls, and data collection protocols, and all formulations that caused >60% loss in 
metabolic activity were considered non-viable and excluded from further analysis.  
4.2.6. Gel retention assay 
 Nanoparticles were formed using 0.01 mg/mL scrambled control RNA (scRNA) in 25 mM 
sodium acetate (NaAc) and polymer at weight ratios to scRNA ranging from 600 wt/wt to 0 wt/wt 
(siRNA) alone. Polymer to siRNA ratios are also described as N:P ratios. These were incubated 
for 10 min at room temperature to allow for particle formation. To compare the effects of a 
nonreducing and reducing environment on the particles, either PBS or PBS containing L-
glutathione (GSH) to yield a final GSH concentration of 0 mM or 5 mM, respectively, were added 
and allowed to incubate at room temperature for 15 min. A solution of 30% glycerol was added to 
the particles in a 1:5 v/v ratio. The particles were loaded into a 1% agarose gel containing 1 µg/mL 
ethidium bromide and electrophoresed at 100 mV for 20 min. Gels were visualized using UV light 
exposure.  
4.2.7. Nanoparticle characterization  
Particle Size and Concentration Determination: Nanoparticle Tracking Analysis 
 All nanoparticles were made in the same manner that they were for transfection and then 
diluted so that their sizes and concentrations could be accurately determined using Nanoparticle 
Tracking Analysis (NTA). NTA was performed using a NanoSight NS500 and analyzed using 
NanoSight NTA 2.4 software. As an example, particles for transfection groups labeled “180 g/mL 
polymer with 20 nM siRNA” were synthesized by forming particles at a polymer concentration of 
1.08 mg/mL and scRNA at 120 nM in NaAc, as these particles would be diluted in a 1:6 v/v ratio 
in media during transfection. For NTA, however, these particles were diluted in PBS following 
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the protocol recommended by Bhise et al.34 All measurements were repeated with three separate 
formulations for each condition. The NTA analysis reported the number-average hydrodynamic 
radius of the particles. All particle concentrations were reported as the number of particles per 
volume that would be present in the transfection wells.  
 siRNA loading was calculated by dividing the total amount of siRNA per transfection well 
by the number of particles per well. This calculation was only completed for particle formulations 
with wt/wt ratios high enough to completely bind all siRNA as determined by the gel retention 
assay. For this reason, any particle formulations with wt/wt ratios at or below 75 wt/wt were 
excluded from siRNA loading calculations.  
Particle Zeta-Potential Determination: Dynamic Light Scattering 
 Particles were formed at the same concentrations and in the same manner as described for 
particle sizing. Particles were diluted 1:650 v/v in PBS and loaded into a disposable cuvette cell. 
Particle surface charge was determined via dynamic light scattering (DLS) using a Malvern 
Zetasizer NanoZS.  
Transmission Electron Microscopy 
 Nanoparticles formed using 1:1 R647 at 180 g/mL and 20 nM siRNA were imaged using 
transmission electron microscopy (TEM). 1:1 R647 was diluted to 2.16 g/mL in 25 mM NaAc, 
scRNA was diluted to 240 nM in NaAc, and the two solutions were combined in a 1:1 v/v ratio 
and allowed to form particles for 10 min at room temperature. Following particle formation, 5 L 
of the nanoparticle solution was placed onto a carbon-coated copper TEM grid and allowed to dry. 
Particles were imaged using a Philips/FEI BioTwin CM120 transmission electron microscope. 
YO-PRO®-1 Iodide Competition Binding Assay 
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 siRNA was diluted to 1.33 µM in 25 mM NaAc and combined in a 1:1 v/v ratio with 1.33 
µM YO-PRO®-1 Iodide in 25mM NaAc in all wells of a black-bottom 96-well plate. Polymers 
were diluted at concentrations ranging from 512 to 0.5 times these concentrations and combined 
in quadruplicates in a 1:2 v/v ratio with the siRNA/YO-PRO solution, and allowed to incubate for 
15 min at room temperature. 25 mM NaAc without polymer was also added in a 1:2 v/v ratio to 
four siRNA/YO-PRO solutions to supply background fluorescence values. Fluorescence was 
measured at 15 min using a BioTek Synergy 2 fluorescence plate reader at 490/510 nm (ex/em).  
4.2.8. Polymer characterization 
Gel Permeation Chromatography  
 GPC was performed using a Waters GPC system with three Waters Styragel columns in a 
series (HR 1, HR 3 and HR4) and a Waters 2414 refractive index detector, both maintained at 40ºC 
throughout all samples, which were loaded using a Waters 717plus autosampler (Waters Corp., 
Milford, MA). All samples were loaded at 5 mg/mL using 94% THF, 5% DMSO, and 1% 
piperidine (v/v) as the eluent at a flow rate of 1.0 mL/min for 40 min. Polymer molecular weights 
were calculated relative to polystyrene standards (Shodex, Japan). 
To assess polymer degradation in various conditions, each polymer R647 or 647 was either 
diluted in PBS or in a solution of 5 mM GSH in PBS to a final polymer concentration of 7 mg/mL. 
Each was allowed to incubate for 5 min at room temperature and was then frozen at -80°C and 
lyophilized. GPC was performed on these samples following the GPC protocol above. Excess salts 
were precipitated out of the GPC solvent and removed by filtration prior to performing GPC. 
4.2.9. Statistical analysis 
 All results are presented as mean  standard error of the mean. Statistical significance 
results for all % GFP knockdown and % loss in metabolic activity were determined using a one-
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way ANOVA with Dunnett’s post-tests using Lipofectamine 2000 as the control. All particle 
formulations that caused > 60% toxicity were considered non-viable and excluded from statistical 
testing. A two-way ANOVA with Tukey’s multiple comparisons post-test was also used to 
compare changes in loss in metabolic activities of cells treated with different polymers using side 
chain and base monomer as the parameters. Statistical significance of results for nanoparticle size 
and ζ-potential were determined using a one-way ANOVA with Tukey’s Multiple Comparison 
post tests. R squared correlation values were calculated compared to either linear or nonlinear 
regressions as labeled in each figure caption. All significance tests with p < 0.05 were considered 
significant.  
 
4.3. Results and Discussion 
4.3.1. Bioreducible polymer synthesis 
We synthesized a new reducible form of a monomer that we have previously used, hexane-
1,6-diyl diacrylate (B6) to form “reducible B6,” 2,2’-disulfanediylbis(ethane-2,1-diyl) diacrylate 
(BR6), in order to form polymers with similar structure and the same charge density as B6 
polymers. Synthesis of BR6 was carried out in a method similar to Chen et. al.35 Briefly, bis(2-
hydroxyethyl) disulfide was acrylated with acryloyl chloride in the presence of triethylamine 
(TEA). Following reaction, TEA HCl precipitate was removed by filtration, and the product was 
purified with aqueous Na2CO3 washes followed by rotary evaporation (Figure 4.3). The product 
was confirmed by proton nuclear magnetic resonance (H1-NMR). 
The two-step polymer synthesis was carried out in a similar manner as in Bhise et. al.32 
Either diacrylate monomer, BR6 or B6, was polymerized with 4-amino-1-butanol (S4) in a 1.01:1 
molar ratio, yielding acrylate terminated base polymers. The B6-S4 or BR6-S4 base polymers were 
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then end-capped with 1-(3-aminopropyl)-4-methylpiperazine (E7) to yield either B6-S4-E7 (647) 
or BR6-S4-E7 (R647). End-cap E7 was chosen as it has been shown to work well for PBAE 
delivery of siRNA in our preliminary studies with non-reducible polymers.36 Polymer size and 
structure were confirmed using gel permeation chromatography (GPC) and H1-NMR, 
respectively.†  GPC results of R647 yielded MN of 3745 Da, MW of 7368 Da, and a PDI of 1.967. 
GPC results of 647 yielded a comparable size profile (MN 4037 Da, MW 6221 Da, PDI 1.597). 
4.3.2. Assessment of polymer-siRNA binding and nanoparticle formation and 
biodegradation 
 The siRNA binding capability of each polymer was evaluated by a YO-PRO®-1 Iodide 
competition binding assay (Figure 4.4), in which YO-PRO®-1 Iodide fluoresces upon binding 
siRNA and is quenched as it is displaced by increasing concentrations of polymer. Over the 
polymer concentrations tested, R647 showed comparable to slightly higher siRNA binding affinity 
compared to 647 as measured by YO-PRO®-1 Iodide quenching. 
Polymer-siRNA binding was further characterized using a gel retention assay (Figure 4.5), 
in which nanoparticles are added to the wells of an agarose gel, and tightly bound siRNA is unable 
to migrate under electric field (100 V). In order to repeat this assay in conditions mimicking the 
reducing cytoplasmic environment, GSH was added to the particles (final concentration 5 mM) 
immediately prior to electrophoresis. Without GSH, both R647 and 647 showed complete siRNA 
complexation with polymer:siRNA weight ratios (wt/wts) as low as 75:1. In the presence of 
cytoplasmic levels of GSH, R647 completely released siRNA, even at the highest wt/wt examined, 
while 647 binding was unaffected. GPC results of each polymer show that incubation with 5 mM 
GSH for 5 min is capable of degrading R647 but not 647 (Figure 4.6). These results combined 
with the competition binding data show that R647 can not only condense and protect siRNA as 
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well as or slightly better than 647 when in extracellular conditions but is also able to completely 
release siRNA within minutes of exposure to cytoplasmic GSH levels. 
 Nanoparticles formed from R647 and 647 were characterized by size via nanoparticle 
tracking analysis (NTA) using a NanoSight NS500 and surface charge (ζ-potential) via dynamic 
light scattering (DLS) using a Malvern Zetasizer NanoZS (Figure 4.7). For each polymer, 
nanoparticles were formed at either 450 wt/wt or 112.5 wt/wt. For all four formulations tested, 
nanoparticle diameter remained between 111 nm and 118 nm, which falls in the appropriate size 
range for efficient cellular uptake.37 For particles formed at 112.5 wt/wt with either R647 or 647, 
ζ-potential was neutral (between -10 and +10 mV), while particles formed at 450 wt/wt with R647 
or 647 had a ζ-potential of 19.0 ± 1 mV and 20.6 ± 1 mV, respectively.  
4.3.3. In vitro assessment of siRNA delivery to human GBM using novel bioreducible PBAE 
 Gene knockdown and cellular loss in metabolic activity were evaluated in glioblastoma 
GBM 319 cells expressing constitutive GFP,38 using siRNA targeted at GFP with sequence 5'-
CAAGCUGACCCUGAAGUUCTT (sense) and 3'-GAACUUCAGGGUCAGCUUGCC 
(antisense), or a scrambled control siRNA (scRNA) with sequence 5'-
AGUACUGCUUACGAUACGGTT (sense) and 3'-CCGUAUCGUAAGCAGUACUTT (anti-
sense) (Figure 4.8). Loss in metabolic activity was measured 24 h post transfection using a 
CellTiter 96® AQueous One Solution cell proliferation assay and read using a BioTek® 
Synergy™ 2 Microplate Reader. GFP expression was measured 9 d post-transfection using a BD 
Accuri™ C6 flow cytometer (emission filter: 530/30 nm). Transfections were performed with 26.7 
nM siRNA using R647 or 647 at either 450 wt/wt or 112.5 wt/wt. The 450 wt/wt formulation of 
647 achieved 75 ± 12% GFP knockdown but with 94 ± 1% loss in metabolic activity, indicating 
that this treatment was very toxic. The 112.5 wt/wt formulations of R647 and 647 did not exhibit 
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marked loss in metabolic activity, but were unable to achieve substantial GFP knockdown at 2 ± 
4% and 4 ± 4% knockdown, respectively. This result is not surprising as polymer hydrophobicity 
has been shown to promote better siRNA delivery; however, there is no concentration at which 
647 is both safe and effective.19 Incredibly, R647 at 450 wt/wt achieved 92 ± 1% GFP knockdown, 
with no measurable loss in metabolic activity. This demonstrates that addition of a bioreducible 
moiety to the PBAE backbone not only improved siRNA delivery but also attenuated toxicity. 
Compared to the leading commercially available reagent Lipofectamine™ 2000, R647 achieved 
more than double the % knockdown and prevented typically observed cytotoxicity. 
4.3.4. Synthesis and characterization of bioreducible/hydrophobic PBAEs 
We were able to successfully synthesize and characterize bioreducible and hydrophobic 
PBAEs. Bioreducible monomer 2,2’-disulfanediylbis(ethane-2,1-diyl) diacrylate BR6 was 
synthesized in a method similar to Chen et al.35 Synthesis of bioreducible and hydrophobic 
polymers was achieved by mixing backbone monomers 2,2’-disulfanediylbis(ethane-2,1-diyl) 
(BR6) and hexane-1,6-diyl diacrylate (B6) at ratios of either 1:0, 3:1, 1:1, 1:3, or 0:1 prior to 
polymerization with side chain monomers 3-amino-1-propanol (S3), 4-amino-1-butanol (S4), or 
5-amino-1-pentanol (S5). Polymers were then endcapped with small molecule 1-(3-aminopropyl)-
4-methylpiperazine (E7) (Figure 4.9). As an example, a polymer synthesized with a 3:1 BR6:B6 
ratio, side chain S3, and end-capped with E7 will be referred to as “3:1 R637”, while the same 
polymer with a 0:1 BR6:B6 ratio will be referred to as “637.” BR6 has almost the same structure 
as B6, except that it contains a disulfide linkage.  As the ratio of BR6:B6 increases, so does the 
bioreducibility of the combined polymer. Proton nuclear magnetic resonance (1H NMR) was used 
to confirm the identity and purity of the polymers (Figure 4.10), while gel permeation 
 146 
chromatography (GPC) was used to confirm the size and polydispersities of the polymers (Table 
4.1). 
4.3.5. Trends in in vitro delivery of bioreducible/hydrophobic PBAEs 
The in vitro siRNA delivery efficacy and cytotoxicity of each of these fifteen polymers 
was evaluated in primary human glioblastoma (GBM 319) cells expressing constitutive GFP,38 
using GFP-targeting or a scrambled control siRNA (scRNA). Lipofectamine 2000 and siRNA 
alone were used as controls with 20 nM siRNA. To evaluate the effect of polymer structure, 
nanoparticles were formed with all fifteen polymers to yield final in vitro concentrations of 180  
g/mL polymer and 20 nM siRNA. These results, which are presented in Figure 4.11, show 
interesting trends with regard to polymer bioreducibility and hydrophobicity. First, the results 
show that as the polymer side chain becomes more hydrophobic, toxicity increases, a conclusion 
supported by the statistical results shown in Table 4.2. An example is polymer 1:1 R647 that 
formed nanoparticles that caused -9  11% (essentially zero) loss in metabolic activity versus 
polymer 1:1 R657, which has a side chain longer by only one hydrocarbon but formed 
nanoparticles that caused 77  13% loss in metabolic activity. Second, the results show that 
polymer bioreducibility significantly reduces cytotoxicity. For example, polymers based on 1:1 
BR6:B6, in which ~50% of repeat units are bioreducible, have dramatically less cytotoxicity than 
polymers based on 1:3 BR6:B6, in which only ~25% of repeat units are bioreducible (Table 4.2). 
A particular example of this extreme toxicity change with a small change to polymer structure is 
1:1 R647, which formed nanoparticles that caused no significant loss in metabolic activity, versus 
1:3 R647-based nanoparticles, which caused a loss in metabolic activity of 83  1%.  
The tuneable toxicities of these polymers is interesting, as polymer hydrophobicity has 
been shown to promote enhanced nucleic acid delivery19, 31; therefore, hydrophobic polymers, such 
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as 647, may be effective for siRNA delivery but are too toxic to have an effective therapeutic 
window. By combining hydrophobic monomers with bioreducible ones, we have been able to 
harness the useful properties of hydrophobicity while reducing cytotoxicity and promoting 
cytoplasmic cargo release. Polymer R647, for example, formed nanoparticles that achieved 81  
3% GFP knockdown versus 3:1 R647, which achieved 91  1%, a significant increase (p < 0.05 
by Student’s T test), resulting only from making 25% of repeat units more hydrophobic. Another 
interesting result from these studies was that eight of the polymeric nanoparticles tested achieved 
significantly higher GFP knockdown than Lipofectamine 2000 without causing significantly 
higher loss of metabolic activity. An example fluorescence image of 1:1 R647 nanoparticle treated 
cells demonstrating safety and efficacy is shown in Figure 4.12e.  
In order to further elucidate the nanoparticle properties favorable for safe and effective 
siRNA delivery, we sought to examine the effects of changing nanoparticle formulation and the 
resulting physical properties associated with these changes. First, siRNA dose-dependency was 
examined by delivering siRNA at final in vitro doses ranging from 1-160 nM using polymer 1:1 
R647 at a fixed concentration of 180 g/mL (Figure 4.12a,c). An intriguing result from this 
experiment is that we were able to achieve significantly higher GFP knockdown using only 5 nM 
siRNA (76  14%) compared to leading commercially-available Lipofectamine 2000 with 20 
nM siRNA  (40  7%).  Importantly, none of the formulations tested was significantly more toxic 
to the cells than Lipofectamine 2000. Additionally, we achieved 63  16% GFP knockdown with 
as little as 1 nM siRNA, demonstrating the efficiency of these bioreducible siRNA-containing 
nanoparticles. Interestingly, we did not see a particularly strong siRNA dose-dependent trend of 
GFP knockdown within the range of nanoparticle formulations tested, as almost all siRNA doses 
evaluated caused uniformly high knockdown. Of the nine polymer/siRNA doses tested, seven 
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achieved more than 75% knockdown and were significantly more effective than Lipofectamine 
2000. For these samples, knockdown correlated semilogarithmically with siRNA dose (R2 = 
0.8649).  
Polymer concentration dependency was examined by carrying out transfections with 20 
nM siRNA and varying 1:1 R647 concentrations from 11.25-360 g/mL (Figure 4.12b,d). 
Interestingly, GFP knockdown correlated linearly with polymer concentration with R2 = 0.9440. 
In order to elucidate the mechanisms behind these surprising results, we analyzed the nanoparticle 
physical properties associated with each delivery method to determine the size, zeta potential, 
nanoparticle concentration, and siRNA loading of each formulation. siRNA loading was calculated 
from the nanoparticle concentration, total siRNA dose, and siRNA molecular weight. Nanoparticle 
concentration measurements were quantified in a manner consistent with the protocol described 
by Bhise et al.34 
4.3.6. Trends in bioreducible/hydrophobic PBAE nanoparticle physical properties 
In order to evaluate the ability of the polymers to complex with siRNA to form 
nanoparticles, we determined the polymer/siRNA weight ratios (wt/wts) at which siRNA became 
completely complexed.  We performed a gel retention assay using 1:1 R647 with wt/wts ranging 
from 37.5-600 wt/wt (Figure 4.13). We found that siRNA is completely bound to 1:1 R647 at 
wt/wts as low as 150 wt/wt, but not at 75 or 37.5 wt/wt. This study also enabled us to validate that 
siRNA loading could not be accurately calculated for nanoparticle formulations at these lower 
wt/wts. In order to demonstrate the siRNA release efficacy of this polymer in a reducing 
environment comparable to the cytosol,17 particles were incubated in a solution of 5 mM 
glutathione for 15 min prior to electrophoresis. All formulations tested showed complete siRNA 
release, showing that siRNA unloading can occur within minutes of reaching the cytosol, in an 
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environmentally triggered manner, due to the disulfide linkages in the polymer. While there are 
also ester linkages in these bioreducible PBAEs, the half-life for hydrolysis of the ester bonds in 
this class of materials is on the order of hours,39 while the half-life for bioreduction of the disulfide 
bonds is on the order of minutes in the presence of glutathione.21  While Figure 4.13 shows that 
intracellular siRNA release is likely driven by disulfide degradation, the hydrolytic degradability 
of the polymers may afford an additional reduction in potential toxicity. 
Nanoparticle properties were measured using the same formulations shown in Figure 
4.12a, in which siRNA dose was varied from 1-160 nM and 1:1 R647 concentration remained the 
same at 180 g/mL. Nanoparticle diameter was shown to correlate with siRNA dose on a 
semilogarithmic scale (R2 = 0.9077), while zeta potential remained consistently between 18-22 
mV (Figure 4.14a). Size measurements were also completed using 0 nM siRNA, which showed 
smaller polymeric particles, 78  4 nm in size. Nanoparticle concentration remained nearly 
constant with changing siRNA dose, even with 0 nM siRNA, staying between 1.29-1.66 x 1011 
particles/mL (R2 = 0.0013). siRNA loading was calculated and demonstrated a linear correlation 
with siRNA dose (R2 = 0.9980).  
We repeated the same experiments, this time using the nanoparticle formulations shown in 
Figure 4.12b, where siRNA dose remained constant at 20 nM and 1:1 R647 concentration was 
varied from 11.25-360 g/mL. Polymer concentration did not correlate well with either 
nanoparticle diameter (R2 = 0.3012) or zeta potential (R2 = 0.4280) (Figure 4.14b). Nanoparticle 
concentration, however, fit a linear regression versus polymer concentration (R2 = 0.9496). This 
resulted in siRNA loading values that exponentially decayed with increasing polymer 
concentration (R2 = 0.9989), meaning that the most effective siRNA delivery formulations in this 
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group consisted of the highest nanoparticle concentrations but with the lowest siRNA loading 
values. 
When calculating siRNA loading, we were calculating average siRNA loading across a 
nanoparticle batch. We believe that siRNA loading within these batches is also roughly uniform 
based on the presence of a constant nanoparticle concentration across all siRNA doses as well as 
linearly increasing nanoparticle diameters with increasing siRNA dose. To further characterize 
nanoparticle size and siRNA loading, we performed transmission electron microscopy (TEM) on 
1:1 R647 at 180 g/mL with 20 nM siRNA and compared the size histogram results from NTA of 
this nanoparticle formulation to the corresponding nanoparticle formulation without siRNA 
(Figure 4.15). TEM shows a roughly uniform size distribution, with the presence of a few larger 
particles/aggregates (Figure 4.15a). This matches the NTA analysis as well (Figure 4.15b). The 
NTA histogram of the nanoparticles containing 20 nM siRNA (113  2 nm) were distinct from the 
smaller nanoparticles containing 0 nM siRNA (78  4 nm). Due to this greater size and 
monodisperse distribution, it is most likely that as siRNA dose is increased, each nanoparticle 
contains more siRNA per particle, rather than a significant fraction of nanoparticles remaining 
empty, which would have resulted in a bimodal particle distribution. 
We envision that these bioreducible siRNA nanoparticles could potentially be used for 
local intracranial delivery of siRNA for the treatment of glioblastoma.  In this approach, they 
would applied in a manner analogous to the GLIADEL® Wafer following surgical resection of 
glioblastoma.   Although we intend for this potential therapeutic to be used for local delivery, 
rather than systemic delivery, we also looked at transfection in the presence of serum proteins, 
which are known to reduce the efficacy of many gene delivery systems.  We found that 
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bioreducible PBAE polymers can enable high (80  4%) GFP knockdown in the presence of 10% 
serum-containing media and knockdown can persist for at least two weeks (Figure 4.16). 
 
4.4. Conclusions 
 We have synthesized and characterized a novel bioreducible PBAE for siRNA delivery to 
primary human glioblastoma that is both efficacious and non-cytotoxic. The reducible polymer 
R647 was shown to bind siRNA as well as or slightly better than its non-reducible analog 647. It 
was determined that this new polymer is capable of condensing siRNA in nanoparticles with the 
same physical properties as the previously established 647 particles. It was also shown that siRNA 
release from R647 occurs within minutes of entering a reducing environment comparable to 
cytosol. We finally demonstrated that R647 nanoparticles that differed from 647 only in 
reducibility were able to achieve near-complete gene knockdown with no toxicity in human brain 
cancer cells, while analogous 647 nanoparticles were either extremely toxic or ineffective. This 
new class of polymer has exciting therapeutic potential as a safe and effective siRNA delivery 
vehicle. 
We were able to show that combining polymer hydrophobicity, a property known to 
promote enhanced siRNA and DNA delivery,19, 31 with bioreducibility decreased the cytotoxic 
effects typical of hydrophobic polymers while optimizing environmentally triggered cytoplasmic 
cargo release to enhance siRNA delivery. These nanoparticles are safe and effective even at very 
low siRNA doses. We examined the effects of changing nanoparticle formulation and were able 
to show that, with this class of materials, nanoparticle concentration is largely determined by 
polymer concentration and that higher polymer concentrations promote enhanced siRNA delivery. 
Gene knockdown was shown to be very effective (91  1%) with moderate doses of siRNA (20 
nM), and effective (63  16%) even at very low doses of siRNA (1 nM). Bioreducible PBAEs with 
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tuneable hydrophobicities have exciting potential as safe and efficient siRNA delivery vehicles for 
nanomedicine applications.  
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Table 4.1. Gel permeation chromatography results of all polymers 
 
  
Polymer Mn Mw PDI 
R637 2344 3899 1.66 
3:1 R637 2623 4548 1.73 
1:1 R637 2882 5046 1.75 
1:3 R637 3416 5711 1,67 
637 2369 3244 1.37 
R647 2474 4001 1.62 
3:1 R647 2843 4900 1.72 
1:1 R647 3211 5597 1.74 
1:3 R647 3483 6347 1.82 
647 3962 6193 1.56 
R657 2628 4102 1.56 
3:1 R657 3233 4198 1.30 
1:1 R657 2779 4683 1.69 
1:3 R657 3560 6038 1.70 
657 2357 4158 1.76 
R646 2984 5360 1.67 
R65Ac 3233 3460 1.07 
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Figure 4.1. Cytotoxicity of monomer E7 to glioblastoma cells at 24 h post-transfection. 
  

































Figure 4.2. NMR spectra of polymers R647, 647, and 1:1 R647. The ratio of BR6:B6 
incorporated into polymer 1:1 R647 was calculated by comparing the integrals of the peaks 
found at δ4.2-4.4 versus δ3.9-4.1 (1.00 vs. 1.04). R647 base polymer: (d6-DMSO, 400Hz), 
δ1.25-1.5 (4H, br, NCH2CH2CH2CH2OH), δ2.3-2.5 (6H, br, OOCCH2CH2N and 
NCH2CH2CH2CH2OH), δ2.6-2.7 (4H, t, OOCCH2CH2N), δ2.9-3.1 (4H, t, COOCH2CH2S), δ3.3-
3.4 (2H, br, obsc, NCH2CH2CH2CH2OH), δ4.2-4.4 (4H, t, COOCH2CH2S). H
1-NMR of 647 base 
polymer: (d6-DMSO, 400Hz), δ1.25-1.5 (8H, br, NCH2CH2CH2CH2OH and COOCH2CH2CH2), 
δ1.5-1.65 (4H, br, COOCH2CH2CH2), δ2.3-2.5 (6H, br, NCH2CH2CH2CH2OH and 
OOCCH2CH2N), δ2.6-2.7 (4H, br, OOCCH2CH2N), δ3.3-3.4 (2H, br, obsc, 
NCH2CH2CH2CH2OH), δ3.9-4.1 (4H, br t, COOCH2CH2CH2). H
1-NMR of 1:1 R647 base 
polymer: (d6-DMSO, 400Hz), δ1.25-1.5 (8H, br, NCH2CH2CH2CH2OH and COOCH2CH2CH2), 
δ1.5-1.65 (4H, br, COOCH2CH2CH2), δ2.3-2.5 (6H, br, NCH2CH2CH2CH2OH and 
OOCCH2CH2N), δ2.6-2.7 (4H, t, OOCCH2C δ3.9-4.1 (4H, br t, COOCH2CH2CH2), H2N), δ2.9-
3.1 (4H, t, COOCH2CH2S), δ3.3-3.4 (2H, br, obsc, NCH2CH2CH2CH2OH), δ3.9-4.1 (4H, br t, 
COOCH2CH2CH2), δ4.2-4.4 (4H, t, COOCH2CH2S). H
1-NMR of E7 endcap: (d6-DMSO, 
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400Hz), δ1.50, (2H, quint, NHCH2CH2CH2N<(CH2CH2)>NCH3), δ2.13 (3H, s, 
NHCH2CH2CH2N<(CH2CH2)>NCH3), δ2.3-2.4 (10H, br, obsc, 














Figure 4.4. Polymer/siRNA competitive binding assay for R647 and 647. Polymer to siRNA 
binding strength is assessed by quenching of YO-PRO®-1 Iodide fluorescence over increasing 
polymer concentrations. 
  





























Figure 4.5. Gel retention assay. Gel electrophoresis image of siRNA complexed with R647 (left) 
or 647 (right) in the absence (0 mM) or presence (5 mM) of GSH. Numbers above each well 





Figure 4.6. GPC results of R647 (left) and 647 (right) following degradation study. Red dashed 
lines show GPC chromatogram of untreated polymers, green dashed lines show each polymer 
following a 5 min incubation in PBS, solid blue lines show each polymer following a 5 min 
incubation in PBS containing 5 mM GSH. The results demonstrate that a reducing environment 











































R647 in PBS with GSH
 162 
 
Figure 4.7. Nanoparticle size and surface charge. Nanoparticle diameter and ζ-potential of 
particles formed using either R647 or 647 at either 450 wt/wt or 112.5 wt/wt. Nanoparticle 
diameter was measured using NTA. ζ-potential was measured using DLS.  Statistical 
significance was calculated by one-way ANOVA with Tukey’s Multiple Comparison post-tests. 
Nanoparticle diameters of all samples were not significantly different (p > 0.05). Nanoparticle 


















































Figure 4.8. Day 9 gene knockdown of GFP+ GBM 319 cells transfected with R647 and 647 at 
either 450 or 112.5 wt/wt with 26.7 nM siRNA targeted against GFP. Left panel: Brightfield 
images of R647, 450 wt/wt treated cells (A,B) and 647, 112.5 wt/wt treated cells (I,J) show 
viable cells while 647, 450 wt/wt treated cells (E,F) show significant toxicity. Fluorescence 
images of R647, 450 wt/wt treated cells show significantly less GFP expression when 
formulations contain GFP siRNA (C) versus scrambled control siRNA (D). Fluorescence images 
of 647, 112.5 wt/wt treated cells show comparable GFP expression in both GFP siRNA (K) and 
scrambled control treated cells (L). Right panel: Graphical representation of knockdown and loss 
in metabolic activity results. Lipofectamine™ 2000 positive control with 26.7 nM siRNA is used 
as the control for statistical comparisons by one-way ANOVA with Dunnett’s post-tests (* = 





Figure 4.9. Polymer synthesis scheme. Diacrylate backbone monomers BR6 and B6 were 
randomly copolymerized at a ratio of X:Y with side chain S3, S4, or S5, (demonstrated with S4 
above). The resulting acrylate-terminated base polymers were then endcapped with small 






Figure 4.10. Gene knockdown and loss in metabolic activity of polymers with varying 
bioreducibility and hydrophobicity. Results shown include day 1 loss in metabolic activity and 
day 9 gene knockdown of GFP+ GBM 319 cells transfected with all polymers using 180 μg/mL 
polymer and 20 nM siRNA targeting GFP, normalized to cells treated with the same nanoparticle 
formulation using scrambled control RNA. Lipofectamine 2000 is used as the control for 
statistical comparisons by one-way ANOVA with Dunnett’s post-tests (* = p<0.05, ** = p< 0.01, 






Figure 4.11. GFP knockdown and loss of metabolic activity in GFP+ GBM 319 cells transfected 
with various formulations of 1:1 R647 siRNA nanoparticles. All knockdown values are 
normalized to scrambled control RNA. (A) Transfection results using 180 μg/mL polymer with 
siRNA doses ranging from 1-160 nM. The Lipofectamine 2000 control shown used 20 nM 
siRNA. (B) Transfection results using 20 nM siRNA with polymer concentrations ranging from 
11.25-360 μg/mL. (C) Correlation of knockdown efficiency and varying siRNA doses with 
polymer concentration fixed at 180 μg/mL fitted to a semilogarithmic line. (D) Correlation of 
knockdown efficiency and varying polymer concentrations with siRNA concentration fixed at 20 
nM fitted to a linear regression. (E) Phase contrast (top) and fluorescence (bottom) images of 
GFP+ GBM cells treated with 1:1 R647 at 180 μg/mL and 20 nM of either siRNA targeting GFP 
(left) or scrambled control RNA (right) nanoparticles. Lipofectamine 2000 is used as the 
control for statistical comparisons by one-way ANOVA with Dunnett’s post-tests (* = p<0.05, 





Figure 4.12. Gel retention assay of 1:1 R647 particles formed at varying wt/wts and incubated 
for 15 min at room temperature in the absence (top) or presence (bottom) of 5 mM GSH. 





Figure 4.13. Characterization of nanoparticle size, zeta potential, concentration, and loading of 
nanoparticles synthesized with 180 μg/mL 1:1 R647 and varying siRNA doses (A, C) or with 20 
nM siRNA and varying polymer concentrations (B, D). Size and concentration were measured 
by NTA, zeta potential was measured using DLS, and siRNA loading was calculated from 
concentration. (A) Nanoparticle size positively correlates with siRNA dose on a semilogarthimic 
scale, while zeta potential does not change. (B) Nanoparticle size and zeta potential do not 
strongly correlate with polymer concentration. (C) Nanoparticle concentration remains consistent 
despite changing siRNA dose, while siRNA loading increases linearly. (D) Nanoparticle 
concentration linearly increases with polymer concentration resulting in exponential decay of 





Figure 4.14. Characterization of nanoparticle size distribution. (A) TEM image of nanoparticles 
made with 1:1 R647 at 180 μg/mL and 20 nM siRNA. (B) Nanoparticle size distribution of 1:1 





Figure 4.15. Gene knockdown in serum-containing media. Results show timecourse of GFP 
knockdown in GFP+ glioblastoma cells following transfection in media containing 10% serum. 
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Cancer-selective nanoparticles for combinatorial siRNA delivery to 




The goal of this work was to create a novel siRNA delivery nanotechnology capable of 
treating and preventing the recurrence of glioblastoma, the most malignant primary human brain 
cancer.1-3  There is increasing evidence that brain tumor recurrence is due to the presence of a 
subset of cancer cells that are stem-like and tumor-propagating. These cells are believed to be 
able to survive conventional treatments and to be able to migrate away from the primary tumor 
site and form new tumors.4, 5 RNA interference (RNAi), a natural cellular process that can 
prevent the expression of genes in a sequence-specific manner, can be induced by the 
introduction of short interfering RNA (siRNA) into the cells.6 Using siRNA to turn off the genes 
that allow GBM cells to survive treatment, to migrate, and to form new tumors has the potential 
to prevent tumor recurrence following treatment. However, siRNA delivery is challenging. Viral 
siRNA delivery has many potential problems such as tumorigenicity and immunogenicity, and is 
generally limited to carrying one type of siRNA, as multiple doses could increase the risks of 
using them in patients.7 
In Chapter 4, we showed that we have been able to synthesize a novel, bioreducible 
poly(beta-amino ester) (PBAE)-based nanoparticle capable of safe and effective delivery of 
siRNA to primary human glioblastoma cells.8 We have also shown that we can achieve near 
complete gene knockdown of a fluorescent marker gene using only a fraction of the siRNA that 
                                                     
This chapter contains material modified from the following article, previously published as: 
Kozielski, K.L.; Tzeng, S. Y.; Hurtado de Mendoza, B. A.; Green, J.J: Bioreducible cationic polymer-based 
nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery to primary human brain 
cancer cells. ACS Nano 2014, 8, 3232-3241.  
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we can load into the nanoparticles.9 This work led us to hypothesize that since only a fraction of 
the loaded siRNA was needed for gene knockdown, perhaps we could load several different 
siRNAs into each particle and still achieve simultaneous knockdown of all targeted genes. 
Herein we will discuss the ability of bioreducible PBAEs to simultaneously and robustly 
knockdown the expression of multiple genes that promote tumor survival and enable recurrence. 
  We will also show in vitro work that demonstrates that these nanoparticles preferentially 
induce RNAi in GBM cells and not in healthy human brain cells. Synthesizing nanoparticles 
capable of selectively delivering siRNA to tumor cells would allow us to target any gene 
necessary to tumor survival without worrying about delivering a potentially harmful siRNA to 
surrounding healthy cells. Targeting genes that allow tumor cells to survive, migrate, and form 
new tumors will allow us to create a technology capable of reducing GBM cells’ proliferative 
and regenerative capacity. Moreover, delivering multiple siRNAs will allow us to shut down 
parallel biological pathways simultaneously so that compensatory mechanisms cannot restore the 
cell’s malignant phenotype. Generating a tumor-targeting therapy capable of simultaneously 
shutting down multiple pathways that enable tumor behavior has the potential to be a selective 
and robust GBM therapy. 
 
5.2. Materials and Methods 
5.2.1. Materials 
 All chemicals used to synthesize bioreducible PBAE monomer BR6 were purchased from 
Sigma-Aldrich Chemical Company (St. Louis, MO) and used without further purification. PBAE 
monomers were purchased from Alfa Aesar (Ward Hill, MA). All siRNA oligos were purchased 
from Origene Technologies (Rockville, MD), with the exception of AllStars Human Cell Death 
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siRNA (siDeath), which was purchased from Qiagen. Western blotting antibodies for Yes-
associated protein 1 (YAP1), Sodium-potassium-chloride cotransporter 1 (NKCC1), Survivin, 
Roundabout homolog 1 (Robo1), Endothelial growth factor receptor (EGFR), and -Actin were 
purchased from vendors listed in Table 5.1. Cannulas for orthotopic tumor implantation and 
nanoparticle administration were purchased from Plastics One Inc. (Roanoke, VA).  
5.2.2. Bioreducible polymer synthesis 
 Monomer BR6 was synthesized as previously described in Chapter 4. Briefly, bis(2-
hydroxyethyl) disulfide was acrylated with acryloyl chloride in anhydrous conditions in the 
presence of triethylamine (TEA). TEA HCl precipitate was removed via filtration, and other 
impurities were removed via aqueous washes of Na2CO3, followed by water. The final product 
was purified from organic solvents using rotary evaporation. Polymer synthesis of polymer R646 
was carried out in a method similar to as described in Chapter 4, although tetrahydrofuran 
(THF) was used as the polymerization solvent and the polymerization reaction temperature was 
60ºC. Following polymerization and end-capping, unreacted monomer was removed via ether 
purification, in which the polymer solution was mixed in a 1:5 v/v ratio with diethyl ether, 
centrifuged at 3220 RCF, and excess ether removed via decantation. This was repeated, and 
remaining ether was allowed to evaporate from the polymer under vacuum. The polymer was 
resuspended in DMSO at 100 mg/mL, and polymers were stored under desiccant at -20ºC.  
5.2.3. Cell Culture 
fNPC 34 cells were utilized to compare siRNA delivery between primary human 
glioblastoma cells and healthy human primary cells found in the brain.  fNPC 34 cells are 
primary fetal neural progenitor cells obtained as described previously following procedures 
approved by the Johns Hopkins University Institutional Review Board.10 fNPCs cells were 
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grown in 65% GIBCO® DMEM, 32% GIBCO® DMEM-F12, 2% B-27® Serum-Free 
Supplement, 1% Antibiotic-Antimycotic (Invitrogen), 10 g/mL each of basic fibroblast growth 
factor (Roche Applied Science), epidermal growth factor (Sigma), Leukemia inhibitory factor 
(Millipore), and 5 mg/mL Heparin (Sigma). Primary human GBM cells were isolated from 
intraoperative samples by the Quinones laboratory.10 GBM cells were grown in in 97% GIBCO® 
DMEM-F12, 1% GIBCO® Antibiotic-Antimycotic (Invitrogen), 2% B-27® Serum-Free 
Supplement, and 20 g/mL each of basic fibroblast growth factor (Roche Applied Science) and 
epidermal growth factor (Sigma) for all experiments. Tissue culture plates were coated in 5 
g/mL laminin (Sigma) for to allow GBM and fNPC cells to adhere for all experiments. Primary 
human neurospheres (GBM1A, used for orthotopic tumors) were grown in the same media and 
conditions as all other GBM, but cells were grown in suspension for culture and only plated onto 
laminin-coated plates for in vitro experiments. For all in vitro experiments, cells were plated at a 
density of 47 x 103 cells/cm2 and allowed to adhere overnight.  
5.2.4. In vitro delivery of siRNA 
 For all transfections, polymer R646 and siRNA were separately diluted in 25 mM NaAc, 
and mixed in a 1:1 v/v ratio and allowed to self-assemble into nanoparticles for 10 min prior to 
being added to cells. Nanoparticles were incubated with cells for 2 h, and then the media were 
removed and replaced with fresh media. For all transfections following Figure 5.1 the total 
concentrations of R646 and siRNA were 270 g/mL and 120 nM, respectively. For experiments 
in which more than one siRNA was used in a nanoparticle formulation, siRNA oligos were 
blended in 25 mM NaAc prior to exposure to polymer. 
 For cellular uptake experiments, scrambled control RNA (scRNA) was first labeled with 
a Cy5 fluorophore using the MirusBio Label IT Nucleic Acid labeling kit following 
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manufacturer’s instructions. Nanoparticles stuck to the surface of cells were removed by washing 
with heparin sulfate prior to flow cytometry. Flow cytometry and cell preparation was otherwise 
carried out as described in Chapter 4, in which a BD Accuri™ C6 flow cytometer equipped with 
a Hypercyt autosampler was used to collect data, and FlowJo 7 software was used for data 
analysis.  
5.2.6. Quantification of siRNA-induced cell killing 
 Five days following transfection with either siDeath or scRNA, cells were stained with 
1:200 propidium iodide (PI), fixed with 10% formalin containing methanol (for membrane 
permeabilization), and stained with 1:200 4',6-diamidino-2-phenylindole (DAPI). Microscopic 
images were captured at 5X magnification using a Zeiss Axio observer A1 microscope with a Zeiss 
Axiocam MRm camera and AxioVision software. Fluorescence was provided by an Exfo X-Cite® 
series 120Q. Live and dead cells were quantified using ImageJ v1.47 software, and dead cells were 
subtracted from the live cell count to yield the total cell count for each well.  
5.2.7. Western Blotting 
 Except where noted otherwise, in vitro cell harvests were conducted 3 days post-
transfection. In vitro protein lysates were isolated using 5.2 L/cm2 of radioimmunoprecipitatoin 
assay (RIPA) buffer in tissue culture flasks. Cells were dissociated via cell scraping, lysates were 
kept on ice for 30 min with vortexing at 5 min intervals. Cell debris was removed by centrifugation 
at 19.2 x 103 RCF, and the supernatant was collected and stored at -80C. For in vivo protein 
isolation, animals were sacrificed at 3 days following nanoparticle administration, and 
subcutaneous tumors were cut from surrounding tissue. Tumor tissue was homogenized in RIPA 
buffer, and debris removed via centrifugation as described above.  
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 All protein electrophoresis was carried out using 4-12% NuPAGE Noves Bis-Tris gels 
(ThermoFisher Scientific) in 10% 3-(N-morpholino)propanesulfonic acid (MOPS) buffer 
(ThermoFisher Scientific) at 135V for 90 min. Proteins were transferred to a polyvinylidene 
fluoride (PVDF) membrane using a Pierce G2 Fast Blotter (ThermoFisher Scientific) following 
manufacturer’s instructions. All blocking and antibody solutions contained 5% milk in 1X Tris-
buffered saline with Tween 20 (TBST). Primary antibody incubations were completed overnight 
at 4C, and secondary antibody incubations for 1 hr at room temperature. Antibody dilutions and 
specifications are found in Table 5.1.  
5.2.8. Subcutaneous human GBM model and nanoparticle administration 
 Subcutaneous human GBM tumors were created in the flank of 4 week-old athymic 
nu/nu mice by injecting 2 million GBM 612 cells into the subcutaneous space. Isofluorane was 
used to anesthetize the mice. Tumors were allowed to form for 1 month to allow the tumors to 
reach approximately 1 cm3 in size. Nanoparticles were injected directly into the tumor space with 
a total siRNA dose of 27 ug per tumor. Tumors were harvested for Western blotting analysis as 
described above.  
5.2.9. Orthotopic human GBM model and nanoparticle administration 
 All experiments were conducted using 4 week-old athymic nu/nu mice. Transcranial 
cannulas (Plastics One Inc., Roanoke, VA) were implanted using a stereotactic frame to implant 
the tip of the cannula within the right striatum of the brain. Cyanoacrylate glue was used to 
attach the cannula to the skull, and suturing was used to close the surrounding skin. 
Ketamine/xylazine was used as an anesthetic.  
Animals were inoculated with 500,000 luciferase-positive GBM1A cells using an internal 
cannula inserted within the transcranial cannula. A total of 4 L of cell suspension was injected 
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at 1 L/min. Lyophilized nanoparticles were prepared as previously described11 and 4 L of 
nanoparticle solution was injected at 1 L/min through the cannulas. The total dose of siRNA 
per mouse was 0.6 g. Nanoparticle injections began 14 d following tumor inoculation, and were 
repeated twice weekly for two weeks.  
5.2.10. In Vivo Imaging System (IVIS) analysis of tumor growth 
 Luciferase-positive GBM tumors were imaged using an IVIS Spectrum (Caliper Life 
Sciences) and analyzed using Living Image software (PerkinElmer). Animals were injected 
intraperitoneally with 4.5 mg D-Luciferin potassium salt (GoldBio) in 1X PBS 10 min prior to 
imaging. Mice (n=3) were imaged at 14, 17, and 21 days post tumor inoculation.  
5.2.11. Brain tissue harvest, histological preparation and analysis 
 Four weeks following tumor inoculation, animals were anesthetized using 
ketamine/xylazine and their brains perfused using 10% formalin via intracardiac administration. 
The skulls were removed and brains stored in 10% formalin overnight. Brains were transferred to 
a solution of 30% sucrose for two days, then Optimal Cutting Temperature (OCT) compound 
(Fisher Scientific) overnight. Brains were frozen in OCT, and cut into 14 m slices using a Leica 
CM1905 cryostat. Histological slices (3 animals per group, 6 sections per animal) were stained 
with hematoxylin and eosin (H&E), and slides were photographed using a Zeiss Axio observer 
A1 microscope with a Zeiss Axiocam MRm camera at 2.5X magnification. Tumor growth 
inhibition was determined by computer-assisted morphometric quantification of tumor area in 
H&E-stained histologic sections using AxioVision 4.8 software.  
5.2.12. Statistical Analysis 
 All data is presented as the mean  the standard error of the mean. Transfection efficacy 
and cellular uptake of siRNA nanoparticles in GBM versus fNPC cells, and tumor burden were 
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analyzed using a two-tailed t-test. P-values < 0.05 were considered statistically significant in all 
cases. 
 
5.3 Results and Discussion 
To evaluate the therapeutic potential of the bioreducible nanoparticles in vitro, primary 
human glioblastoma and primary human non-cancer neural progenitor cells were both transfected 
with the same bioreducible nanoparticles containing siRNA that could cause cell death to 
successfully transfected cells. We evaluated the brain cancer killing potential of these 
nanoparticles, their potential off-target cytotoxicity to non-cancer human primary cells, and the 
potential for the nanoparticles to effectively target siRNA delivery to brain cancer cells over 
healthy brain cells. 
 To accomplish this goal, we optimized siRNA delivery to human fetal neural progenitor 
cells (fNPC 34s) and GBM 319 cells over a range of polymer and siRNA concentrations. We found 
R646 to be optimal for siRNA delivery to the fNPC 34 cells, which included minimizing 
cytotoxicity, and was therefore utilized for subsequent functional siRNA delivery studies. 
Functional delivery efficacy was detected using a positive control cell death-inducing siRNA, with 
which successfully delivered siRNA would result in cell death. Cell death was measured using 
DAPI and propidium iodide (PI) to stain healthy and dying cells, respectively, and cell death was 
calculated using fluorescence microscopy followed by quantification with ImageJ software. 
Nanoparticle toxicity was calculated by normalizing scrambled RNA (scRNA)-treated cell counts 
to untreated cell counts, while siRNA delivery efficacy was calculated by normalizing death 
siRNA-treated cell counts to scRNA-treated cell counts. 
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For all R646 nanoparticle formulations tested, the GBM 319 cells showed near-complete 
siRNA-mediated cell death (79 – 97%) while the fNPC 34 cells had 0 - 27% siRNA-mediated cell 
death under the same conditions (Figure 5.1). For certain nanoparticle formulations, high 
knockdown leading to specific cell death of human glioblastoma cells was achieved (>90%) while 
non-specific cytotoxicity to both human glioblastoma and healthy human neural cells was kept 
low (< 20%). As the siRNA itself was not specific to GBM 319 cells over fNPC 34 cells and the 
same particle and siRNA doses were utilized, this finding suggests that bioreducible PBAE-based 
nanoparticles themselves preferentially transfect cancer cells over non-cancer cells.  
In order to determine if this knockdown was robust in siRNA delivery to GBM from 
multiple patients, we repeated the cell-killing experiment in GBM cells from four patient 
intraoperative samples, as well as cells from three different fNPC tissue samples. Despite the 
heterogeneity between patient GBM tissue, we found that the nanoparticles preferentially 
transfected and killed the GBM cells (72  9%) while avoiding the healthy cells (6  12%) (Figure 
5.2).9 This result was exciting in that we found that our nanoparticles are tumor selective, meaning 
that we could potentially prevent harmful side effects in healthy brain tissue when delivering them 
in vivo.  
 In order to elucidate the mechanism by which cancer-selective delivery was achieved, we 
tested to see if nanoparticle uptake was different in the two cell types. We used Cy5 fluorphore-
labeled siRNAs in the R646 nanoparticles, repeated the transfections, and used flow cytometry to 
measure the percent of cells positive for Cy5. Interestingly we found no significant difference 
between the percent of cells positive for siRNA in either cell type (94  2% in GBM vs. 94  1% 
in fNPC) (Figure 5.3a). We also used the geometric mean Cy5 intensity measurement to indirectly 
measure the amount of nanoparticles taken up by each cell, and also found no significant difference 
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between the two cell types (121  23 normalized fluorescence units (NFU) in GBM vs. 169  58 
NFU in fNPC) (Figure 5.3b). This result is interesting in that it shows that the bulk uptake of 
nanoparticles into each cell does not seem to be the obstacle preventing successful fNPC 
transfection.  
 In order to assess the therapeutic potential of bioreducible PBAE nanoparticles, we then 
wanted to see if we were able to knockdown genes important to GBM behavior. We began with 
Roundabout homolog 1 (Robo1), a protein identified as key to GBM migration.12 In order to first 
determine what the timeline of our knockdown would be, we delivered siRobo1 to GBM in vitro 
and harvested cells each day for 4 days. We began with a cocktail of 3 siRobo1 oligos blended 
within each particle,  as we purchased them from OriGene Technologies, which guarantees that at 
least 2 of their oligos will achieve successful knockdown upon transfection. This would allow us 
to have at least two thirds of the encapsulated siRNA be functional. We found that nanoparticle 
delivery of siRobo1 was able to successfully knockdown Robo1 expression from days 1 – 4 post-
transfection (Figure 5.4a). In similar experiments conducted knocking down Yes-associated 
protein 1 (YAP1) and Sodium-potassium-chloride cotransporter (NKCC1) we were able to 
maintain gene knockdown for at least 7 days post-transfection (Figure 5.4b,c). For all future in 
vitro siRNA delivery experiments we harvested at 3 days post-transfection, as this seemed to be 
universally appropriate timing for all proteins tested.  
 For each gene, we then wanted to select one of the three siRNA oligo options. We 
transfected GBM cells in vitro using each oligo (labeled A, B, or C) using a blend of all three as a 
positive control and untreated cells and scRNA-treated cells as negative controls. For five proteins 
(Robo1, YAP1, NKCC1, Survivin, and endothelial growth factor receptor (EGFR)) we were able 
to find sequences capable of successful knockdown (Figure 5.5). (See Table 5.2 for full list of 
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oligos). For all further experiments, we used only one oligo targeting each gene as indicated in 
Table 5.2.  
 We then wanted to assess the potential to codeliver each siRNA while maintaining 
knockdown of each individual gene. We formed nanoparticles maintaining the total siRNA dose 
at 120 nM, but we blended in various concentrations of siRobo1 with scRNA, varying from 100% 
siRobo1 to 1 %. We were able to show that even with as little as 5%, or 6 nM siRobo1, we were 
still able to achieve near-complete gene knockdown (Figure 5.6a). This indicates that in a Robo1 
knockdown study in which we attempt to use siRNAs targeting multiple genes, it would be 
possible to use as little as 6 nM siRobo1 and leave the remaining 114 nM to knockdown other 
genes. We have also been able to see similar knockdown strength in experiments done targeting 
YAP1 and NKCC1 (Figure 5.6b,c).  
 Finally, we wanted to show that this combination knockdown was possible as we 
hypothesized. We formed nanoparticles loaded with 24 nM each of Robo1, YAP1, NKCC1, 
Survivn, and EGFR (this will be referred to as “siRNA-5”) for a total dose of 120 nM. We found 
that we were able to successfully knockdown each gene using a single nanoparticle formulation 
(Figure 5.7). We attempted a similar experiment in a subcutaneous model of human GBM in 
athymic mice, and were able to show knockdown of Survivin, EGFR, and NKCC1 (Figure 5.8).  
 As our ultimate goal was to change the malignant, proliferative phenotype of GBM, we 
then tested the effect of siRNA-5 knockdown on tumor growth in an orthotopic model of GBM. 
We inoculated athymic mice with luciferase-expressing primary human GBM (GBM1A) into the 
right striatum, allowed tumors to grow for 14 d, and then used intracranial cannulas to deliver 
siRNA-5 nanoparticles intratumorally twice weekly for two weeks. Using the In Vivo Imaging 
System (IVIS) Spectrum system and intraperitoneal delivery of D-Luciferin, we indirectly 
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tracked tumor size using bioluminescence at 0, 7, and 14 days following the start of nanoparticle 
treatment (Figure 5.9c). At day 14 following the start of treatment, we found tumor bioluminescent 
flux for scRNA treated tumors to be 17.3  5.4 x 107 photons/sec, higher than siRNA treated 
tumors, which had a flux of 6.9   2.5 x 107 photons/sec. 
 Animals were sacrificed for histological analysis of the tumors at 14 d following the start 
of nanoparticle treatment. Histological sections were stained with hematoxylin and eosin (H&E) 
in order to visualize tumors and calculate tumor burden (Figure 5.9a,b,d). We found that tumor 
burden in mice treated with siRNA-5 nanoparticles was significantly lower (3.5  0.6 mm2) than 
those treated with scRNA nanoparticles (6.9  0.4 mm2).  
 
5.4. Conclusions 
We have demonstrated that bioreducible PBAEs selectively deliver siRNA and enable gene 
knockdown in primary human brain cancer while avoiding gene knockdown in healthy brain tissue 
cells. This effect is efficient and robust, in that we have shown this in four different patient GBM 
cells. This presents an interesting opportunity in siRNA-based nanomedicine as future siRNA 
targets and siRNA combinations may not need to be limited to proteins that would specifically 
effect cancer cell viability without harming the surrounding tissue, but instead could enable 
effective targeting and knockdown of any protein necessary to tumor survival as the material itself 
could provide cancer specificity. We have also expanded upon work shown in Chapter 4, in which 
we demonstrated knockdown with low siRNA doses, and shown that we can effectively 
knockdown five genes simultaneously in both in vitro and in vivo human GBM models. We have 
also shown the potential to eventually increase this to ten or twenty genes. Bioreducible PBAE 
codelivery of five genes to in vivo human GBM tumor models showed gene knockdown and a 
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reduction in tumor growth following treatment. This shows the potential of bioreducible PBAEs 
as a potent, combinatorial, and cancer-specific siRNA delivery vehicle.  
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5.5. Tables 




Table 5.2. siRNA oligos used, their sequences, and the assessment of their ability to knockdown 
their respective target protein in the human GBM cells tested. Sequences marked with an asterisk 







Figure 5.1. Delivery of death siRNA to cancer and non-cancer brain cells using polymer R646. 
(A-B) Delivery efficacy of death positive control siRNA to cancer (GBM 319) and non-cancer 
(fNPC 34) cells using a range of bioreducible PBAE nanoparticle formulations. All % siRNA-
mediated death values are calculated versus cell counts of scrambled control RNA-treated cells. 
(C-D) Toxicity of nanoparticle treatments to GBM 319 and fNPC 34 cells. (E) Phase contrast 
images of fNPC 34 (top) and GBM 319 (bottom) cells following treatment with nanoparticles 




Figure 5.2. Bioreducible PBAE nanoparticles selectively transfect primary human GBM cells 
versus primary human neural progenitor cells (fNPCs). siRNA-mediated death following 
transfection using a death positive control siRNA shows significantly more cell killing in the 






























Figure 5.3. Nanoparticle uptake is not statistically different between GBM and fNPC cells. (A) 
The percent of cell positive for fluorophore-labeled siRNA is not statistically different. (B) The 
geometric mean fluorescence of fluorophore-labeled siRNA within each cell, and indirect measure 










Figure 5.5. Western blotting images showing the selection of the most effective siRNA oligos for 





Figure 5.6. Dose response of gene knockdown in primary human GBM of genes Robo1 (A), YAP1 





Figure 5.7. Simultaneous knockdown of 5 genes following in vitro transfection of primary human 





Figure 5.8. Simultaneous knockdown of 3 genes following in vivo transfection of primary 
human GBM in a subcutaneous tumor model with a single formulation of bioreducible PBAE 




Figure 5.9. PBAE nanoparticle codelivery of 5 siRNAs reduced tumor growth in an orthotopic 
model of human GBM. Hemotoxylin and eosin-stained histological slides of siRNA-5 treated 
tumors (A) show reduced tumor burden versus scRNA treated tumors (B, quantification in D). 
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Delivery of microRNA to human glioblastoma for the reduction of tumor 




More than 78,000 new cases of brain cancer are diagnosed in the U.S. each year with 
glioblastoma (GBM) being the most common and deadly form1. Despite aggressive treatment 
consisting of surgical resection and radiotherapy/chemotherapy, the median life expectancy for 
GBM patients remains only between 14 and 20 months, highlighting the need for new therapeutic 
approaches2.  Treatment options for GBM remain limited in part due to the difficulty in delivery 
of drugs through the blood-brain barrier (BBB) and resistance of tumor cells to chemotherapy 
drugs3, 4.  These tumors are heterogeneous at the cellular level and contain cells that vary in their 
capacity to propagate tumor growth5. Among these different cell subpopulations are multi-potent 
stem-like cells (also referred to as cancer stem cells or CSCs) that are critical determinants of 
tumor propagation, therapeutic resistance, and recurrence following treatment. Substantial 
evidence indicates that cancer cells are highly plastic and dynamically transition bi-directionally 
between stem-like/tumor propagating cells (CSC state) and more differentiated/non-tumor 
propagating states (non-CSC state) in response to contextual epigenetic events6. The mechanisms 
driving these phenotypic transitions represent a vulnerability amenable to therapeutic targeting7.  
Epigenetic modifications, involving alterations in chromatin structure and function such as 
histone modification, DNA modification, and deregulation of non-coding RNAs, are important 
determinants of gene expression and essential drivers of neoplastic phenotypes8, 9. Non-coding 
RNAs, in particular miRNAs, are emerging as critical epigenetic regulators of cell fate and 
oncogenesis. MiRNAs act by selectively inhibiting gene expression primarily by targeting mRNA 
for degradation usually via complementary 3’-UTR seed sequences. Numerous miRNAs have 
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been found to regulate tumorigenesis and cancer cell stemness by virtue of their capacity to target 
tumor-suppressing or tumor promoting transcripts10. We recently showed that the coordinated 
actions of Oct4 and Sox2 induce a tumor-propagating stem-like state in GBM cells through a 
mechanism that involves the induction of DNMTs and down-regulation of a network of miRNAs 
through promoter DNA methylation. We further showed that two of the miRNAs repressed by 
Oct4/Sox2, miR-148a and miR-296-5p, efficiently inhibit the GBM stem-like phenotype and their 
repression is required for the induction of GBM tumor propagating capacity by Oct4/Sox2, making 
their reconstitution an excellent strategy for therapeutic intervention11, 12. 
Despite the improved understanding of the molecular determinants of GBM stem cells and 
tumor propagating capacity, translating these advances remains a challenge13. Viral methods to 
introduce nucleic acid cargo to cells, while effective, have to potential to cause tumorigenic and 
immunogenic responses14. Viral gene delivery is also limited in its clinical translation due to 
factors such as scalability and limited cargo size15. The latter concern is particularly critical for 
codelivery of multiple nucleic acid cargoes, as viral delivery of two miRNA constructs would 
likely require exposure to viral vectors twice, increasing the chance of insertional mutagenesis or 
an inflammatory response with each exposure. Nonviral vectors are not limited in their scalability, 
and can be designed to avoid immunogenic and tumorigenic activities. Additionally, nonviral 
delivery vehicles can carry hundreds of DNA plasmids16, or RNA oligos17 within a single 
nanoparticle.  
Nonviral nucleic acid delivery can be carried out using lipid-based18, inorganic19, or 
polymeric20 nanoparticle systems. Cationic polymers such as poly(L-lysine) (PLL) and 
polyethyleneimine (PEI) are capable of encapsulating nucleic acid cargoes into nanoparticles and 
facilitating endosomal cellular uptake due to the charge interaction between the cationic polymers 
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and anionic cell surface21. While PLL-based nanoparticles often remain sequestered within 
endosomal compartments, PEI nanoparticles have a high buffering capacity which enables them 
to escape the endosome20. Poly(beta-amino ester) (PBAE) nanoparticles are cationic and have a 
high buffering capacity, but promote superior gene delivery versus PEI as they contain 
hydrolytically-cleavable ester bonds. This reduces cytotoxicity as well as enhances cargo release, 
a necessary step in successful transfection22.  
 Like most gene delivery vehicles, PBAEs were first optimized for DNA delivery, and 
although DNA and RNA oligos such as miRNA share some physicochemical similarities, the 
materials that are effective for DNA delivery often vary from those that are effective for RNA 
delivery23. We recently developed a novel, bioreducible PBAE analog, designed to encapsulate 
short interfering RNA (siRNA) into nanoparticles and release it upon entering the reducing 
environment in the cytosol24. We were able to show that bioreducibility imparted reduced 
cytotoxicity, promoted cytoplasmically-targeted release and effective gene knockdown in primary 
human GBM in vitro. We were also able to demonstrate selective delivery of siRNA to GBM 
versus healthy neural progenitor cells, and the ability to deliver more than 600 siRNA molecules 
per nanoparticle17. It is due to these results that we chose to use these bioreducible PBAEs for 
miRNA delivery in the work presented herein. MiRNA and siRNA are both short (21-28nt), double 
stranded RNA oligos who block mRNA translation via RNA interference (RNAi) in the cytosol25. 
We therefore hypothesized that the materials that are effective for siRNA delivery would also be 
effective miRNA delivery vehicles.   
In this report we combine this cutting-edge nanoparticle technology with our newly 
discovered stem cell inhibiting miRNAs to develop miRNA nanoparticles to treat gliomas. We 
developed and characterized novel PBAE polymers that can effectively deliver miRNA mimics 
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and inhibit the stem cell phenotype of GBM neurosphere cells in vitro. For the first time, we show 
these miRNA nanoparticles distribute throughout an established tumor in vivo, and more 
importantly, that delivering these tumor-suppressing miRNAs using these biomaterials inhibits the 
growth of established GBM tumor in mouse models. Our findings demonstrate that identifying 
and validating stem cell-inhibitory miRNAs in combination with current advances in 
nanomedicine will undoubtedly impact the development of novel therapies for targeting the CSC 
population and treating GBM. 
 
6.2. Materials and Methods 
6.2.1. GBM Neurosphere Culture  
GBM-derived neurosphere lines (GBM1A and GBM1B) were originally derived and 
characterized by Vescovi and colleagues26 and the A172-iGSC line was developed by us11. 
Neurospheres were cultured in serum-free medium containing DMEM/F-12 (Invitrogen, Carlsbad, 
CA, USA), supplemented with 1% BSA, 20 ng/ml epidermal growth factor (EGF) and 10 ng/ml 
fibroblast growth factor (FGF).  
6.2.2. Materials  
 All chemicals used to synthesize bioreducible monomer 2,2’-disulfanediylbis(ethane-2,1-
diyl) (BR6) were purchased from Sigma-Aldrich (St. Louis, MO) and used without further 
purification. All other monomers used for polymer synthesis were purchased from Alfa Aesar 
(Ward Hill, MA). AllStars Human Cell Death siRNA was purchased from Qiagen. The following 
mature miRNA mimics used in the study were purchased from Dharmacon (GE Healthcare): hsa-
miR-148a-3p (C-300540-05-0005), hsa-miR-296-5p (C-300659-03-0005), and microRNA 
Hairpin Inhibitor Transfection Control with Dy547 (IP-004500-01-05). 
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6.2.3. Bioreducible polymer synthesis 
 Bioreducible monomer BR6 was synthesized as previously described.24 Briefly, the 
acrylation of bis(2-hydroxyethyl) disulfide was carried out in tetrahydrofuran (THF) anhydrous 
conditions with acryloyl chloride as the acrylation reagent and in the presence of triethylamine 
(TEA). Following overnight reaction at room temperature, the TEA HCl precipitate was removed 
via filtration, THF was removed via rotary evaporation, and the impure product was dissolved in 
dichloromethane (DCM). The product was purified using aqueous washes of Na2CO3, followed by 
water, after which DCM was removed via rotary evaporation.  
 Polymers were synthesized in a method similar to Kozielski et al.17 in which monomer 
BR6 was polymerized at a 1.01:1 molar ratio with monomer 4-amino-1-butanol (S4) at 500 mg/mL 
in THF at 60C for 24 h. Polymers were endcapped in THF at 100 mg/mL with 0.2 M -(3-
(aminopropyl)amino)methanol (E6) at room temperature for 1 h while stirring. Unreacted 
monomers were removed by precipitating out polymer using diethyl ether, centrifuging at 3220 
RCF, and decanting off ether. This was repeated, and the polymer was stored under vacuum to 
allow ether to evaporate. The final polymer product was dissolved in dimethyl sulfoxide (DMSO) 
at 100 mg/mL and stored at -20C under dessicant.  
6.2.4. Bioreducible PBAE nanoparticle formulation and screening in GBM neurospheres 
 Nanoparticle formulations were screened using a AllStars Human Death Control siRNA 
(siDeath), a blend of siRNAs that target genes necessary for human cell survival. GBM1A and 
GBM1B cells were plated on poly-L-lysine (PLL) coated tissue culture flasks and allowed to 
adhere overnight. R646 polymer was complexed with either siDeath or a scrambled control RNA 
(scRNA) in 25 mM sodium acetate (NaAc); the solution was mixed, and nanoparticles were 
allowed to self-assemble for 10 min. Nanoparticles were added directly to the cell culture media, 
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and each RNA was at a final concentration of  120 or 80 nM, with final polymer concentrations of 
330, 270, or 310 g/mL. Nanoparticles were incubated with cells for 2 h, after which they were 
removed and replaced with fresh media. Nanoparticles were allowed to release from the tissue 
culture flask and form neurospheres for 5 d, after which cells were imaged to assess cell death.  
 All further in vitro work was carried out in the same manner, using a final RNA 
concentration of 120 nM, and a final R646 concentration of 270 g/mL. For all groups, the total 
dose of each functional miRNA was kept at 60 nM, while the total miRNA dose was 120 nM. As 
an example, “miR-148a + miR-296-5p” nanoparticles contained 60 nM miR-148a and 60 nM miR-
296-5p, while “miR-148a” nanoparticles contained 60 nM miR-148a and 60 nM miR-Ctrl. This 
enables us to keep the nanoparticle physical properties consistent while maintaining the same dose 
of functional miRNA the same if it being used alone or in combination. 
6.2.5. Bioreducible PBAE nanoparticle characterization 
Transmission Electron Microscopy 
 Nanoparticles were synthesized as described above and the solution was placed onto a 
carbon-coated copper TEM grid and allowed to dry. Particles were imaged using a Philips/FEI 
BioTwin CM120 transmission electron microscope. Image J software was used to analyze particle 
size as captured via TEM images.  
Nanoparticle Tracking Analysis 
 Nanoparticles were synthesized as described above and diluted in PBS at a 1:400, 600, or 
800 v/v ratio prior to loading particles into a NanoSight NS500. Particles were tracked and their 
size and concentration determined using NanoSight NTA 2.4 software. All measurements were 
repeated with three formulations of nanoparticles to allow us to determine batch-to-batch 
variability. All particle concentrations represented are scaled so that they report the number of 
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particles per volume that would be present in the in vitro transfection wells. The loading of siRNA 
molecules per particle was calculated by dividing the dose of siRNA in each transfection by the 
number of particles per well. 
Dynamic Light Scattering 
 Nanoparticles were synthesized as described above and diluted in PBS at a 1:6 v/v ratio 
prior to loading into a disposable cuvette cell. Nanoparticle size and surface charge (-potential) 
were measured using Dynamic Light Scattering (DLS) via a Malvern Zetasizer NanoZS. 
Nanoparticles were measured from three separate formulations to account for synthesis variability. 
Nanoparticle hydrodynamic diameter is reported as the mean and SEM of the Z-average diameter.  
Gel retention analysis of nanoparticles in extracellular and cytosolic reducing conditions 
 Nanoparticles were formed as previously described, and diluted at a 1:100 v/v ratio in either 
artificial cerebrospinal fluid (aCSF) or PBS containing 5 mM glutathione (GSH). aCSF is a 
solution of ions that mimics the ionic composition of human CSF.27 Glutathione is present in 
human cells’ cytosol in concentrations ranging from 1 – 8 mM, while extracellular concentrations 
range from 5 – 50 M.28 Nanoparticles were incubated in either solution at 37C while shaking, 
and samples of each solution were removed at 0 min, 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 
8h. Upon removal of the nanoparticles, 30 mg/mL sucrose was added as a cryoprotectant, samples 
were frozen at -80C, and lyophilized. Particles were resuspended to their original concentration 
using deionized water and a 30% solution of glycerol was added to the particle solution in a 1:5 
v/v ratio. Particles were loaded into a 1% w/v agarose gel containing 1 g/mL ethidium bromide 
and electrophoresed at 100 mV for 15 min, after which gels were visualized using UV light 
exposure.  
6.2.6. QRT-PCR and miRNA expression  
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Total RNA was extracted from cells using RNeasy Mini Kit (Qiagen). cDNA was made by 
reverse-transcribing 1 g of total RNA using MuLV Reverse Transcriptase and Oligo (dT) primers 
(Applied Biosystems). qRT-PCR was performed with a Bio-Rad CFX detection System (Bio-Rad) 
and expression of target genes was measured using Power SYBR green PCR kit (Applied 
Biosystems). Samples were amplified in triplicate and relative gene expression was analyzed using 
Bio-Rad CFX manager software and normalized to 18S RNA. Primer sequences used were 
previously described11, 12.  
For miRNA analysis, total RNA including small RNA was extracted using miRNeasy kit 
and 1 g of total RNA was used as template to generate cDNA using miScript II RT kit according 
to manufacturer’s protocol. Mature miRNA expression was detected using miScript SYBR green 
PCR kit using probes for RNU6 (Cat.# MS00033740), miR-148a (MS00003556), and miR-296-
5p (Cat. # MS00016401). All kits and probes used to detect mature miRNAs were purchased from 
Qiagen. 
6.2.7. Tumor formation in vivo 
A transcranial cannula was placed so that the tip is in the right caudate/putamen of female 
athymic nude NCR Nu/Nu mice (8-week old). One week after cannula placement, animals 
received either GBM1A or A172-iGSC neurospheres cells via the cannula and assigned into 
different treatment groups in a non-blinded, non-randomize manner29, 30. Using the same cannula, 
control cohort received nanoparticles loaded with a non-targeting control miRNA labeled with 
Dy547 and the experimental group received nanoparticles loaded with the indicated miRNAs.  
For in vivo delivery, nanoparticles were synthesized using the same polymer to miRNA w/w ratio 
as in all earlier studies (150 w/w), but the total polymer concentration was 5 mg/mL so that we 
could synthesize particles at a higher concentration. Particles were cryoprotected using 30 mg/mL 
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sucrose prior to freezing and lyophilization following previously established protocols.31 For use 
in vivo, nanoparticles were resuspended using deionized water to a final polymer concentration of 
16.7 mg/mL and a final sucrose solution of 100 mg/mL. 
Number of animals used for each experiment is indicated in the corresponding figure 
legend. Tumor growth inhibition was determined by computer-assisted morphometric 
quantification of tumor area in H&E-stained histologic sections as previously described30. Data 
for all in vivo experiments are shown as the mean tumor area distribution of all animals used in the 
study. All animal procedures were approved by the Johns Hopkins Institutional Animal Care and 
Use Committee (Protocol# MO14M307), and were in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals.  
6.2.8. Statistical Analysis 
 All experiments were performed in triplicates and repeated at least twice in each cell model. 
All values are represented as mean  the standard error of the mean. Statistical significance results 
for miRNA overexpression, neurosphere formation, stem marker knockdown were determined 
using a one-way ANOVA with Dunnett’s post-tests using miR-Ctrl as the control. All other 
statistical significance was determined using a one-way ANOVA with Tukey’s post-tests. All 
significance tests with p < 0.05 were considered significant.  
 
6.3. Results and Discussion 
6.3.1. PBAE nanoparticles deliver miRNAs to human GBM in vitro. 
To determine the optimal Polymer:RNA ratio and dosing required to transfect GBM 
neurospheres, PBAE/siRNA conjugates were prepared by mixing increasing amounts of PBAE 
polymer (Figure 6.1) with a scrambled siRNA or a cell-killing positive control siRNA (siDeath). 
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These PBAE/siRNA formulations were then used to transfect GBM1A and GBM1B neurospheres 
and siRNA-induced cell death was measured qualitatively versus scrambled control RNA (siCtrl)-
treated cells. Combining 270 g/ml of PBAE polymer with either 80nM or 120nM of siDeath 
strongly enhanced neurosphere cell killing compared to cells transfected with the siCtrl. (Figure 
6.2). As 270 g/mL PBAE with either 120 nM or 80 nM siCtrl both showed no nanoparticle-
mediated toxicity, we chose to use 270 g/mL PBAE with 120 nM RNA for a polymer:RNA 
weight ratio (wt/wt) of 150 for all remaining experiments. As previously demonstrated, this higher 
RNA dose with a lower polymer wt/wt would allow us to load more RNA molecules into each 
nanoparticle17 and therefore increase the number of nanoparticles that can carry several different 
miRNAs within a single particle. 
6.3.2. PBAE nanoparticles encapsulate miRNA into nanoparticles and effectively release 
miRNA in a cytosolic redox environment. 
 The physical and chemical properties of gene delivery nanoparticles often play a major 
role in their success as gene delivery vehicles. We physically characterized the nanoparticles 
formed by incubating bioreducible PBAE polymers with miRNA, as this has previously never 
been demonstrated and we were unsure of what nanostructure, if any, would form. In order to 
determine if bioreducible PBAEs could encapsulate miRNA into nanoparticles, we physically 
characterized nanoparticle formation and miRNA binding. We formed nanoparticles at a polymer 
to miRNA weight ratio (wt/wt) of 150 wt/ wt and measured nanoparticle hydrodynamic diameter 
and zeta potential using dynamic light scattering (DLS), hydrodynamic diameter and 
concentration via nanoparticle tracking analysis (NTA), and nanoparticle dried size via 
transmission electron microscopy (TEM). We were able to show via TEM that we were able to 
form miRNA nanoparticles with a round morphology (Figure 6.3a.) Zeta-potential was 
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measured to be 18  0.4 mV (Figure 6.3c). Via DLS, the nanoparticle hydrodynamic diameter 
was 159  4 nm, and via NTA, the hydrodynamic diameter was 138  3 nm (Figure 6.3a,b). The 
disparity between nanoparticle size as measured via DLS versus NTA is anticipated as DLS 
yields an intensity-weighted measurement, which weighs larger particles more than smaller ones 
when calculating an average, while NTA yields a number-average measurement, explaining why 
the average size via NTA is smaller. Via TEM, nanoparticle size was measured to be 56  2 nm. 
This difference in these modes of measurement is important in that TEM measures the dried size 
of the nanoparticles, while DLS and NTA measure the hydrodynamic diameter. Nanoparticle 
concentration upon in vitro delivery was measured to be 1.3   .12 x 1010 particles/mL (Figure 
6.3d).  
 In order to determine if these nanoparticles are able to completely encapsulate miRNA, 
we performed a gel retention assay, in which nanoparticles are loaded into an agarose gel, and 
tightly bound RNA is unable to electrophorese under an applied voltage. We first incubated 
miRNA nanoparticles in artificial cerebrospinal fluid (aCSF) to mimic the redox and ionic 
environment in the brain extracellular space32. We found that all miRNA was bound by PBAE 
polymer. Given that all miRNA is bound into nanoparticles at this formulation, the nanoparticle 
concentration, and our known in vitro dose of 120 nM miRNA, this indicates that the average 
miRNA loading within each nanoparticle is 5456  512 miRNA molecules per particle (Figure 
6.2e). This was an important finding, as a major advantage of using nanoparticle delivery versus 
a viral vector is facile codelivery. However, previous work showing codelivery of plasmid DNA 
demonstrated that having two plasmids within the same batch of particles is not sufficient, that 
the plasmids must be blended within the particles themselves in order to successfully deliver 
both plasmids to each cell33. Having thousands of miRNAs within a single nanoparticle would be 
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beneficial, as both miR-148a and miR-296-5p need to be codelivered to successfully reduce 
tumor cell stemness. 
We continued to incubate the nanoparticles in aCSF and found that miRNA remained 
completely bound within the first hour of aCSF incubation, began to release at 2 hr and 
completely released by 8 hr. To assess miRNA binding in an environment mimicking the 
reducing cytosolic space, we incubated miRNA nanoparticles in 5 mM glutathione (GSH), the 
primary reducing agent in the cytosol28. In the presence of GSH, miRNA began to release within 
5 min of incubation, and was completely released within 30 min (Figure 6.2f). The quick release 
of miRNA is dually important, as polymer degradability reduces cytotoxicity34 and because 
dissociation of nucleic acid cargo from its carrier is a necessary step for transfection35, 36. 
6.3.3. PBAE nano/miRs inhibit the GBM stem cell phenotype in vitro. 
miRNAs and siRNAs share chemical, physical, biological, and biochemical properties37 
prompting us to hypothesize that the polymer formulations we developed to deliver siRNAs will 
also efficiently deliver miRNAs. To test this hypothesis mature miRNA mimics labeled with 
Dy547 were complexed with PBAE polymers to generate PBAE nano/miRs used to transfect GBM 
neurospheres. Nanoparticle assembly and payload delivery was monitored using fluorescent 
microscopy. We detected fluorescence from the Dy547-labeled control miRNA starting 3 days 
after the transfection and the signal persisted for at least 12 days (Figure 6.4a, 6.5). These results 
show that we can stably and efficiently deliver miRNAs using this PBAE formulation.  
One major advantage of nonviral gene delivery via cationic polymers is that particles can 
be easily loaded with individual miRNAs or combinations by simply incubating polymer with 
RNA to allow electrostatically-induced self-assembly13, 38. We recently identified two miRNAs, 
i.e. miR-148a and miR-296-5p, that are down-regulated during GBM stemness induction by 
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Oct4/Sox2 and whose reintroduction inhibits the stem cell phenotype and tumor-propagating 
potential of these cells 11, 12. To measure the ability of these PBAE polymers to deliver these bio-
active miRNAs, nano/miRs  consisting of control miRNA (miCtrl), miR-148a mimic, miR-296-
5p mimic, or miR-148a+miR-296-5p (comb.) were prepared and used to transfect GBM 
neurospheres. The total RNA concentration was kept at 120 nM, and miR-148a or miR-296-5p 
were either blended with miCtrl or one another, so that the total dose of each functional miRNA 
remained at 60 nM in all conditions. Expression of mature miRNAs was measured using qRT-
PCR 3 days after transfection.  Transfecting GBM neurospheres using miR-148a nano/miRs 
increased levels by 24-fold and using this approach to deliver miR-296-5p increased levels by 27-
fold. The combination nano/miR increased levels of miR-148a and miR-296-5p by 16- and 30-
fold respectively (Figure 6.4b). To directly test the effects of these nano/miRs on the GBM stem 
cell phenotype, two distinct neurosphere lines were transfected using the formulations mentioned 
above and the sphere formation capacity of these cells was measured 12 days after transfection. 
MiRNA delivery using this approach significantly inhibited sphere forming capacity (Figure 6.4c) 
concurrent with the decreased expression of stem cell drivers and markers Sox2, Nanog, and Olig2 
(Figure 6.4d). These data recapitulate our previous results using lenti-viral systems for miRNA 
reconstitution11, 12 and suggests that PBAE polymers are an excellent vehicle to deliver bio-active 
miRNAs in vitro.  
6.3.4. PBAE nanoparticles penetrate an orthotopic model of human GBM, deliver miRNA 
to human GBM, and reduce the GBM stem cell phenotype in vivo. 
A major obstacle that prevents drug delivery to the brain is the blood brain barrier, which 
limits the accessibility of highly charged molecules such as miRNAs or PBAE polymers, making 
systemic delivery of nano/miRs very challenging39. To circumvent this obstacle we used a 
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technique that closely resembles the clinically translatable convection enhanced delivery (CED) 
to test the biological effects of our nano/miRs in vivo30. A trans-cranial cannula was placed so that 
the tip is inside the right caudate/putamen of mice. One week after cannula placement, animals 
received A172-iGSCs11 cells via the cannula and 3 weeks after cell implantation, we started the 
PBAE nano/miR delivery. Twice per week animals received slow infusions of control miRNA 
mimics labeled with Dy547 or miR-148a via the cannula to optimally localize delivery to tumor 
site. Brains were collected and sections were visualized using fluorescent microscopy and 
compared to the adjacent H&E stained counterparts. The expression of fluorescently labeled 
control miRNA was detectable in ~70% of the tumor volume (Figure 6.6a), demonstrating we can 
efficiently deliver miRNAs to an established tumor using our PBAE formulation. To test if the 
miRNAs delivered using this protocol retained their biological function, we measured the 
expression of Dnmt1 and Dnmt3b, two well described miR-148a targets11, in tumor sections using 
immunohistochemistry (Figure 6.6b). Tumor treated with miR-148a nano/miRs had significantly 
lower expression levels of both Dnmt1 and Dnmt3b compared to control treated animals, 
indicating the miRNAs retain their biological activity.  
6.3.5. miRNA codelivery via PBAE nanoparticles reduces GBM growth and promotes tumor 
killing in an orthotopic model of human GBM. 
It is well accepted that stem-like cells drive the tumor-initiation and that loss of self-
renewal capacity or differentiation of these cell population results in loss of tumor-propagating 
capacity4, 6. To test if reconstituting these stem cell inhibitory miRNAs prevents the growth of an 
established tumor, GBM1A neurospheres, which closely recapitulate the tumor pathology of GBM 
patients26, were implanted in animals using the same experimental paradigm as before (Figure 
6.6c). Tumors were then treated with control miRNA, miR-148a, miR-296-5p, or the combination. 
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Consistent with the stem cell inhibitory properties of miR-14a and miR-296-5p, we observed 
decreased tumor burden in all three treated groups, with the combination having the most profound 
effect (Figure 6.6d,e). This decrease in tumor size coincided with an increase in tissue necrosis 
(Figure 6.6f) and activation of apoptosis (Figure 6.6g), as measured by histopathology and 
cleaved Caspase 3 immunohistochemistry respectively. These findings demonstrate that PBAE 
nano/miRs inhibit the growth of an established GBM tumor in an orthotopic xenograft model and 
suggest this approach can be successfully developed into new ways to treat brain tumors. 
6.3.6. miR-148a delivery sensitizes GBM to killing via radiation therapy.  
We then assessed the ability of miR-148a delivery via nanoparticles to sensitize GBM 
tumors to radiation therapy (Figure 6.7). We used immunohistochemical analysis to assess tumor 
progression in each group by assessing vascularization, apoptosis, and miR-148a activity (Figure 
6.8a). Laminin staining allowed us to visualize blood vessels, and we found that miR-148a treated 
tumors, both with and without IR showed significantly less vessels per field of view than control 
tumors (miR-Ctrl and no IR) (Figure 6.8b). We stained for cleaved caspase-3 to assess tumor 
apoptosis and found that miR-148a, with and without IR, showed significantly higher expression 
of the apoptotic marker than control mice (Figure 6.8c). We also measured expression of DNA 
methyl transferase-3b (DNMT3b), a target of miR-148a, and showed that both miR-148a treated 
groups showed a significant reduction in DNMT3b expression (Figure 6.8d). 
 Finally, we used hemotoxylin and eosin (H&E) staining to visualize tumors and calculate 
tumor burden. We showed that miR-148a nanoparticle treatment combined with IR therapy 
significantly reduced tumor volume to 12  4 mm2, versus miR-Ctrl treated mice without IR (79 
 11 mm2) and with IR (75  13 mm2) (Figure 6.9).  Radiation had no significant effect on tumor 
volume versus control. This suggests that nanoparticles carrying miR-148a to tumor cells 
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sensitized the tumor to radiation therapy. As our in vitro data showed that we could use miR-148a 
delivery to reduce the tumor-propagating and stem-like phenotype of GBM cells, we believe that 
this caused the radiation sensitization.  
 
6.4. Conclusion 
 Herein, we have described the synthesis of a novel, bioreducible PBAE capable of 
encapsulating miRNA into nanoparticles and delivering it intracellularly. We have demonstrated 
that imparting bioreducibility enables near-immediate cargo release when nanoparticles reach their 
subcellular target location in the cytosol. We have demonstrated that this property enables the 
nanoparticles to successfully carry RNA into human GBM cells, and that their fast degradation 
profile significantly reduces cytotoxicity. We have shown that we can load miR-148a and miR-
296-5p, either alone or in combination, into these nanoparticles and deliver it to human brain 
cancer in vitro, and that this significantly reduces the stem-like and tumor propagating phenotype 
of GBM. When delivered intratumorally, miR-148a or miR-296-5p nanoparticles significantly 
reduce tumor vacularization, increase tumor apoptosis, and decrease the expression of a target of 
miR-148a. In combination, these effects are strengthened. We have shown that delivery of miR-
148a or miR-296-5p reduces tumor size and increases tumor killing, and that combination miR-
148/296-5p delivery enhances this effect. Finally, we have shown that miR-148a nanoparticle 
treatment sensitizes GBM to radiation therapy and reduces tumor burden. The results presented 
herein show that bioreducible PBAE nanoparticles have the potential to be a safe, effective, and 
tumor-specific delivery vehicle for intratumoral delivery of RNA cargos. They also suggest that 
bioreducible PBAE nanoparticles carrying miR-148a have the potential to sensitize brain tumors 




Figure 6.1. Bioreducible PBAE polymer synthesis. (A) PBAE monomer structures are shown, 
including bioreducible monomer BR6. (B) Bioreducible PBAE synthesis is carried out via Michael 
Addition of diacrylate monomer BR6 and amine-containing monomer S4 at a 1.1:1 BR6:S4 ratio 
to yield acrylate-terminated polymer BR6-S4. This polymer is endcapped with amine-containing 
monomer E6 to yield BR6-S4-E6 (R646), a polymer that has redox-responsive disulfide moieties 





Figure 6.2. PBAE Polymers can efficiently deliver siRNAs to GBM neurospheres. GBM1A (A) 
and GBM1B (B) neurospheres were dissociated into single cell, seeded onto 96-well plates pre-
treated with Poly-L-Lysine (1.0x104 cells/well) and transfected with increasing amounts of PBAE 
polymers loaded with either 80nM or 120nM of a control siRNA (siCtrl.) or a toxic siRNA 





Figure 6.3. PBAEs form nanoparticles with miRNA and effectively release it in a reducing 
environment. PBAE polymers were used to form nanoparticles with miRNA and their physical 
properties in varying conditions were characterized. (A) TEM imaging of PBAE/miRNA 
nanoparticles showing dried particle size a morphology. (B) Nanoparticle hydrodynamic diameter 
as measured using either intensity-weighted (DLS) or number-average (NTA) measurement, and 
dried nanoparticle diameter as measured by TEM. (C) Nanoparticle surface charge (-potential) is 
reported as measured via DLS. (D,E) Nanoparticle concentration as measured by NTA is reported 
to show the concentration delivered in vitro, and the calculated miRNA loading in each 
nanoparticle. (F) A gel retention assay was performed to assess miRNA binding in artificial CSF 
(aCSF) versus in 5 mM glutathione (GSH), to mimic the extracellular versus intracellular space 
within the brain. miRNA that is tightly bound within PBAE nanoparticles is unable to run along 





Figure 6.4. PBAE nano/miRs inhibit the GBM stem cell phenotype. GBM1A and GBM1B 
neurospheres were dissociated into single cell, seeded onto plates pre-treated with Poly-L-Lysine 
(1.5x105 cells/ml) and transfected with either miR-Ctrl., miR-148a, miR-296-5p, or the 
combination (120nM) using PBAE polymers (270mg/ml).  (A) miR-Ctrl labeled with Dy547 was 
visualized 9 days after transfection using fluorescent microscopy. (B) Expression of mature miR-
148a and miR-296-5p was measured by qRT-PCR 3 days after transfection. (C) Equal numbers of 
GBM1A or GBM1B cells transfected with nano/miRNA conjugates were cultured in neurosphere 
medium containing EGF/FGF for 12 days and neurosphere numbers (>100µm diameter) were 
quantified by computer-assisted image analysis. (D) qRT-PCR analysis to measure expression of 





Figure 6.5. PBAE nanoparticle delivery of Dy547-labeled miRNA successfully penetrates GBM 





Figure 6.6. miR-148a and miR-296-5p co-delivery using PBAE polymers inhibits GBM tumor 
growth in vivo.  3.0x104 A172-iGSCs cells were injected into the right striatum of Nod SCID mice. 
3 weeks after injection, 5 L of PBAE/miRNA conjugates were convected into the brains twice a 
week for 3 weeks. Brains were collected, fixed and 20 m sections were cut. (A) miR-Ctrl labeled 
with Dy547 was visualized using fluorescent microscopy (top, left panel) and compared to 
adjacent H&E stained sections (bottom, left panel). The intra-tumoral distribution of the nanomiR 
conjugates was calculated as the ratio of fluorescence area divided by tumor area X 100 (N=3, 
right panel). (B) Immunohistochemical analysis of DNMT1 and DNMT3b in tumor sections 
treated with miR-Ctrl or miR-148a (left panel). Quantification of DNMT1 and DNMT3b 
expression in tumor sections treated with miR-Ctrl. or miR-148a using computer-assisted 
densitometry analysis (right panel) (C) Schematic summarizing treatment schedule for in vivo 
delivery of nano/miR conjugates. (D) Representative H&E stained brain sections from mice 
implanted with GBM1A neurosphere cells treated with the indicated Nano/miR conjugates.  
Maximum tumor X-sectional areas following treatment with Nano/miR conjugates representing 
viable tumor tissue (E) and necrotic tumor tissue (F) were quantified from H&E stained sections 
using ImageJ software. (G) Apoptotic index was measured in tumor sections by 





Figure 6.7. Nanoparticles carrying miRNA convert brain tumor stem cells to cancer cells, 





Figure 6.8. Immunohistochemical analysis of tumor tissue. Laminin staining shows reduced 
vessel area per field of view in tumors treated with miR-148a nanoparticles with and without 
radiation, indicating reduced tumor vascularization, a marker of aggression (B). Cleaved 
Caspase-3 staining shows increased tumor cell apoptosis in tumors treated with miR-148a 
nanoparticles both with and without radiation (C) DNMT-3b staining shows miR-148a 
nanoparticles reduce the expression of DNMT-3b, a direct target of miR-148a (D). Radiation 





Figure 6.9. In vivo delivery of miR-148a nanoparticles with combined with ionizing radiation 
(IR) reduces tumor burden in mice versus miR-Ctrl-treated mice with IR, suggesting that miR-
148a nanoparticles sensitized the tumor to radiation therapy. Radiation alone shows no 
significant reduction in tumor burden. Tumors treated with miR-148a alone show some decrease 
in tumor burden, but this is not significant. This highlights the importance of using miR-148a 
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 Highlighted by the NIH NIBIB “New Nanoparticle Gene Therapy Treats Brain Cancer in Rats.”  
April 10, 2015 
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10. Kozielski, K.L.; Tzeng, S. Y.; Hurtado de Mendoza, B. A.; Green, J.J: Bioreducible cationic 
polymer-based nanoparticles for efficient and environmentally triggered cytoplasmic siRNA delivery 
to primary human brain cancer cells. ACS Nano 2014, 8, 3232-3241.  
11. Kozielski, K.L.; Tzeng, S. Y.; Green, J. J.: A bioreducible linear poly(beta-amino ester) for siRNA 
delivery. Chemical Communications 2013, 49, 5319-5321. 
12. Kozielski, K.L.;* Tzeng, S.Y;* Green, J.J.: Bioengineered nanoparticles for siRNA delivery. WIREs 
Nanomedicine and Nanobiotechnology 2013, 5, 449-468. 
13. Kozielski, K.L.;* Tzeng, S. Y.;* Green, J. J.: siRNA nanomedicine: the promise of bioreducible 
materials. Expert Review of Medical Devices 2013, 10, 7-10. 
14. Sunshine, J. C.; Akanda, M. I.; Li, D.; Kozielski, K.L.; Green, J. J.: Effects of base polymer 
hydrophobicity and end-group modification on polymeric gene delivery. Biomacromolecules 2011, 
12, 3592-3600. 
15. Reid, B.; Tzeng, S.; Warren, A.; Kozielski, K.L.; Elisseeff, J.: Development of a PEG Derivative 
Containing Hydrolytically Degradable Hemiacetals. Macromolecules 2010, 43, 9588-9590. 
16. Saliaris, A. P.; Amado, L. C.; Minhas, K. M.; Schuleri, K. H.; Lehrke, S.; John, M. S.; Fitton, T.; 
Barreiro, C.; Berry, C.; Zheng, M.; Kozielski, K.L.; Eneboe, V.; Brawn, J.; Hare, J. M.: Chronic 
allopurinol administration ameliorates maladaptive alterations in Ca2+ cycling proteins and beta-
adrenergic hyporesponsiveness in heart failure. American Journal of Physiology-Heart and 
Circulatory Physiology 2007, 292, H1328-H1335. 
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2. Green, J.J.; Popel, A.S.; Sunshine, J.C.; Shmueli, R.B.; Tzeng, S.Y.; Kozielski, K.L.; “Polymeric 
Systems for Delivery of Peptides and Other Biological Agents” U.S. Prov. Patents 61/542,995 and 
61/543,046.  Filed: October 4, 2011. 
3. Green, J.J.; Popel, A.S.; Sunshine, J.C.; Shmueli, R.B.; Tzeng, S.Y.; Kozielski, K.L.; 
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1. Kim, J.J.;* Kozielski, K.L.;* Wilson, D.R.;* Green, J.J.: Biodegradable polymeric nanoparticles for 
gene delivery. In Perspectives in Micro and Nanotechnology for Biomedical Applications. Xu, C. and 
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Awards and Recognition 
 
- Whitaker International Program Post-Doctoral Scholarship (2016) 
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- Johns Hopkins University Institute for Nanobiotechnology Annual Symposium Poster 
Competition Third Place Award (2016) 
- Ruth L. Kirchstein F31 NIH National Research Service Award Fellowship, National Cancer 
Institute (2015-present) 
- ARCS Foundation Scholarship recipient (2015-present) 
- Founding Member of the JHU Graduate Women’s Empowerment Network (2013-present) 
- Founding Member, Vice President (2013-2015), and Academic Chair (2011-2013) of the 
Translational Tissue Engineering Center Student Association 
- NSF Fellowship recipient to attend the International Summer School on Biocomplexity and 
Biodesign (2013) 
- NIH Cancer Nanobiotechnology Training Center Fellowship recipient (2012) 
- NSF GRFP Honorable Mention (2011 and 2012) 
- Dean’s list (2006-2010) 
- Centennial Athletic Conference Honor Roll for volleyball (2009 and 2010) 
- Vice President (2008-2010) and Treasurer (2007-2008) of Johns Hopkins Society of Women 
Engineers  
 
Invited Talks and Oral Conference Sessions 
 
1. Kozielski, K.L.; Lopez-Bertoni, H.; Lal, B.; Vaughan, H.; Laterra, J.; Green, J.J. MicroRNA delivery via 
poly(beta-amino ester) nanoparticles as a treatment for human glioblastoma. Presentation. (2016) 10th 
World Biomaterials Congress, Montreal, QC Canada. 
2. Kozielski, K.L.; Lopez-Bertoni, H.; Lal, B.; Vaughan, H.; Laterra, J.; Green, J.J. Environmentally 
triggered miRNA nanoparticles as a treatment for human glioblastoma. Presentation. (2015) US-Japan 
Symposium on Drug Delivery Systems, Lahaina, HI. 
3. Kozielski, K.L.; Lange, R.; Green, J.J. Cutting Edge Treatment of Brain Tumors. Presentation. (2015) 
Johns Hopkins University School of Medicine Partnering Toward Discovery Seminar Series, Baltimore, 
MD. 
4. Kozielski, K.L.; Green, J.J. Environmentally-triggered nanoparticles for selective and combinatorial 
delivery of siRNA and DNA for the treatment of brain cancer. Presentation. (2015) Johns Hopkins 
University Department of Biomedical Engineering Seminar Series, Baltimore, MD. 
5. Kozielski, K.L.; Lopez-Bertoni, H.; Lal, B.; Vaughan, H.; Laterra, J.; Green, J.J. Nanoparticles for 
miRNA Delivery as a Potent and Combinatorial Treatment for Glioblastoma. Presentation. (2015) 
Biomedical Engineering Society Annual Meeting, Tampa, FL. 
6. Kozielski, K.L.; Vaughan, H.; Kim, B.H.; Tzeng, S.Y.; Magraviti, A.M.; Wang, Y.; Guerrero-Cazares, 
H.; Quinones-Hinojosa, A.; Brem, H.; Tyler, B.; Green, J.J.: Poly(beta-amino ester) nanoparticles for 
selective and combinatorial delivery of siRNA and DNA to brain cancer. Presentation. (2015) 6th Annual 
Advanced Study Institute on Global Healthcare Challenges, Izmir, Turkey.  
7. Kozielski, K.L.; Vaughan, H.; Kim, B.H.; Tzeng, S.Y.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.; 
Green, J.J.: Poly(beta-amino ester) nanoparticles for selective and combinatorial delivery of siRNA to 
brain cancer. Presentation. (2015) Society for Biomaterials, Charlotte, NC. 
8. Kozielski, K.L.; Vaughan, H.; Kim, B.H.; Tzeng, S.Y.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.; 
Green, J.J.: Environmentally triggered nanoparticles for efficient and cancer-specific DNA and siRNA 
delivery to glioblastoma. Presentation. (2015) Johns Hopkins School of Medicine Neurooncology 
Monthly Research Meeting, Baltimore, MD. 
9. Kozielski, K.L.; Vaughan, H.; Kim, B.; Tzeng, S.Y.; Guerrero-Cazares, H.; Quinones-Hinojosa, A.; 
Green, J.J.: Bioreducible nanoparticles for efficient and combinatorial siRNA delivery to primary human 
glioblastoma. Presentation. (2014) Johns Hopkins University Institute for Nanobiotechnology Mini 
Symposium, Baltimore, MD.  
10. Kozielski, K.L.; Tzeng, S.Y. Hurtado de Mendoza, B.A.; Green, J.J. Environmentally triggered 
nanoparticles for efficient and cancer-specific siRNA delivery to primary human glioblastoma. 
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Presentation. (2014) 5th Annual Advanced Study Institute on Global Healthcare Challenges, Antalya, 
Turkey.  
11. Kozielski, K.L.; Tzeng, S.Y.; Green, J.J. Crosslinked and bioreducible poly(beta-amino ester)-based 
nanoparticles for enhanced siRNA delivery. Presentation. (2013) BMES Annual Meeting, Seattle, WA. 
12. Kozielski, K.L.; Tzeng, S.Y.; Green, J.J. Bioreducible, crosslinked nanoparticles for efficient and 
environmentally triggered siRNA delivery to human glioblastoma cells. Presentation. (2013) 12th Annual 
Summer School for Biocomplexity and Biodesign, Istanbul, Turkey. 
13. Kozielski, K.L.; Green, J.J.: Bioreducible poly(beta-amino ester)s for siRNA delivery. Presentation. 
(2012) BMES Annual Meeting, Atlanta, GA. 
 
Conference Abstracts and Poster Presentations 
 
1. Bishop, C.J.; Tzeng, S.Y.; Kozielski, K.L.; Quinones-Hinojosa, A.; Green, J.J. Polymeric nanoparticle 
systems for non-viral gene delivery. Presentation. (2016) 10th World Biomaterials Congress, Montreal, 
QC Canada. Johns Hopkins University Institute for Nanobiotechnology Annual Symposium, Baltimore, 
MD. 
2. Zamboni, C.; Kozielski, K.L.; Radant, N.; Higgins, L.J.; Pomper, M.G.; Green, J.J. Effective and cancer-
specific siRNA delivery to human hepatocellular carcinoma cells mediated by poly(beta-amino ester) 
nanoparticles. Presentation. (2016) 10th World Biomaterials Congress, Montreal, QC Canada. 
3. Kozielski, K.L.; Lopez-Bertoni, H.; Lal, B.; Vaughan, H.; Laterra, J.; Green, J.J. Environmentally 
triggered miRNA nanoparticles as a treatment for human glioblastoma. Poster. (2016)  
4. Mangraviti, A.; Tzeng, S.Y.; Gullotti, D.; Kozielski, K.L.; Sarabia-Estrada, R.; Brem, H.; Tyler, B.; 
Olivi, A.; Green, J.J.; Quinones-Hinojosa, A. Brain Tumor Gene Delivery via Non-Viral Engineered 
Adipose Mesenchymal Stem Cells Extend Survival In Vivo. Poster. (2016) 84th AANS Annual Scientific 
Meeting, Chicago, IL. 
5. Mangraviti, A.; Tzeng, S.Y.; Gullotti, D.; Kozielski, K.L.; Seng, M.; Abbadi, S.; Schiapparelli, P.; 
Sarabia-Estrada, R.; Brem, H.; Tyler, B.; Olivi, A.; Green, J.J.; Quinones-Hinojosa, A. Non-viral 
Genetically Engineered Adipose Mesenchymal Stem Cells for Brain Tumor Therapy. Presentation. 
(2015) Biomedical Engineering Society Annual Meeting, Tampa, FL. 
6. Li, X.; Kozielski, K.L.; Cheng, Yu-Hao; Green, J.J.; Mao, H. Nanoparticle-mediated Transdifferentiation 
of Astrocytes into Non-glial Cells. Presentation. (2015) Biomedical Engineering Society Annual Meeting, 
Tampa, FL. 
7. Mangraviti, A; Tzeng, S.Y.; Kozielski, K.L.; Wang, Y.; Jin, Y.; Gullotti, D.; Pedone, M.; Buaron, N.; 
Liu, A.; Wilson, D.; Hansen, S.; Rodriquez, F.; Gao, G.; DiMeco, F.; Brem, H.; Olivi, A.; Tyler, B.; 
Green, J.J. Polymeric Nanoparticles for Non-Viral Gene Therapy Extend Brain Tumor Survival In Vivo. 
Poster. (2015) Biomedical Engineering Society Annual Meeting, Tampa, FL. 
8. Li, X.; Cheng, Y.; Kozielski, K.L.; Liu, H.; Green, J.J.; Mao, H.(2015) Tissue Engineering and 
Regenerative Medicine Society World Congress, Boston, MA. 
9. Kozielski, K.L.; Vaughan, H.; Kim, B.H.; Tzeng, S.Y.; Mangraviti, A.; Wang, Y.; Guerrero-Cazares, H.; 
Quinones-Hinojosa, A.; Brem, H.; Tyler, B.; Green, J.J. Poly(β-amino ester) nanoparticles for selective 
and combinatorial delivery of siRNA and DNA to brain cancer. Poster. (2015) Johns Hopkins University 
Institute for Nanobiotechnology Annual Symposium, Baltimore, MD. 
10. Zamboni, C.G.; Higgins, L.J.; Kozielski, K.L.; Minn, I.; Pomper, M.G.; Green, J.J.; Cancer-specific 
nanoparticles mediated DNA delivery to human hepatocellular carcinoma using synthetic poly(beta-
amino ester) vectors. Presentation. (2015) Society for Interventional Radiology, Atlanta, GA. 
11. Mangraviti A.M; Tzeng S.Y.; Kozielski, K.L.; Wang Y.; Jin Y.; Gullotti D.; Pedone M.; Buaron N.; Liu 
A.; Wilson D.R.; Hansen S.; Rodriguez F.; Gao G.D.; DiMeco F.; Brem H.; Olivi A.; Tyler B.; Green J.J.; 
Brain tumor non-viral gene therapy via polymeric nanoparticle extends survival in vivo. Presentation. 
(2015) AANS/CNS Section on Tumors, 11th Biennial Satellite Symposium, Washington D.C. 
12. Hung, B.P.; Hutton, D.L.; Kozielski, K.L.; Bishop, C.J.; Naved, B.; Green, J.J.; Dorafshar, A.H.; 
Grayson, W.L. PDGF-BB enhances osteogenesis in adipose-derived but not marrow-derived 
 231 
mesenchymal stem cells. Poster. (2014) Tissue Engineering and Regenerative Medicine International 
Society Annual Meeting, Washington, D.C. 
13. Kozielski, K.L.; Vaughan, H.; Kim, B.; Tzeng, S.Y.; Green, J.J.; Environmentally triggered nanoparticles 
for efficient and cancer-specific siRNA delivery to primary human glioblastoma. Poster. (2014) Tissue 
Engineering and Regenerative Medicine International Society Annual Meeting, Washington, D.C. 
14. Mangraviti, A.; Tzeng, S.Y.; Seng, M.; Abbadi, S.; Kozielski, K.L.; Schiapparelli, P.; Wijesekera, O.; 
Sarabia-Estrada, R.; Brem, H.; Tyler, B.; Olivi, A.; Green, J.J.; Quinones-Hinojosa, A.: BMP4-secreting 
hAdMSCs engineered with nanoparticles: A non-viral MSC-based therapy for glioblastoma. Presentation. 
(2014) 19th Annual Scientific Meeting of the Society for Neuro-Oncology, Miami, FL. 
15. Kozielski, K.L.; Tzeng, S.Y.; Hurtado de Mendoza, B.A.; Green, J.J. Environmentally triggered, 
bioreducible nanoparticles for efficient and cancer-specific siRNA delivery to primary human 
glioblastoma cells. Poster. (2014) Johns Hopkins University Institute for Nanobiotechnology Annual 
Symposium, Baltimore, MD. 
16. Kozielski, K.L.; Tzeng, S.Y.; Green, J.J. Bioreducible poly(beta-amino ester)s for siRNA delivery. 
Poster. (2013). Johns Hopkins University Institute for Nanobiotechnology Annual Symposium, 
Baltimore, MD. 
17. Reid, B; Kozielski, K.; Elisseeff, J.H.: Modifying polyethylene glycol hydrogel degradation rate post-




Johns Hopkins University Biomedical Engineering, Advisor: Dr. Jordan Green  (2011-present) 
- Creating a method to engineer stem cells isolated from patient adipose tissue to migrate to brain 
tumors and secrete tumor-killing factors (Biomaterials publication). 
- Developing several technologies involving in vitro and in vivo delivery of therapeutic siRNA, 
miRNA, mRNA, and DNA with the goal of altering gene expression in human glioblastoma, 
Schwann cells, and adipose-derived, mesenchymal, and induced pluripotent stem cells for cancer 
therapy and tissue engineering. (ACS Nano 2015, Stem Cells, Biomaterials Science publications) 
- Synthesized and characterized a new class of bioreducible polymers for siRNA delivery to 
primary human glioblastoma and demonstrated their tumor-selective delivery capabilities (ACS 
Nano 2014, Chemical Communications publications, co-inventor on patents) 
- Characterized a library of gene delivery polymers including by using Nuclear Magnetic 
Resonance (Biomacromolecules publication) 
 
University of California, Berkeley Chemical and Biomolecular Engineering, Advisor: Dr. David Schaffer 
(2010) 
- Worked on a project using siRNA targeted at multiple regions of the HIV genome in order to 
prevent HIV infection in T cells.  
 
Johns Hopkins University Biomedical Engineering, Advisor: Dr. Jennifer Elisseeff (2006- 2010) 
- Contributed to a project designing a biodegradable poly(ethylene glycol) hydrogel. I assisted in 
elucidating and fine-tuning the chemical composition of randomly oxidized poly(ethylene 
glycol). (Macromolecules publication) 
- Cultured primary and stem cells within a 3D hydrogel environment and analyzed their abilities to 
form cartilage in vitro.  
 
Johns Hopkins University Division of Cardiology and Institute for Cell Engineering, Advisor: Dr. Joshua 
Hare (2005-2006) 
- Ran biochemical analyses for a project studying the intracellular effect of heart failure treatment 




Extracurricular and Volunteer Experience 
 
Johns Hopkins Graduate Women’s Empowerment Network (GWEN) (2013-present) 
GWEN was formed when fellow female colleagues and I realized how disconnected we were 
from other women at Hopkins and that the disparity of women in leadership roles often begins 
just after graduate school. Since founding GWEN in October 2013, we have organized monthly 
networking events, a speaker series featuring women in leadership roles in JHU, and began a 
monthly newsletter releasing student highlights and news involving women in science.  
 
Johns Hopkins Translational Tissue Engineering Center (TTEC) Student Association (2011-2014) 
The TTEC Student Association was formed to organize course and qualifying exam information 
for Cell and Tissue Engineering students within the JHU BME department, and to facilitate 
networking and collaboration within TTEC. As the founding members of TTECSA, fellow 
students and I have catalogued and clarified course and exam requirements, organized the annual 
TTEC retreat, coordinated student candidate interviews, and ran several social and networking 
events. I have served as Treasurer (2011-2013) and Vice President (2013-2014).  
 
Johns Hopkins Center for Global Health, Tanzania (2011) 
Two coworkers and I designed and built a bicycle-powered grain mill specific to the needs of 
subsistence farmers in East Africa. Through funding from JHU, we were able to travel to 
Kongwa, Tanzania to train locals to build, operate, and troubleshoot the grain mill.  
 
Johns Hopkins Varsity Volleyball Team (2006-2010) 
 
Maria Immaculata Children’s Education Center of Nairobi (2008) 
Maria Immaculata is an orphanage and school for orphaned and underprivileged children from 
the slums surrounding Nairobi, Kenya. While there, I taught geometry, algebra, and high school 
level biology in the secondary school and ran after school athletic activities for the students. 
 
Johns Hopkins University Interfaith Center Katrina Relief Project (2007 and 2008) 
I participated in construction projects to rebuild houses destroyed or damaged by Hurricane 
Katrina. 
 
Johns Hopkins University Society of Women Engineers (2007-2010) 
 
Teaching Assistant Experiences 
 
Computing for Engineers and Scientists (2009) 
This course employs MATLAB to teach programming and numerical computation for solving 
problems in engineering. I held weekly office hours, planned and lead review sessions, and 
organized and ran a lecture. 
 
Cellular Engineering (2013) 
 This is an upper level undergraduate and graduate course teaching advanced topics in cell 
engineering such as gene delivery, synthetic biology, and modeling of cellular processes. I held 
weekly office hours, organized review sessions, and graded student’s homeworks and exams.  
 
Cell and Tissue Engineering Lab:  Gene Delivery Lab Module (2014) 
 This is a laboratory-based course where students learn fundamental techniques required to work 
in a cell or tissue engineering lab such as cell culture, gene delivery, and encapsulating cells in 
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scaffolds. I ran the gene delivery lab module which involved preparing all lab materials, assisting 
students during experiments, and evaluating lab reports. 
 
Molecules and Cells (2014) 
This is a Biomedical Engineering undergraduate core course in which students learn fundamental 
topics in cell biology, genetics, and macromolecules. I held weekly office hours, planned and ran 




Bolivia Hurtado de Mendoza (2013) 
 Bolivia was an REU student from Columbus State University. She worked with me during the 
summer of 2013, work which led to her authorship on an ACS Nano paper and a conference 
poster. She has since been a research assistant at the Texas Tech University Health Sciences 
Center, and is currently a Dental Assistant and aspires to go to Dental School.  
 
Barbara Kim (2013 – present) 
Barbara is a Biomedical Engineering undergraduate at Johns Hopkins University. She has been 
working with me since her freshman year, and this work has led to authorship on 2 posters and 4 
conference oral sessions. She will be applying to graduate school this coming fall.  
 
Hannah Vaughan (2014) 
Hannah is a Biomedical Engineering undergraduate at Duke University. She worked with me for 
the summer of 2014 doing research which has led to authorship on 2 posters and 4 talks. Hannah 
will be a Ph.D. student in the Johns Hopkins University Biomedical Engineering Program starting 
Fall 2016. 
 
Casey Vantucci (2015) 
Casey is an REU student from the University of Maryland majoring in Materials Science and 
Engineering who is worked for me the summer of 2015. She assisted me in analyzing in vivo 
experiments dealing with siRNA and DNA delivery to human brain cancer models. Casey will be 
a Ph.D. student in the Georgia Institute of Technology Biomedical Engineering Program starting 
Fall 2016. 
 
Marissa Gionet-Gonzalez (2015) 
Marissa is an REU student from the University of California Riverside studying Chemistry. She 
assisted me in optimizing nanoparticles for intravenous delivery by making them more stable in 
the bloodstream. Marissa will be a Ph.D. student in the UC Davis Biomedical Engineering 
Program starting Fall 2016. 
 
  
 
 
 
